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ABSTRACT 
ETHANOL REGULATION OF GLUCOCORTICOID RESPONSIVE GENES 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
by 
Blair Noel Costin 
Director: Michael Miles, M.D., Ph.D. 
Professor, Department of Pharmacology and Toxicology 
Glucocorticoid hormones modulate acute and chronic behavioral and molecular 
responses to drugs of abuse including psychostimulants and opioids. Acute ethanol 
activates the hypothalamic pituitary adrenal (HPA) axis causing the release of adrenal 
glucocorticoid hormones, but following chronic ethanol the HPA axis is dysregulated in 
both humans and rodents. Thus, there is growing evidence that glucocorticoids might also 
modulate behavioral and molecular responses to ethanol.  
Previous microarray studies in the Miles’ laboratory have shown that the well-
known glucocorticoid responsive gene, Serum and Glucocorticoid-regulated Kinase 1, 
Sgk1, is prominently up regulated by acute ethanol (2 g/kg) in the prefrontal cortex (PFC) 
of DBA/2J mice. Functionally, Sgk1 is an important focal point of intracellular signaling 
cross-talk through which the cell surface receptors, nuclear receptors, and cellular stress 
pathways converge to control many cellular processes including receptor or ion channel 
trafficking, cell proliferation and/or apoptotic responses. In the aforementioned 
microarray studies, Sgk1 was accompanied by a highly correlated group of genes, many 
of which are also known to respond to glucocorticoids. This suggests that stress-related 
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signaling events might play an important role in ethanol regulation of the Sgk1 gene 
network. Prior work by others showed that Sgk1 plays an important role modulating 
synaptic plasticity occurring in memory. Based on these findings, it is hypothesized that 
glucocorticoids and glucocorticoid responsive genes are responsible for modulating acute 
and chronic cellular and behavioral responses to ethanol including locomotor activation 
and ethanol sensitization. In particular, because Sgk1 is regulated by ethanol, has a well-
established role in learning and memory and is responsive to glucocorticoid signaling we 
hypothesize that Sgk1 is involved in modulating acute and chronic cellular and 
behavioral responses to ethanol including ethanol sensitization. 
Our results indicate that the induction of glucocorticoid responsive genes may 
play a role in regulating acute behavioral and cellular responses to ethanol. 
Adrenalectomized (ADX) and mifepristone (RU-486) both impaired acute ethanol (2 
g/kg) induced locomotor activation in DBA/2J mice without affecting basal locomotor 
activity. ADX mice showed microarray gene expression changes in the PFC that 
significantly overlapped with acute ethanol-responsive gene sets derived by our prior 
microarray studies. Additionally, acute ethanol regulates Sgk1 transcription via 
glucocorticoid receptor binding to the Sgk1 promoter. Furthermore, increases in Sgk1 
may occur to compensate for decreases in SGK1 protein and phosphorylation of SGK1 
and its well-known target N-myc downstream-regulated gene 1 (NDRG1) is significantly 
increased 15 minutes following ethanol administration. Finally, Sgk1 intensifies and 
prolongs the expression phase of sensitization in D2 mice. 
Our studies suggest that ethanol’s activation of adrenal glucocorticoid release and 
subsequent glucocorticoid receptor activation may partially modulate ethanol’s acute 
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locomotor activation in male D2 mice.  Furthermore, adrenal glucocorticoid basal tone 
regulates PFC gene expression. A significant set of acute ethanol-responsive genes are 
regulated by adrenal glucocorticoid basal tone suggesting that glucocorticoid regulated 
PFC gene expression may be an important factor modulating acute behavioral responses 
to ethanol. Sgk1 is acutely regulated following ethanol administration by the 
glucocorticoid receptor binding to the Sgk1 promoter. Altogether, these results suggest a 
critical role for the hypothalamic pituitary adrenal axis and Sgk1 in regulating the acute 
and chronic cellular and behavioral responses to ethanol.  
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CHAPTER 1 
Introduction  
Concern over individuals who consume alcohol in excess goes back centuries, but 
it wasn’t until after the 18th Amendment was repealed in 1932, ending Prohibition, that a 
movement developed characterizing alcoholism as a curable illness rather than a disease 
of the will (Jellinek, 1960, Hewitt, 1995). During the 1930s, Bill Wilson and Bob Smith 
founded Alcoholics Anonymous (AA) and the successes of the organization 
demonstrated that alcoholics could recover from alcoholism and live productive lives. By 
the 1950s, public health organizations were addressing alcoholism in health care settings 
and by the 1960s, the American Psychiatric Association declared alcoholism an illness. It 
became clear as perceptions on alcoholism changed that a federal organization must be 
established to coordinate alcohol research and in 1970, President Nixon signed into law a 
bill that would create the National Institute on Alcohol Abuse and Alcoholism (NIAAA). 
Ultimately, this act represented a fundamental shift in the way Americans perceive 
alcohol and alcoholism from the idea that alcoholism resulted from moral failings or 
character flaws to acknowledging alcoholism as a serious, but treatable, public health 
problem (Hewitt, 1995). 
According to the National Institutes of Health as of April, 2010, 28% of adults 
ages 18 and older consume alcohol at levels that put them at risk for developing 
alcoholism, liver disease and other problems (Services, April, 2010). There is no perfect 
definition of alcoholism, but most diagnoses require individuals to have been drinking 
heavily over an extended period of time and to have subsequently suffered multiple major 
life problems due to their alcohol consumption. Additionally, it is estimated that alcohol 
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consumption often meets or exceeds a fifth of spirits or its equivalent in wine or beer per 
day (Schuckit, 1987). At risk drinking increases one’s chances of injuries; health 
problems including liver disease, heart disease, sleep disorders, depression, stroke, 
bleeding from the stomach, sexually transmitted diseases and several types of cancer; and 
drinking during pregnancy increases the risk of birth defects for the unborn child 
(Services, April, 2010). Despite the considerable impact of alcohol on society, the 
molecular mechanisms underlying neuroadaptations or toxicity from ethanol are still 
poorly understood (Vengeliene et al., 2008, Rivier, 1996). 
It is known that ethanol is lipophilic molecule that rapidly crosses the blood-brain 
barrier. Until the 1980s, it was generally believed that ethanol’s actions on biologic 
systems resulted from alterations in the fluidity of cell membranes (Goldstein and Chin, 
1981). More recently, many targets of acute ethanol have been identified including the N-
methyl-D-aspartate (NMDA) receptor, δ-opiate receptor, GABAA, glycine, 5-
hydroxytryptamine 3 (serotonin, 5-HT3) and nicotinic acetylcholine receptors (nAChR) 
as well as L-type Ca2+ channels and G-protein-activated inwardly rectifying K+ channels 
(GIRKs).  NMDA receptors are ionotropic glutamate receptors whose receptor function is 
dose dependently inhibited by acute ethanol (Hoffman et al., 1989, Lovinger et al., 1989, 
Lovinger et al., 1990, White et al., 1990). Ethanol also inhibits the δ-opiate receptor 
(Charness et al., 1983). In addition, alcohol potentiates 5-HT3 (serotonin) receptor 
function (Lovinger, 1999) and neuronal nAChR function (Narahashi et al., 1999). 
Inhibitory GABAA and glycine receptor function is enhanced by acute ethanol (Mihic, 
1999). Ethanol inhibits L-type Ca2+ channels (Wang et al., 1994). Finally, ethanol opens 
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GIRKs (Kobayashi et al., 1999b, Lewohl et al., 1999). Despite the many targets of 
ethanol, GABAA and NMDA receptors are considered the major targets of ethanol. 
Considerable evidence suggests that ethanol’s action on GABA receptors is of 
utmost importance in producing intoxication (Ticku, 1990, Sigel et al., 1993). 	  γ-
aminobutyric acid	  (GABA) is the predominant inhibitory neurotransmitter in the brain 
(Baur et al., 2006). The GABA receptor is the major inhibitory neurotransmitter receptor, 
which has been a long-time focus for studies on ethanol actions (Baur et al., 2006, 
Wallner et al., 2003). GABA acts at two types of receptors GABAA and GABAB. 
GABAA receptors are ligand-gated chloride channels, whereas GABAB receptors are 
coupled to potassium and calcium channels via guanine nucleotide binding proteins (G 
proteins) (Nicoll, 1988). Although GABAB receptors appear to mediate some of ethanol’s 
responses (Allan and Harris, 1989, Mehta and Ticku, 1990), ethanol activation of 
GABAA receptors appears to be more important. It is known that low, intoxicating 
concentrations of ethanol can enhance Cl- flux in synaptoneurosomes (Suzdak et al., 
1986b) and cultured neurons (Mehta and Ticku, 1988). In addition, ethanol-stimulated 
GABAA-mediated chloride flux corresponds closely with ethanol concentrations that 
produce intoxication (Suzdak et al., 1986b, Allan and Harris, 1987, Mehta and Ticku, 
1988, Nishio and Narahashi, 1990) and Ro15-4513, a GABA inverse agonist, reversed 
some of the acute intoxicating effects of ethanol in rats (Suzdak et al., 1986a, Suzdak et 
al., 1986b).  
In 1989, Lovinger et al. first reported that ethanol (5-100 mM) acutely inhibits 
NMDA-activated ion currents in a concentration-dependent manner in cultured mouse 
hippocampal neurons (Lovinger et al., 1989). Ethanol’s inhibitory actions on the channel 
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were further demonstrated by measuring NMDA receptor-mediated excitatory 
postsynaptic potentials in slice cultures from various brain regions (Wright et al., 1996, 
Wirkner et al., 2000, Li et al., 2002, Calton et al., 1998, Nie et al., 1994, Yin et al., 2007). 
The reduction in NMDA receptor activity following acute ethanol exposure is not only 
concentration-dependent, but it also has a rapid onset (Wirkner et al., 2000, Peoples and 
Stewart, 2000, Criswell et al., 2004). While the exact method by which ethanol inhibits 
NMDA receptor function is still unclear, single channel recordings in cultured cortical 
neurons revealed that ethanol decreases the open channel probability and mean open time 
of native NMDA receptors (Wright et al., 1996). Additionally, while acute ethanol 
inhibits NMDA receptors, chronic ethanol exposure increases the synaptic expression of 
NR2B subunit-containing NMDA receptors (Carpenter-Hyland et al., 2004, Hendricson 
et al., 2007). Increases in NMDA receptor number occurs presumably as an adaptive 
response to the prolonged reduction of NMDA receptor activity in the presence of 
ethanol (Kroener et al., 2012).  
Even though alcohol has many targets and alcoholism is a complex disease that 
develops over many years and includes many cycles of withdrawal, craving, and relapse, 
acute behavioral responses to ethanol have predictive validity in terms of risk for high 
levels of ethanol intake in animal models or alcoholism in humans (Schuckit, 1994, 
Metten et al., 1998, Palmer et al., 2002). The behavioral effects of acute ethanol can 
range from loss of inhibition to sedation and even hypnosis, with increasing 
concentrations of alcohol (Vengeliene et al., 2008). Acute behavioral responses to ethanol 
have predictive validity in terms of risk for alcoholism in humans. For example, 
individuals who experience sedation following ethanol consumption are less likely to 
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become alcoholics than those who experience euphoria and disinhibition (Schuckit, 
1994). 
It is known that genetic predisposition is thought to confer more than 50 percent 
of the risk for becoming an alcoholic (Schuckit, 1987, Kalsi et al., 2009). Family studies 
have revealed a threefold to fourfold increased risk for alcoholism in the sons and 
daughters of alcoholics (Schuckit, 1987). Additionally, Schuckit et al. has demonstrated 
that young men with a positive family history of alcoholism show a decreased ataxic 
response to a test dose of ethanol. This strongly predicts the development of alcoholism 
10 years later (Schuckit, 1994). In a recent study, Ramchandani et al. investigated 
whether the mu opioid receptor (OPRM1) 118G variant modulated striatal dopamine 
release in response to ethanol. The functional OPRM1 118G variant confers enhanced 
subjective alcohol responses in humans (Ray and Hutchison, 2007) and a functional 
equivalent in rhesus macaques, the 77G variant, confers enhanced alcohol-induced 
psychomotor stimulation (Miller et al., 2004). The authors found that 118G carriers had a 
markedly more vigorous striatal dopamine (DA) response to ethanol compared to 
subjects homozygous for the major 118A allele. The authors also created humanized 
mice carrying the human exon 1 of the OPRM1 gene either as the major 118A allele or 
with the 118G SNP. Direct microdialysis measures of the response to a rewarding dose of 
ethanol showed a fourfold higher peak dopamine response to the ethanol challenge in 
mice carrying the 118G mutation (Ramchandani et al., 2011). These studies show how 
genetics can influence an individual’s response to ethanol. They also provide an example 
of a recent study in which an animal model helped to develop a better understanding of 
how genetics can influence an human’s response to ethanol.  
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Dramatic increases in possible new targets for the treatment of alcoholism have 
resulted from more recent work using human or animal model genetics and whole 
genome expression profiling with microarrays.  It is well known that ethanol alters gene 
expression patterns both acutely and chronically. The Miles’ laboratory has used acute 
ethanol exposure and genome-wide expression profiling to identify gene networks 
functioning in acute behavioral responses to ethanol or affecting drinking behavior 
(Kerns et al., 2005a, Wolstenholme et al., 2011).  For example, Kerns et al. examined 
gene expression patterns in the mesolimbic dopamine reward pathway of 2 inbred mouse 
strains, DBA/2J (D2) and C57BL/6J (C57), exhibiting contrasting acute behavioral 
responses to ethanol following saline versus acute ethanol administration. The authors 
identified 788 genes differentially expressed in control D2 versus C57 mice and 307 
ethanol regulated genes differentially expressed in the nucleus accumbens (NAC), pre-
frontal cortex (PFC), and ventral tegmental area (VTA) of the 2 mouse strains (Kerns et 
al., 2005a). These results suggest that genetic factors may play a role in mediating the 
divergent responses to ethanol in D2 versus C57 mice. Genes involved in glucocorticoid 
signaling were differentially regulated in the PFC of D2 versus C57 mice (Kerns et al., 
2005a) and it is well known that acute ethanol activates the hypothalamic pituitary 
adrenal (HPA) axis consisting of the hypothalamus, pituitary gland and adrenal glands in 
both humans and rodents leading to the release of the glucocorticoids cortisol in humans 
and corticosterone in rodents (Koob, 2010, Rivier, 1996). This work will use animal 
models to examine the role of the HPA axis in regulating gene expression following 
ethanol administration. Additionally, animal models will be used to determine whether 
the induction of glucocorticoid responsive genes, Serum glucocorticoid kinase 1 (Sgk1) 
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particularly, might play an important role in modifying cellular and behavioral responses 
to ethanol. 
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CHAPTER 2 
Background and Significance 
 In this chapter, we will discuss two key anatomical systems involved in ethanol 
reward and dependence, the mesocorticolimbic dopamine pathway and the 
hypothalamic pituitary adrenal (HPA) axis. These regions are important as we believe 
ethanol’s activation of the HPA axis may play a role in regulating the expression of 
Serum glucocorticoid kinase 1 (Sgk1) in the PFC, part of the mesocorticolimbic 
dopamine pathway. We will also discuss glucocorticoid nongenomic signaling 
mechanisms, which are hypothesized to involve endocannabinoid signaling. We 
believe glucocorticoid nongenomic signaling and endocannabinoid signaling could play a 
role in behavioral responses to ethanol; particularly ethanol induced acute locomotor 
activation. We will use Adeno-Associated Virus 2 (AAV-2) as method of gene delivery 
later in this work to overexpress Sgk1 and we will discuss AAV-2 and why we chose it as 
our gene delivery method. Finally, we will discuss the glucocorticoid responsive, ethanol 
responsive gene Sgk1 and ethanol responsive behaviors that we hypothesize Sgk1, 
glucocorticoids or other glucocorticoid responsive genes may regulate including ethanol 
induced acute locomotor activation and ethanol sensitization. 
 
Mesocorticolimbic Dopamine Pathway 
Neurochemical and behavioral studies have identified the mesocorticolimbic 
dopamine pathway as a key anatomical system involved with ethanol reward and 
dependence (Kalsi et al., 2009). The mesocorticolimbic dopamine pathway projects from 
the ventral tegmental area (VTA) to the nucleus accumbens (NAC), the ventral striatum, 
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the nuclei of the stria terminalis, parts of the amygdala, the hippocampus, the lateral 
septal nuclei, the entorhinal cortex, the mesial frontal cortex, and the anterior cingulate 
cortex (Kandel ER, 2000). All major drugs of abuse, including ethanol, acutely activate 
the mesolimbic dopamine system (Di Chiara and Imperato, 1988). For example, 
neuroimaging techniques have shown that ethanol enhances extracellular dopamine levels 
in the human ventral striatum (Boileau et al., 2003, Urban et al., 2010, Yoder et al., 2007, 
Ramchandani et al., 2011). Furthermore, dopamine levels in the rat NAC increase in 
anticipation of ethanol consumption (Katner et al., 1996, Melendez et al., 2002).  
Increases in dopamine per se are not sufficient to account for the process of 
addiction, after all drugs of abuse increase dopamine levels in naive as well as addicted 
subjects. In the case of cocaine addiction, the magnitude of drug-induced dopamine 
increases, and the intensity of self-reports of the drug’s reinforcing properties appears 
smaller in addicted versus naïve subjects (Volkow et al., 1997). This may be because the 
function of the mesolimbic dopamine system is severely impaired upon cessation of 
subchronic and chronic exposure to drugs of abuse including ethanol. In support of this, 
alterations of brain dopamine systems occur in abstinent alcoholics including reduced 
dopamine synthesis (Heinz et al., 2005) and reduced numbers of dopamine D2 receptors 
in the striatum (Volkow et al., 1996, Volkow et al., 2002, Martinez et al., 2005). The 
decreased function of the mesolimbic dopamine system has been associated with 
enhanced drug intake, perhaps to restore baseline function of the mesolimbic dopamine 
system (Diana et al., 1993, Ahmed and Koob, 2005).  
While less studied than the VTA and NAC, the PFC is increasingly being 
recognized as a region that plays central role in addiction. Frontal lobe decreases in 
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volume have been identified in alcoholic subjects via magnetic resonance imaging 
(Jernigan et al., 1991, Pfefferbaum et al., 1997). The outcome of chronic drug use may be 
frontal cortical cognitive dysfunction, resulting in an inability to inhibit inappropriate 
unconditioned or conditioned responses elicited by drugs, by related stimuli or by internal 
drive states (Jentsch and Taylor, 1999). Work by Volkow et. al suggests that the 
orbitofrontal cortex region of the PFC modulates the value of reward by regulating the 
magnitude of dopamine increases in the ventral striatum and that disruption of this 
regulation may underlie the decreased sensitivity to rewards in addicted subjects. They 
show that methylphenidate, a stimulant drug, induced much smaller dopamine increases 
in the striatum of alcoholic subjects versus control subjects. Furthermore in alcoholics, 
metabolism in PFC regions is not correlated with dopamine changes suggesting that the 
regulation of DA cell activity by prefrontal efferents is disrupted (Volkow et al., 2007). 
The PFC sends glutamatergic efferents to the VTA and the NAC, which modulate the 
function of these brain regions (Jentsch and Taylor, 1999, Carr and Sesack, 2000). These 
efferents play key roles in regulating the firing pattern of dopamine cells and dopamine 
release, respectively (Carr and Sesack, 2000, Gariano and Groves, 1988, Murase et al., 
1993). Disruption of these efferent pathways may contribute to the pathology underlying 
addiction.   
The orbitofrontal cortex and the anterior cingulate cortex are the frontal cortical 
areas most frequently implicated in drug addiction. These regions are involved in higher 
order cognitive and motivational processing and are activated in addicted subjects during 
intoxication, craving, and binge drug consumption, and they are deactivated during 
withdrawal (Goldstein and Volkow, 2002). The cingulate cortex has been linked with 
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conditioned emotional learning, assessments of motivational content and assigning 
emotional salience to internal and external stimuli (Devinsky et al., 1995), and thus its 
activation by dopamine may be one of the mechanisms by which dopamine modulates 
drive (Kiyatkin, 1995). In a study using functional magnetic resonance imaging (MRI) to 
test whether brain activation was detectable in regions associated with cocaine cue-
induced craving, significant activation was detected in the anterior cingulate cortex in the 
cocaine-using group versus control subjects. Additionally, a correlation between self-
reported levels of craving and activation in the anterior cingulate was found supporting 
the idea that the anterior cingulate cortex may be involved in drug craving (Maas et al., 
1998).  
 
Hypothalamic Pituitary Adrenal Axis 
The HPA axis consisting of the hypothalamus, the anterior lobe of the pituitary 
gland and adrenal glands is activated following acute ethanol exposure (Koob, 2010, 
Rivier, 1996). The hypothalamus consists of several nuclei; the one of interest for this 
project is the paraventricular nucleus (PV), which releases the neurotransmitter CRH 
(Rivier, 1996). The axons of CRH containing neurons in the PV nucleus terminate in the 
median eminence (ME), which is located in close proximity to the hypophyseal portal 
vessels (Rivier, 1996). The pituitary is located beneath the hypothalamus and is 
anatomically connected to the hypothalamus by the portal vessels (Rivier, 1996). ACTH 
is released from the corticotrophs in the adenohypophysis of the anterior pituitary (Rivier, 
1996, Dallman et al., 1985). The adrenals are located above the kidneys and are 
composed of the cortex, which synthesizes glucocorticoids, aldosterone and androgens 
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and the chromaffin tissue, which produces epinephrine and norepinephrine (Rivier, 
1996).  
Following ethanol exposure, neurosecretory neurons in the parvocellular 
subdivision of the paraventricular nucleus of the hypothalamus receive convergent 
impulses from several neurotransmitter systems including stimulatory signals from 
serotonergic and noradrenergic neurons and inhibitory signals from GABA and β-
endorphin-releasing neurons that eventually lead to the synthesis and release CRH into 
the portal blood vessels that enter the anterior pituitary gland (Rivier, 1996, Oswald and 
Wand, 2004). Once CRH is released it stimulates ACTH secretion from the anterior 
pituitary (Oswald and Wand, 2004). Binding of CRH to the CRH 1 receptor on pituitary 
corticotropes stimulates the release of ACTH from corticotropes (Rivier, 1996, Heilig 
and Koob, 2007, Koob, 2010, Kiefer and Wiedemann, 2004). ACTH acts on the adrenal 
gland to stimulate the release of glucocorticoids, cortisol in humans and corticosterone in 
rodents (Rivier, 1996, Kiefer and Wiedemann, 2004). Cortisol and corticosterone also 
regulate the HPA axis through a negative feedback mechanism by acting on 
hypothalamic glucocorticoid receptors to decrease CRH release (Munck et al., 1984) and 
in the pituitary, the hormones directly inhibit ACTH release and the production of its 
precursor hormone proopiomelanocortin (POMC) (Rivier, 1996, Kiefer and Wiedemann, 
2004, Dallman et al., 1985). Glucocorticoids enhance glucose availability, modulate 
immune function, maintain vascular tone and regulate gene transcription through the 
direct binding of homodimers or heterodimers of glucocorticoid receptors to nuclear 
DNA, or through protein–protein interactions with transcription factors (Falkenstein et 
al., 2000, Rivier, 1996).  
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Ethanol’s acute stimulatory effect on the HPA axis in both humans and rodents is 
well documented, but the response of the HPA axis to repeated ethanol exposure is more 
variable (Ellis, 1966, Wand and Dobs, 1991b, Zgombick and Erwin, 1988). In humans, 
small subsets of alcoholics (<5%) develop clinical features of hypercortisolism or 
Cushing's syndrome (Smalls et al., 1976, Jordan et al., 1979, Rees et al., 1977). Most 
alcoholics do not develop Cushing’s syndrome, but numerous studies have demonstrated 
inadequate suppression of the HPA axis following the dexamethasone suppression test 
(DST) (McIntyre and Oxenkrug, 1984, Burov et al., 1986, Dackis et al., 1986, Swartz and 
Dunner, 1982). In the most widely employed procedure for the DST in psychiatry, the 
long-acting synthetic steroid dexamethasone is administered and cortisol levels are 
measured the next day. Dexamethasone acts by mimicking feedback effects of 
glucocorticoids on the HPA axis. It suppresses the release of cortisol into plasma by 
blocking release of CRH from the hypothalamus and ACTH from the anterior pituitary 
(1987). It must be recognized that characterization of the HPA axis in alcoholics is 
complicated. HPA axis dysfunction in alcoholics could also be due to abnormalities 
related to ethanol-induced liver disease (Bode et al., 1978), withdrawal (Burov et al., 
1986), malnutrition (Bode et al., 1978), and depression (Dackis et al., 1986). Depressed 
individuals frequently show hypercorticolism and their HPA axes do not suppress 
appropriately following the DST (Coppen et al., 1983, Wand and Dobs, 1991b). It has 
been suggested that approximately 25-50% of actively drinking alcoholics are also 
depressed (Dackis et al., 1986). One study by Wand et al., characterized the HPA axis in 
a group of actively drinking, nondepressed chronic alcoholics, without evidence of liver 
disease or withdrawal. Most alcoholics in this study showed a blunted response to acute 
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intervening stress, including CRH, low dose ACTH, and metyrapone, a cortisol synthesis 
inhibitor, blockade suggesting that alcoholics have ethanol-induced HPA axis injury and 
perhaps cannot respond appropriately to nonethanol-induced stress. (Wand and Dobs, 
1991b). Additionally, the animal literature also suggests that chronic ethanol exposure 
can impair the ability of the HPA axis to respond to stress (Dave et al., 1986). 
 
Glucocorticoid Nongenomic Signaling Mechanisms 
Although it has long been recognized that steroid hormones exert their effects on 
neuronal function through their classical actions or their ability to modulate gene 
transcription in the nucleus, many glucocorticoid effects have been documented to occur 
in a fashion that cannot be explained by genomic regulation (de Kloet, 2000, Dallman, 
2005). Such findings have prompted the hypothesis that glucocorticoids possess 
membrane-associated receptors through which nongenomic signaling may evoke rapid 
effects on physiology and behavior and it is now believed that glucocorticoids exert their 
actions through both genomic and nongenomic pathways (Dallman, 2005, de Kloet, 
2000). In the 1990s, a high-affinity binding site for corticosterone, which seemed to meet 
all of the criteria for a functional membrane-associated corticosteroid receptor, was 
partially purified and characterized in neuronal membranes from the amphibian brain 
(Moore and Orchinik, 1994). The studies by Orchinik and Moore demonstrated that in the 
Taricha granulosa (a rough-skinned newt) glucocorticoid receptors were present in 
neuronal membranes and associated with G proteins to modulate intracellular signaling. 
In the newt, a clear bioassay was established in which glucocorticoids were found to 
dampen stimulus-induced neuronal activation of medullary neurons, which resulted in a 
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reduction of courtship clasping behavior, all of which occurred in a time span of 10 
minutes (Moore and Orchinik, 1994). These findings stimulated similar research in 
rodents, the result of which was an array of mixed findings that were less conclusive than 
the newt studies.  
The search for the mammalian membrane-bound glucocorticoid receptor had 
come to a halt, until a laboratory used in vitro electrophysiological recordings of neurons 
in the paraventricular nucleus of the rat hypothalamus to demonstrate that glucocorticoids 
rapidly suppressed glutamatergic release onto parvocellular neurons through a 
mechanism that involved postsynaptic activation of a membrane-bound glucocorticoid 
receptor (Di et al., 2003). Activation of this receptor launched a G protein signaling 
cascade that induced synthesis of endocannabinoid ligands, which traversed back across 
the synapse where they bound to presynaptic CB1 receptor localized on glutamatergic 
terminals and inhibited subsequent glutamate release (Di et al., 2003).  A pathway was 
defined in which glucocorticoids elicited a nongenomic induction of endocannabinoids, 
which in turn was the catalyst for glucocorticoids to modulate local neuronal transmission 
(Hill and McEwen, 2009). This model was also applied to the newt preparation and it was 
shown that the ability of glucocorticoids to inhibit sensory-evoked stimulation of 
medullary neurons and courtship clasping was also mediated by endocannabinoids in this 
model (Coddington et al., 2007). These studies integrated glucocorticoid activation of a 
membrane-bound G protein receptor and endocannabinoid synthesis that could inhibit 
neurotransmitter release.  
 
The Endocannabinoid System 
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The current project expanded to also investigate the nongenomic actions of 
glucocorticoids and this required additional knowledge of the endocannabinoid system. 
Δ9-tetrahydrocannabinol (THC), the active component of marijuana, as well as other 
exogenous and endogenous cannabinoids, have been demonstrated to bind to and activate 
two types of cannabinoid receptors that have been cloned, CB1 (Matsuda et al., 1990). 
and CB2 (Gerard et al., 1991). These receptors are members of the superfamily of G 
protein coupled receptors and exert their actions predominantly through Gi/o proteins 
(Howlett, 2002, Howlett, 2005). Cannabinoid receptor activation decreases cyclic 
adenosine monophosphate (cAMP) production via inhibition of adenylyl cyclase and they 
activate mitogen-activated protein kinase (Howlett, 1984, Howlett, 2004). Cannabinoid 
receptors also decrease Ca2+ conductance (Mackie and Hille, 1992, Caulfield and Brown, 
1992) and increase K+ conductance through inwardly-rectifying K+ channels (Mackie et 
al., 1995).  
CB1 receptors are distributed throughout the central nervous system and the 
periphery; whereas CB2 receptors are mainly associated with immune cells in both the 
CNS and periphery (Cabral and Marciano-Cabral, 2005, Van Sickle et al., 2005, Xi et al., 
2011). In particular, CB1 receptors are expressed at high densities in the hippocampus, 
frontal cortex, basal ganglia and cerebellum (Ong and Mackie, 1999). CB1 receptors are 
localized on presynaptic terminals of both GABAergic (Katona et al., 1999) and 
glutamatergic neurons (Huang et al., 2001, Szabo and Schlicker, 2005). It has been 
consistently shown that on-demand activation of CB1 receptors by their endogenous 
agonists, endocannabinoids (ECs), modulates the release of different neurotransmitters in 
many brain areas, including those involved in cognition, memory and maintenance of 
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mood, such as the hippocampus and the prefrontal cortex (Wilson and Nicoll, 2002, 
Freund et al., 2003). Depolarization-induced suppression of inhibition (DSI) occurs when 
cannabinoid receptor activation causes transient suppression of the inhibitory GABAergic 
synaptic events in a cell (Llano et al., 1991, Pitler and Alger, 1992). Conversely, when 
suppression of the transient stimulatory neurotransmitter (e.g. glutamate) occurs it is 
called depolarized-induced suppression of excitation (DSE) (Kreitzer and Regehr, 2001). 
Both result in cannabinoid receptor mediated hyperpolarization of a repetitively 
depolarized neuron, which suppresses subsequent vesicular fusion and release of 
glutamate or GABA. 
The two best-characterized endogenous CB1 receptor ligands include AEA and 2-
arachidonoylglycerol (2-AG) (Devane et al., 1992, Mechoulam et al., 1995). Both AEA 
and 2-AG are postsynaptically synthesized signaling molecules that are not stored in 
vesicles, but are generated on demand from membrane phospholipid precursors to act in a 
retrograde fashion on presynaptically localized CB1 receptors (Hill et al., 2010, Clapper 
et al., 2009). AEA is a partial agonist at CB1 and 2-AG is a full agonist (Ahern, 2003, 
Ahn et al., 2009, Long et al., 2009). The endogenous endocannabinoid signaling lifespan 
is regulated by ill-defined uptake processes and by intracellular hydrolysis of AEA by 
fatty acid amide hydrolase (FAAH) and 2-AG by monoacylglycerol lipase (MAG-L), 
respectively (Hill et al., 2010). Genetically engineered FAAH knockout (KO) mice are 
severely impaired in their ability to degrade AEA and exhibit 10- to 15-fold increases in 
brain AEA levels (Cravatt et al., 2001).  
 
Adeno-associated Virus Serotype 2 (AAV-2) 
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Gene therapy consists of the introduction of nucleic acid into a patient’s cells for a 
therapeutic purpose. Viruses can be used as gene-therapy vectors. Viruses used for gene 
therapy purposes include, among others, retroviruses (Miller, 1990, Miller and Rosman, 
1989), adenoviruses (Smith, 1995, Berkner, 1988) and adeno-associated viruses (Smith, 
1995, Miyake et al., 2012). Retroviruses are a class of enveloped viruses containing 
single-stranded RNA as the viral genome. Viral RNA is reverse transcribed to yield 
double-stranded DNA, which integrates at random into the host genome and is expressed 
in a wide variety of cell types over extended periods. Retroviral expression is limited to 
replicating cells (Smith, 1995, Vannucci et al., 2013). Adenoviruses are nonenveloped 
viruses containing linear double-stranded DNA that can infect both non-dividing and 
dividing cells. Adenoviruses display low pathogenicity and wide cellular tropism, but 
they are also highly immunogenic and this limits their use (Smith, 1995, Vannucci et al., 
2013). Adeno-associated virus is a linear, non-enveloped, single-stranded DNA virus that 
requires co-infection with certain other viruses to replicate. Wild type AAV can integrate 
into the host chromosome in a specific region of chromosome 19 in cells in the absence 
of helper virus. AAV provides long-term expression in both dividing and nondividing 
cells, is not known to cause disease and induces mild immune responses (Smith, 1995, 
Vannucci et al., 2013, Daya and Berns, 2008, Terzi and Zachariou, 2008). 
In our studies, we chose to use adeno-associated Virus (AAV) for gene delivery 
because of its long-term expression, lack of pathogenicity, and the virus’ ability to infect 
dividing and nondividing cells (Daya and Berns, 2008, Terzi and Zachariou, 2008). 
Twelve AAV serotypes with unique properties have been used to produce most 
expression vectors. The AAV-2 serotype shows CNS and liver specific expression and 
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enters the cell through the heparin sulfate proteoglycan (HSPG) receptors (Miyake et al., 
2012, Summerford and Samulski, 1998). Competition experiments have demonstrated 
that soluble heparin can block AAV-2 binding and transduction (Summerford and 
Samulski, 1998). Within the CNS, AAV-2 shows neuron specific expression (Daya and 
Berns, 2008, Terzi and Zachariou, 2008).  
Studies in our lab (Bhandari et al., 2012) and others have successfully used rAAV 
to over-express various proteins in the brain and alter behavioral responses. For example, 
Homer proteins are known to be important in calcium signaling events, glutamate 
receptor signaling/trafficking, and synaptic remodeling (Szumlinski et al., 2004). Homer2 
knockout mice show a phenotype similar to that of animals withdrawn from repeated 
cocaine administration and infusion of Homer2b-AAV into the NAC of Homer2 
knockout animals reverses this phenotype (Szumlinski et al., 2004). Furthermore, over 
expression of ΔFosB in the orbitofrontal cortex (OFC) sensitizes rats to the locomotor 
stimulant actions of cocaine (Winstanley et al., 2009). Animals over-expressing ΔFosB 
through the use of ΔFosB-AAV in the OFC appear pre-sensitized showing enhanced 
locomotor responses to acute cocaine which are indistinguishable from rats receiving 
chronic cocaine treatment (Winstanley et al., 2009). 
 
Serum Glucocorticoid Kinase I (Sgk1) 
Sgk1 is a glucocorticoid responsive gene involved in synaptic plasticity and 
learning and memory that is known to regulate the function of ion channels, play an 
important role in intracellular cross-talk, and allow the convergence of cell surface 
receptors, nuclear receptors, and cellular stress pathways (Firestone et al., 2003, Lee et 
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al., 2006, Ma et al., 2006, Tsai et al., 2002).  Sgk1 was identified in 1993 in a screen of 
glucocorticoid responsive genes in mammillary tumor cell lines (Webster et al., 1993). 
Since that time it has been identified as being transcriptionally controlled by a wide 
variety of additional hormones and regulators including the increase of cytosolic Ca2+ 
activity and NO, transforming growth factor β, interleukin 6, thrombin, endothelin, cell 
shrinkage, and Rett syndrome, to name a few (Lang et al., 2010, Meng et al., 2005, 
BelAiba et al., 2006, Wolf et al., 2006, Chen et al., 2009, Nuber et al., 2005). It is also 
known that Sgk1 availability and function are regulated transcriptionally, post-
transcriptionally and via post-translation modifications. It is phosphorylated and activated 
as a downstream action of both the PI 3-kinase pathway and the MAPK/ERK signaling 
pathways (Lee et al., 2006, Firestone et al., 2003). Activation of SGK1 after exposure to 
serum triggers entry of SGK1into the nucleus, whereas activation of SGK1 by 
glucocorticoids enhances cytosolic localization of the kinase (Firestone et al., 2003). 
Additionally, the phosphorylation and activation of Sgk1 by PDK1 may stimulate its 
entry into the nucleus (Park et al., 1999).  
It is now known that a single Sgk1 mRNA produces 4 different protein isoforms 
with different N-termini due to alternative sites of initiation of translation (Arteaga et al., 
2007).  The long isoforms, 49-kDa, 47-kDa, are more abundant, localize to the ER 
membrane, and are rapidly degraded (Arteaga et al., 2007).  The short isoforms, 45-kDa 
and 42-kDa, are expressed at low basal levels, have decreased protein turnover and 
localize to the cytoplasm and nucleus (Arteaga et al., 2007).  The isoforms have distinct 
functions as, for example, the 49-kDa isoform stimulates the epithelial sodium channel 
(ENaC) and the 42-kDa isoform phosphorylates glycogen synthase kinase-3β (GSK3 β) 
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(Arteaga et al., 2007). Sgk1 is expressed in the human pancreas, liver, heart, lung, 
skeletal muscle, placenta, kidney and brain (Waldegger et al., 1997). Two additional 
mammalian isoforms of Sgk have been identified, termed Sgk2 and Sgk3, and their 
catalytic domains share 80% amino acid sequence identity with one another and with 
Sgk1 (Kobayashi et al., 1999a). 
In addition to having additional isoforms and alternative sites of initiation of 
translation, alternative splicing produces two distinct isoforms of Sgk1 in the brain, Sgk1 
and Sgk1.1, that are driven by distinct promoters and differ in N-terminal exons (Arteaga 
et al., 2008).  Sgk1.1 is a brain-specific Sgk1 isoform that modulates the Acid-sensing ion 
channel 1 (ASIC1) and the δ-ENaC and is more stable than Sgk1 due to the absence of a 
proteasomal degradation signal in its N-terminus (Arteaga et al., 2008, Raikwar et al., 
2008, Wesch et al., 2010). Additionally, Sgk1.1 was recently found to regulate M-
current, which plays a central role in neuronal excitability (Miranda et al., 2013). Sgk1’s 
function has been most thoroughly characterized in the aldosterone-sensitive distal 
nephron (ASDN) where it is induced by aldosterone and modulates transcellular sodium 
reabsorption by activating the sodium/potassium ATPase and enhancing transport of 
ENaC channels to the cell surface (Vallon et al., 2005).   
In addition to regulating ion transport in the ASDN, Sgk1 plays an important role 
in modulating synaptic plasticity in the brain and spinal cord.  It is well documented that 
Sgk1 is involved in memory consolidation of spatial learning (Lee et al., 2006, Tsai et al., 
2002, Lee and Rivier, 1997) as well as neuronal plasticity and long-term potentiation in 
hippocampal neurons (Ma et al., 2006).  Sgk1 was also identified by microarray analysis 
and confirmed to be involved in synaptic plasticity in the spinal cord during induction 
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and maintenance of inflammatory pain states (Geranton et al., 2007).   
More recent studies have demonstrated a significant role for Sgk1 in the central 
nervous system, particularly the PFC. Sgk1 transcription is enhanced with neurological 
disorders (Wang et al., 2010) and neurodegenerative diseases (Schoenebeck et al., 2005). 
Wang et al. showed that SGK1 expression was enhanced in the temporal neocortex of 
patients with drug-refractory epilepsy and was also highly expressed in the rat brain 
during different phases of the epileptic process. Additionally, SGK1 expression was 
related with the elevation of the glutamate transporter EAAT3, and EAAT3 expression 
decreased following SGK1 knockdown (Wang et al., 2010). In neuronal disease, SGK1 
regulates glutamate transporters (Bohmer et al., 2004, Schniepp et al., 2004) and up-
regulates glutamate receptors (Liu et al., 2010). One group of researchers showed that 
corticosterone increased alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR)-mediated synaptic transmission and AMPAR membrane trafficking 
in PFC pyramidal neurons. This mechanism was dependent on SGK phosphorylation of 
the guanosine nucleotide dissociation inhibitor (GDI) at Ser-213. The GDI then formed a 
complex with Rab4 facilitating a cycle of Rab4 mediated recycling of AMPARs to the 
synaptic membrane (Liu et al., 2010). Additional studies from this group showed that 
acute stress induced a potentiation of glutamatergic transmission in the PFC through an 
SGK1/3-induced increase in the delivery of NMDARs and AMPARs to the synaptic 
membrane. More specifically, acute stress activated glucocorticoid receptors, which 
regulated Sgk1/3 expression, SGK1/3 activation of Rab4 increased the trafficking and 
function of NMDARs and AMPARs, and this process leads to potentiated synaptic 
transmission (Yuen et al., 2011). Finally, Miyata et al. showed that a chronic stress 
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paradigm that elevated plasma corticosterone levels similar to those found in depressed 
individuals lead to activation of the phosphatidylinositol 3-kinase (PI3K)-3-
phosphoinositide-dependent protein kinase (PDK1), Sgk1, and Ndrg1 pathway with 
increases in both Sgk1 mRNA and SGK1 phosphorylation (Miyata et al., 2011). 
The Miles’ laboratory previously showed that Sgk1, along with several other 
glucocorticoid responsive genes, was upregulated in PFC of D2 mice following acute 
ethanol exposure (Kerns et al., 2005a).  Other investigators have also shown Sgk1 
induction in the brain following acute ethanol (Treadwell and Singh, 2004, Piechota et 
al., 2010b), morphine (Piechota et al., 2010b), heroin (Piechota et al., 2010b), 
methamphetamine (Piechota et al., 2010b) or amphetamine (Gonzalez-Nicolini and 
McGinty, 2002).  Similar to findings in Kerns et al., Piechota et al. identified a group of 
genes (including Fkbp5 and Sgk1) that increased following ethanol and opioid 
administration that are controlled, in part, by the release of steroid hormones. After 
showing Sgk1 induction following acute ethanol, morphine, heroin, and 
methamphetamine, Piechota et al. showed that knockdown of Sgk1 resulted in alterations 
to dendritic spines in mice, possibly reflecting an altered potential for plastic changes 
(Piechota et al., 2010b). 	  
Locomotor Activation 
 
Drug-induced locomotor stimulation is a common response to many drugs of 
abuse, including ethanol, in rodents and is known to involve the mesocorticolimbic 
dopamine pathway (Boehm et al., 2002). It is known that 1 to 2 g/kg doses of ethanol 
stimulate locomotor activity in D2 mice and this stimulant response can be blocked by 
dopamine receptor antagonists (Boehm et al., 2002, King et al., 2002).  It has been 
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suggested that ethanol’s locomotor stimulating effects in rodents serve as a model of 
human ethanol-induced euphoria and arousal (Boehm et al., 2002, Palmer et al., 2002, 
Phillips et al., 2002) or the increased locomotion may represent heightened anxiety over 
the perception of ethanol’s physiological effects (Boehm et al., 2002). The idea that 
ethanol’s locomotor activating effects serve as a model of human ethanol-induced 
euphoria is interesting as Stewart, De Wit, and Eikelboom proposed that euphoric effects 
of drugs actually show sensitization rather than tolerance with repeated administration, 
whereas dysphoric effects tolerate (Stewart et al., 1984). Additionally, King et al. 
examined the acute subjective and objective effects of ethanol in heavy drinkers versus 
light drinkers and found that elevated initial sensitivity to the positive stimulant effects of 
alcohol is associated with greater alcohol consumption in humans and may be a predictor 
of the likelihood of an individual to develop alcoholism (King et al., 2002).   
Mouse lines that differ in sensitivity to ethanol’s locomotor activating effects 
have been produced via selective breeding and can be used to evaluate traits associated 
with the risk for high levels of alcohol consumption (Beckstead and Phillips, 2009).  
Although they exhibit little difference in basal locomotor activity, following ethanol 
treatment FAST-1 and 2 mice are more sensitive to ethanol’s locomotor stimulating 
properties and SLOW-1 and 2 mice are insensitive to ethanol’s locomotor activating 
properties—although it could also be said that the SLOW lines reflect greater sensitivity 
to ethanol-induced sedation (Boehm et al., 2002). FAST mice, those more sensitive to the 
stimulant effects of ethanol, consume more ethanol than SLOW mice (Beckstead and 
Phillips, 2009).  FAST AND SLOW mice show differences in HPA axis sensitivity 
(Boehm et al., 2002).  In a dose-response and time-course analysis of corticosterone 
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(Rosser et al.) levels in SLOW and FAST mice, saline treated SLOW mice returned to 
near basal CORT levels more quickly than saline treated FAST mice and SLOW mice 
showed significantly higher serum CORT levels at 45 and 90 minutes following 2 g/kg 
ethanol administration than 2 g/kg ethanol treated FAST mice (Boehm et al., 2002).  
FAST and SLOW mice show differences in dopamine levels in the mesolimbic dopamine 
pathways as FAST mice exhibit greater dopamine levels in the NAC than SLOW mice 
following both ethanol and cocaine treatment (Meyer et al., 2009).  The two mouse lines 
also show differences in dopaminergic neuron spontaneous firing in the ventral 
midbrain—the spontaneous firing rate being higher basally in FAST mice and 
significantly increased in FAST mice following acute ethanol administration (Beckstead 
and Phillips, 2009).  It is suspected that the difference in dopaminergic neuron firing is 
due to differences in nonselective cation conductance as blocking nonselective cation 
conductance can eliminate the difference in firing rate between FAST and SLOW mice 
(Beckstead and Phillips, 2009).  There were also differences in GABAergic input to 
dopamine neurons—the amplitude of GABAA inhibitory postsynaptic currents being 
significantly larger in midbrain dopamine neurons obtained from SLOW mice, but there 
was no difference in GABAA transmission between ethanol treated dopamine neurons 
obtained from FAST and SLOW mice (Beckstead and Phillips, 2009).  Thus, studies of 
ethanol induced acute locomotor activation can have predictive validity in terms of the 
liability for high levels of ethanol intake in animal models.  	  
Sensitization 	  
Behavioral sensitization, or the augmentation of the locomotor activating effects 
of a drug with repeated exposure, appears to be a common denominator across different 
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classes of addictive drugs, involves the mesocorticolimbic dopamine pathway and is a 
long-lasting change in the behavioral response to drugs (Lessov and Phillips, 2003, 
Phillips et al., 1997a).  Behavioral sensitization may be relevant to drug addiction 
because progressive enhancements of the incentive qualities of the drug, and associated 
stimuli, may mediate compulsive drug-seeking and drug-taking behavior (Phillips and 
Fibiger, 1990, Robinson and Berridge, 1993, Taylor and Horger, 1999). Both rodents and 
humans have been shown to sensitize to the locomotor activating properties of ethanol 
(Masur and Boerngen, 1980, Newlin and Thomson, 1991). While studies with human 
volunteers in which an abused drug was administered more than once have been rare, 
Newlin and Thomson found that sons of alcoholics tended to show chronic sensitization 
in finger pulse amplitude across sessions with alcohol, particularly in the early stages of 
the response to the drug (Newlin and Thomson, 1991). In contrast, low-risk participants, 
who reported no parental history of alcoholism, tended to demonstrate chronic tolerance 
to alcohol (Newlin and Thomson, 1991). Newlin and Thomson's model in which high-
risk individuals derive greater reward and euphoria from alcohol than do low-risk 
individuals in the rising alcohol curve is different from that described by Schuckit earlier 
in which high-risk participants have a blunted response to alcohol compared with low-
risk individuals (Newlin and Thomson, 1991, Schuckit, 1994). 
In animal models, sensitization can be separated into two phases, induction and 
expression (Harrison and Nobrega, 2009b).  The induction of behavioral sensitization 
includes the sequence of cellular events that leads to enduring changes in neural function 
(Harrison and Nobrega, 2009b).  Expression refers to the enduring neural alterations that 
occur following repeated drug administration (Harrison and Nobrega, 2009b).  
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Sensitization in animal models has been observed for psychostimulants, opioids, ethanol 
and stimulants such as nicotine suggesting that drugs of abuse may exert their effects 
through shared neural mechanisms (Lessov and Phillips, 2003).  Furthering the 
suggestion of common mechanisms among abused drugs is cross-sensitization, wherein 
pretreatment with one drug results in the sensitized response to another.  Cross-
sensitization has been observed between ethanol and other drugs of abuse including 
morphine and cocaine (Lessov and Phillips, 2003).  
Sensitization is known to involve drug induced changes in mesocorticolimbic 
dopaminergic projections and sensitization to the effects of psychostimulant drugs has 
been studied in the greatest detail (Roberts et al., 1995, Phillips et al., 1997a, Morice et 
al., 2010).  Dopaminergic system involvement in the sensitized response is clear as 
studies indicate that mice lacking the dopamine transporter (DAT knockout mice) do not 
sensitize to the locomotor activating effects of cocaine or d-amphetamine (Mead et al., 
2002, Spielewoy et al., 2001).  Furthermore, mice heterozygous for the vesicular 
monoamine transporter 2 (VMAT2) that is responsible for transporting monoamines, 
particularly neurotransmitters such as dopamine from the cytosol into vesicles, show a 
profound sensitivity to amphetamine following an initial acute treatment with the drug 
and they do not sensitize to the locomotor activating effects of the drug (Wang et al., 
1997, Uhl et al., 2000). D1 and D3 receptor knockout mice do not show a sensitized 
response to the locomotor activating effects of ethanol (Harrison and Nobrega, 2009a).  
DAT knockouts show increased acute ethanol evoked activity compared to WT and 
heterozygous littermates and do show a sensitized response following repeated ethanol 
administration (Morice et al., 2010). Mouse genetic background plays an important role 
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in sensitization studies and it should be mentioned that all knockouts and heterozygotes 
were on a C57 background except for DAT knockouts used in ethanol studies in which 
case both D2 and C57 DAT knockout mice were generated (Wang et al., 1997, Morice et 
al., 2010, Spielewoy et al., 2001, Takahashi et al., 1997, Uhl et al., 2000, Fukushima et 
al., 2007, Harrison and Nobrega, 2009a). D2 mice, not C57, are the strain of mouse best 
known to sensitize to the locomotor activating effects of ethanol and ethanol-induced 
sensitization was potentiated in DAT knockout mice on a D2 background (Phillips et al., 
1997a).  It is also important to note that results in knockout animals could be due to 
compensatory mechanisms or altered developmental events known to occur in these 
animals.   
Studies investigating the mechanisms mediating ethanol sensitization not 
involving knockout animals have yielded conflicting and diverse results.  For example, 
cross-sensitization was observed between the dopamine uptake inhibitor GBR 12909 and 
ethanol, but not the weaker dopamine uptake inhibitor bupropion (Broadbent et al., 
2005).  The D2/D3 receptor agonist quinpirole did not produce cross-sensitization with 
ethanol in D2 mice, but ethanol-sensitized genetically heterogeneous Swiss mice showed 
increased dopamine D2 receptor binding in the caudate-putamen compared to saline-
treated and ethanol-treated non sensitized Swiss control mice (Broadbent et al., 2005, 
Souza-Formigoni et al., 1999).  The GABAA agonist, THIP, had no effect on the 
development of ethanol induced locomotor sensitization in D2 mice, whereas the GABAB 
agonist, baclofen, blocked the development of ethanol induced locomotor sensitization 
(Broadbent et al., 2003). In male D2 and Swiss albino mice, the uncompetitive NMDA 
receptor antagonist MK-801 blocked the expression of ethanol-induced sensitization 
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(Broadbent et al., 2003, Kotlinska et al., 2006).  However, in D2 mice Broadbent et al. 
showed that MK-801 reduced the stimulant effects of ethanol suggesting it is possible 
that MK-801’s ability to block the expression of sensitization may represent a non-
specific suppression of locomotor activity (Broadbent et al., 2003).  In male D2 mice, the 
NR2B selective uncompetitive NMDA antagonist ifenodil did not effect the expression of 
sensitization and the non-NMDA glutamate receptor antagonists DNQX and GYKI 
52466 decreased or blocked the expression of ethanol sensitization, respectively 
(Kotlinska et al., 2006).  But, GYKI 52466 also reduced the locomotor activity of control 
saline treated animals at the same doses at which it blocked the expression of ethanol 
sensitization (Broadbent et al., 2003).  Again, the differing genotypes of mice used in the 
above studies could account for some of the differences observed, but overall the 
mechanism behind ethanol sensitization appears complex and remains illusive. 
It has been suggested that HPA axis activation is a common pathway by which 
abused drugs induce neuroadaptations leading to sensitization (Roberts et al., 1995, 
Pastor et al., 2008). The HPA axis may play a role in the sensitized response as 
glucocorticoid receptor antagonists or adenalectomy block the induction, respectively, of 
ethanol or psychostimulant locomotor sensitization and stress can substitute for drug 
administration in cross sensitization studies (Roberts et al., 1995, Deroche et al., 1995). 
We were unable to replicate the findings of Roberts et al. in which glucocorticoid 
receptor antagonists block the induction of ethanol sensitization in our own recent 
studies, but we do recognize this could be due to methodological differences (Costin et 
al., 2012). Glucocorticoid receptor antagonists do not block the expression of behavioral 
sensitization to ethanol (Pastor et al., 2008).   
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It is hypothesized that extrahypothalamic central CRH/ CRH 1 may play a large 
role in the expression of ethanol sensitization.  Extrahypothalamic CRH refers to CRH 
that acts outside of the HPA axis to control autonomic and behavioral responses (Koob, 
2010). CRH-like immunoreactivity is present in the neocortex, extended amygdala, 
medial septum, hypothalamus, thalamus, cerebellum and ventral tegmental area (Koob, 
2010). CRH1 and CRH1+2 receptor double knockout mice do not show psychomotor 
sensitization to ethanol, however CRH2 knockout mice do show a sensitized response to 
ethanol (Pastor et al., 2008).  In one study by Pastor et al., CRH1 antagonists attenuated 
the induction and prevented the expression of ethanol induced sensitization (Pastor et al., 
2008).  However, in an earlier study by Fee et al. CRH1 antagonists did not attenuate the 
induction of ethanol sensitization, but did block the expression of ethanol mediated 
sensitization (Fee et al., 2007).  It is suggested that the different findings in these two 
works can be attributed to different doses of the CRH1 antagonist CP-154,526 
administered as Pastor et al. administered 30 mg/kg of the CRH1 receptor antagonist and 
Fee et al. only administered 10 mg/kg CRH1 receptor antagonist in studies examining the 
effects of CP-154, 526 on the initiation of ethanol sensitization (Fee et al., 2007, Pastor et 
al., 2008).  Doses up to 10 mg/kg may not be adequate for full CRH1 receptor occupancy 
and the 30 mg/kg dose of CP-154,526 did not effect locomotor activation in Pastor et al. 
(Pastor et al., 2008).  
Behavioral sensitization to drugs of abuse may involve learning processes as the 
initiation and expression of behavioral sensitization can be largely influenced by 
contextual cues surrounding drug administration. Some authors have even suggested that 
neuroadaptations underlying behavioral sensitization may be closely related to those 
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mediating learning and memory processes (Trujillo and Akil, 1995). In mice, ethanol-
induced locomotor sensitization is potentiated by repeated pairing of ethanol injections 
and the testing chamber (Quadros et al., 2003). Other reports also document that the 
expression of sensitization can be context-speciﬁc (Pert et al., 1990, Badiani et al., 1995a, 
Badiani et al., 2000). In discussing the experimental design for such studies, there are 
typically three groups of animals, animals in the Paired group, animals in the Unpaired 
group and Control animals. The animals in the Paired group are transported from their 
home cage to a unique test environment, where they receive drug treatments. Animals in 
the Paired group usually also receive an injection of saline in their home cage. Animals 
the Unpaired group receive saline in the test environment and the drug later, in their 
home cage. Control animals receive saline in both the test environment and at home. On 
test day, all animals receive a challenge injection of the drug in the test environment. In 
many studies of this kind, sensitization is expressed in the Paired group, but not the 
Unpaired group. Thus, sensitization is said to be context-speciﬁc because it is expressed 
only in the group that previously experienced the drug in the test environment (Robinson 
et al., 1998).  
 
Thesis Objectives 
We hypothesize that glucocorticoids and glucocorticoid responsive genes are responsible 
for modulating acute and chronic cellular and behavioral responses to ethanol including 
locomotor activation and ethanol sensitization. In particular, because Sgk1 is regulated by 
ethanol, has a well-established role in learning and memory and is responsive to 
glucocorticoid signaling we hypothesize that Sgk1 is involved in modulating acute and 
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chronic cellular and behavioral responses to ethanol, specifically ethanol sensitization. 
This hypothesis will tested in the following specific aims:  
1) Determine the role of HPA axis signaling in regulating ethanol related 
behaviors. 
2) Examine the role of the endocannabinoid system in regulating the HPA axis 
following ethanol administration. 
3) Investigate the role of HPA axis signaling in ethanol regulation of Sgk1 in the 
PFC. Further characterize ethanol regulation of Sgk1 mRNA and SGK1 
protein in the PFC of DBA/2J mice.  
4) Explore the role Sgk1 may play in ethanol induced locomotor activation and 
sensitization through the viral overexpression of Sgk1 in the PFC of DBA/2J 
mice. 
Figure 1: Above we present a simplified model of part of our hypothesis. Ethanol 
activates the HPA axis leading to the release of corticosterone (S) in mice. Corticosterone 
acts at the glucocorticoid receptor (GR) which resides in the cytoplasm of the cell bound 
to chaperone proteins (HSP90) in its inactive state. Steroid hormones bind to the 
glucocorticoid receptor causing a change in receptor confirmation (as indicated by the 
change in the receptor shape above), induce GR nuclear translocation and activate 
transcription of target genes containing a Glucocorticoid Response Element (GRE). Sgk1 
is a glucocorticoid responsive gene with a GRE in its promoter. We hypothesize that 
Sgk1 upregulation in the prefrontal cortex may be a downstream effect of HPA axis 
activation by ethanol and may ultimately modulate behavioral responses to ethanol. 
 
effects of the drugs following acute treatment.  VMAT2 heterozygotes also show super sensitivity in their 
ethanol response demonstrating enhanced locomotor activation following acute ethanol administration [5].  It is 
suggested that this sensitivity to acute doses of drug in VMAT2 heterozygotes is due to postsynaptic dopamine 
receptor super sensitivity which likely occurs due to modified cell signaling events [5, 45, 61].  The hypothesis 
that enhanced locomotor responses are due to dopamine receptor super sensitivity caused by cell signaling 
events is supported by the fact that the enhanced response to c caine can be blocked by D1 and D2 dopamine 
receptor antagonists and striatal dopamine D1 and D2
Based on current knowledge of ethanol’s effects on the PFC, HPA axis, Sgk1 and our preliminary data, 
we hypothesize that Sgk1 is involved in modulating acute and chronic behavioral responses to ethanol.  We 
established through microarray analysis of the mesocorticolimbic dopamine pathway that Sgk1, along with 
other glucocorticoid responsive genes, is upregulated in the PFC of D2 mice.  Because Sgk1 is a known 
glucocorticoid responsive gene and because other glucocorticoid responsive genes were also identified as 
ethanol responsive targets in the PFC, we believe that Sgk1 upregulation may be a downstream effect of HPA 
axis activation by etha ol (Fig re 3).  We will test our hypotheses b th by behavioral and pharmacological 
measures.  This work could contribute to understanding of the molecular mechanisms underlying alcoholism 
and eventually influence development of novel pharmacological agents for alcoholism or ethanol-related 
neurological disorders. 
 receptor mRNA was not altered [5, 45, 61].   
Figure 3:  Model of Hypothesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental Approach and Methods. 
Specific Aim 1:  Characterize ethanol regulation of Sgk1 in the PFC of D2 mice. 
 
R tionale:  The relation hip betw en Sgk1 and ethanol has yet to be ext nsively investigated.  Preliminary 
results indicate Sgk1 mRNA is increased up to 3 fold in the frontal pole of D2 mice at 2-4 hrs following acute 
ethanol treatment (4 g/kg; Figure 1).  It is known that there are 5 total isoforms of Sgk1—4 resulting from 
translational processing of Sgk1 weighing 49-kDa, 47-kDa, 45-kDa and 42-kDa and 1 (Sgk1.1) resulting from 
alternative promoter utilization and splicing [20, 21].  It is our goal to investigate Sgk1’s ethanol response by 
measuring Sgk1 translational isoform levels following acute ethanol exposure through Western blotting 
followed by densitometry analysis.  The isoforms Sgk1 and Sgk1.1 are driven by distinct promoters, result from 
alternative splicing and differ in N-terminal exons [21].  Previous microarrays would not have differentiated 
between Sgk1 and Sgk1.1 due to their C-terminal similarities.  Therefore it is possible that Sgk1.1 is also 
regulated by ethanol.  Through the use of Q-rtPCR, we want to measure levels of Sgk1 and Sgk1.1 in 
response to acute ethanol. We will focus our work on PFC since our prior microarray studies identified the 
most prominent Sgk1 induction by ethanol in that brain region [10].   
This series of experiments will indicate which isoforms of Sgk1 are most prominent following acute 
ethanol treatment and help to elucidate ethanol’s cellular mechanism of action.  If following ethanol treatment, 
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CHAPTER 3 
Role of Adrenal Glucocorticoid Signaling in Prefrontal Cortex Gene Expression and 
Acute Behavioral Responses to Ethanol 
INTRODUCTION 
Ethanol and other drugs of abuse acutely activate the hypothalamic pituitary 
adrenal (HPA) axis leading to glucocorticoid release (Piechota et al., 2010b), and 
alcoholics show a blunted HPA axis while drinking and upon withdrawal (Costa et al., 
1996, Wand and Dobs, 1991a).  Glucocorticoid hormones are the final step in activation 
of the HPA axis and are known to function in the biological response to stress and 
circadian activity (Marinelli et al., 1997, De Kloet et al., 1998).  Not only do 
glucocorticoids regulate the stress response, but their feedback regulation helps to 
terminate HPA activation (De Kloet et al., 1998). 
Drug-induced locomotor stimulation is a common acute response to drugs of 
abuse, including ethanol, in rodents (Boehm et al., 2002, Phillips et al., 1992). It is 
suggested that ethanol’s locomotor stimulation in rodents serves as a model of human 
ethanol-induced euphoria and arousal (Boehm et al., 2002, Palmer et al., 2002, Phillips et 
al., 1992).  Behavioral sensitization, a long-lasting augmentation of the locomotor 
activating effects of a drug with repeated exposure, also occurs across different classes of 
addictive drugs, and represents a form of neural plasticity affecting chronic behavioral 
responses to ethanol and other drugs (Phillips et al., 1997a). Sensitization has been 
observed for psychostimulants, opioids, and ethanol, suggesting that drugs of abuse may 
exert effects on neural plasticity through shared mechanisms (Lessov and Phillips, 2003).  
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It has been suggested that HPA axis activation is a common pathway by which 
abused drugs induce neuroadaptations leading to sensitization (Deroche et al., 1995, 
Roberts et al., 1995, Piechota et al., 2010b). Studies have shown that the HPA axis plays 
a role in the sensitized response as stress can substitute for drug administration in cross 
sensitization studies and adrenalectomy blocks the induction of psychostimulant 
locomotor sensitization (Roberts et al., 1995, Deroche et al., 1995).  However, not all 
studies with adrenalectomized (ADX) animals have reached the same conclusion. 
Badiani et al. found that ADX does not alter amphetamine sensitization (Badiani et al., 
1995b) and Prasad et al. showed that corticosterone does not mediate long term cocaine 
sensitization  (Prasad et al., 1998).  
Our laboratory and others have used genome-wide expression profiling to identify 
gene networks functioning in acute and chronic behavioral responses to ethanol (Kerns et 
al., 2005a, Treadwell and Singh, 2004, Wolstenholme et al., 2011).  We previously 
identified a group of genes prominently regulated by acute ethanol in prefrontal cortex 
(PFC) of DBA2/J (D2) mice, but not C57BL/6 mice (Kerns et al., 2005b). Contained in 
this group were well-characterized glucocorticoid responsive genes such as Fkbp5 and 
Sgk1.  D2 mice show a robust locomotor activation response following acute ethanol 
administration, and reliably show locomotor sensitization upon repeated ethanol (Phillips 
et al., 1997a), whereas C57 mice do neither.  Taken together, these results and prior work 
by Phillips and colleagues (Phillips et al., 1997b) suggests that glucocorticoid signaling 
might play a role in modulating acute ethanol locomotor activation and the initiation of 
locomotor sensitization.  Here we have further studied the relationship between 
glucocorticoid signaling and acute ethanol locomotor activation. Our results show that 
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glucocorticoid signaling and glucocorticoid-responsive genes may represent an important 
endophenotype modulating the acute response to ethanol. 
 
MATERIALS AND METHODS 
Animals 
Mice were maintained in a temperature controlled room (23±1°C) with 12 h light/dark 
cycles and free access to standard chow (Harlan Teklad #7912, Madison, WI) and water.  
Cages and bedding (Harlan Sani-chips, #7090A, Harlan, Teklad, Madison, WI) were 
changed weekly.  All tests were carried out between 0900 and 1200 h. Procedures were 
approved by the Institutional Animal Care and Use Committee of Virginia 
Commonwealth University and followed the NIH Guide for the Care and Use of 
Laboratory Animals. All mice were DBA2/J mice from Jackson Laboratories (Bar 
Harbor, Maine) purchased at 10-13 weeks of age. ADX and SHAM mice were 
adrenalectomized or SHAM treated at Jackson and delivered following recovery from 
surgery.  ADX mice were supplemented with 1% w/v saline solution in their drinking 
water.  All mice were allowed to habituate to the animal facility for at least 1 week prior 
to testing.  
Adrenalectomy 
All adrenalectomies and SHAM procedures were conducted using aseptic and atraumatic 
surgical techniques at Jackson laboratories and were approved by the institution’s Animal 
Care and Use Committee. Surgeries were performed using the lateral abdominal 
approach. Left and right adrenal glands were removed through separate incisions. The 
animals were anesthetized using tribromoethanol and carprofen was administered for 
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analgesia and the surgical site was prepared. The animals were placed in right lateral 
recumbency and a 5-8mm incision was made parallel and ventral to the spine and 
midway between the last rib and iliac crest. The underlying muscle was opened and the 
adrenal gland was located cranial to the left kidney. The adrenal gland was grasped with 
ring forceps and exteriorized.  The adrenal and adjacent adipose tissues were excised. 
The incisions in the abdominal wall and skin were closed separately. Bupivacaine was 
applied topically to the incision site for local analgesia. Skin closure material was 
removed prior to shipment. The same procedure was followed for excision of the right 
adrenal gland except the skin incision was made immediately caudal to the last rib. This 
adjustment was necessary to accommodate for the more cranial location of the right 
adrenal gland relative to the left in the abdomen. 
Drugs 
All drugs were administered intraperitoneally (i.p.). Saline solutions were 0.9% w/v 
sterile saline.  Ethanol solutions were prepared from 200-proof absolute anhydrous 
ethanol (Pharmco-Aaper brand, Brookfield, CT).  Ethanol was administered at 20% v/v 
in 0.9% saline.  RU-486 (Sigma, St. Louis, MO), was dissolved by sonication in 20% w/v 
beta-cyclodextrin (Sigma, St. Louis, MO). 
Behavioral Testing 
Mice were habituated to injections with saline in their home cage for 2 days prior to 
experiments and allowed a 1-hour acclimation period to the behavioral room prior to 
testing.  Locomotor activity was measured immediately following injection with either 
saline or ethanol during a 10-minute session in locomotor activity chambers (Med-
Associates, model ENV-515; St. Albans, VT).  Loss-of-righting reflex (LORR) assays 
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were done following 3.8 g/kg ethanol administration.  After ethanol injection, mice were 
returned to their home cage until they exhibited LORR as defined by the inability to right 
themselves three times in 30 seconds after placement in the supine position in a V-shaped 
trough. The duration of LORR was calculated by subtracting time of onset of LORR from 
the time at recovery from LORR.  Anxiety testing was done using the light-dark 
transition model (Crawley and Goodwin, 1980).  Five behavioral experiments were 
performed:   
Exp. 1 -- Glucocorticoid receptor blockade by RU-486 and acute locomotor 
responses to ethanol:  Six groups of mice (n = 7-9) were treated as follows: vehicle + 
saline (VS), vehicle + 2 g/kg ethanol (VE), 20 mg/kg RU + saline (RU20 S), 20 mg/kg 
RU + 2 g/kg ethanol (RU20 E), 35 mg/kg RU + saline (RU35 S), and 35 mg/kg RU + 2 
g/kg ethanol (RU35 E).  On test day 3, RU-486 was administered 30 minutes prior to 
ethanol or saline.  Control mice received vehicle followed by saline or ethanol.  
Measurement of locomotor activity was performed as described above.   
Exp. 2 -- Ethanol acute locomotor activation and sensitization following ADX:  ADX 
and control animals (n=14-30) received one of three treatments: saline-saline (SS), saline-
ethanol (SE) or ethanol-ethanol (EE) (Table 1).  Animals were tested on day 3 for acute 
responses to either saline (SS, SE) or ethanol (EE).  The dose of ethanol used for test 
days (days 3 and 14) was 2.0 g/kg.  On days 4-13, animals received daily injections in 
their home cages of either saline (SS, SE) or 2.5 g/kg ethanol (EE).  On test day 14 the SS 
group received saline, the SE group received ethanol and the EE group received ethanol 
as on day 3.   
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Exp. 3 -- Effects of RU-486 on initiation of ethanol sensitization:  Four groups of D2 
mice (n = 9) were treated according to the sensitization protocol and either vehicle or 
RU-486 pretreatment was administered prior to drug:  vehicle + saline, RU + saline, 
vehicle + ethanol and RU + ethanol.  On test day 3, vehicle or 25 mg/kg of RU-486 was 
administered 30 minutes prior to 2.0 g/kg ethanol or saline.  Days 4-13 mice received 
vehicle + saline (VS) or 2.5 g/kg ethanol (VE), or 25 mg/kg RU-486 + saline (RS) or 
ethanol (RE).  On day 14, only vehicle pretreatment was administered for all groups and 
locomotor activation was measured as described above in response to saline (VS, RS) or 
2 g/kg ethanol (VE, RE).  
Exp. 4 -- Anxiolytic-like response to ethanol following ADX: ADX and SHAM mice 
were tested in the light-dark transition model of anxiety.  Testing took place in locomotor 
activity chambers described above with a black plastic partition inserted, dividing the 
chamber in half.  SHAM and ADX mice (n=12-14) were restrained in a conical tube for 
15 minutes, removed, injected with either saline or ethanol and placed into activity 
chambers facing the dark compartment. 
Exp. 5 -- The Effect of ADX or RU-486 on Ethanol-Induced Loss of Righting Reflex 
(LORR):  Mice (n = 6-7) were either adrenalectomized or injected with 35 mg/kg RU-
486 prior to injection with ethanol and LORR measurement.  Treatment groups include: 
ADX, 3.8 g/kg ethanol; SHAM, 3.8 g/kg ethanol; RU-486, 3.8 g/kg ethanol; VEH, 3.8 
g/kg ethanol.  RU-486 and VEH were administered 30 minutes prior to ethanol.  
Radioimmunoassay (RIA) 
Four hours following ethanol or saline administration in behavioral Exp. 1, trunk blood 
was collected from individual mice.  Serum was isolated by centrifugation at 2500 x g for 
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15 minutes and stored at -80°C until RIA.  A RIA containing I125 labeled corticosterone 
(MP Biomedicals, Cleveland, Ohio) was performed according to the manufacturer’s 
instructions. 
Brain Micropunch Dissection 
Four hours following ethanol or saline administration in Exp. 1 at the time of blood 
collection, brain tissue was also collected.  In a separate experiment, ADX and SHAM 
D2 mice (n = 4-5) were habituated to handling for two days, on day 3 they were 
sacrificed and brains were extracted.  Collection of brain tissue occurred exactly as 
described in Kerns et al. (Kerns et al., 2005a).  The medial prefrontal cortex (PFC) 
dissection contained tissue from the dorsal and ventral anterior cingulate and some 
secondary motor cortex.  
RNA Isolation and Microarray Hybridization 
RNA was isolated from PFC tissue samples using the RNeasy Protect Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions.  RNA concentration and 
quality was assessed by Experion automated electrophoresis (BioRad, Hercules, CA).  
100ng total RNA were transcribed into double-stranded cDNA using the GeneChip® 3’ 
IVT Express Kit (Affymetrix, Santa Clara, CA).  Biotin-labeled cRNA was synthesized 
from cDNA, purified and fragmented according to the manufacturer’s instructions.  
Labeled cRNA from individual animals (n=3/group) was hybridized to a single 
microarray.  Samples were analyzed with oligonucleotide arrays (Affymetrix Mouse 
Genome 430A 2.0 array) with array hybridization and scanning performed according to 
the manufacturer.  
Microarray and Bioinformatics Analysis 
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Microarray data were processed using GeneChip Operating Software v4.1 (GCOS, 
Affymetrix) and normalized to a mean total hybridization intensity of 190.  Array quality 
was assessed by accepting arrays with a scaling factor < 3, 3’–5’ actin ratio < 2, and by 
examining chip validity and linearity.  Chip-chip correlations all exceeded 0.98 and 
percent present calls by the Affymetrix GCOS software were greater than 58% for all 
arrays.  Probesets with RMA expression values < 3.5 consistently across all microarrays 
were filtered to reduce variance from low expressing genes.   Differential gene expression 
between ADX and SHAM treated mice was assessed using the R (R Development Core 
Team, 2011) implementation of the S-score algorithm (Kennedy et al., 2006). For a 
single gene, an |S-score| > 2 corresponds to a p-value < 0.05.  We used the Benjamini-
Hochberg false discovery rate (FDR) method to calculate q-values for all S-scores.  The 
differential expression of genes with q-values < 0.05 were considered statistically 
significant.  Additional bioinformatics analyses were performed using Toppgene 
(http://toppgene.cchmc.org/) with a Bonferroni correction and p-value cutoff of 0.05. The 
networks were generated through the use of IPA (Ingenuity® Systems, 
www.ingenuity.com).  
Quantitative Real Time Polymerase Chain Reaction (Q-rtRCR) 
cDNA was generated from 1 mg total RNA by reverse transcription with the iScript 
CDNA kit (Bio-Rad, Hercules, CA) following the manufacturer’s instructions. Q-rtPCR 
was performed using the iCycler iQTM system (Bio-Rad) according to the 
manufacturer’s instructions for SYBR Green I-based detection.  Quantification of gene 
expression levels was determined based on the threshold cycle for each well using the 
provided software and all results were normalized to multiple reference genes using 
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Genorm as described in Vandesompele et al. (Vandesompele et al., 2002).  Primers used 
were as follows, Fkbp5 (Forward-GCCGACTGTGTGTGTAATGC and Reverse-
CACAATACGCACTTGGGAGA), Gpr6 (Forward-CCTCATCTTACACTTCGTGTTCC 
and Reverse-GGTCCACTGTGATAGCAAGCA), Gapdh (Forward-
TTCCAGTATGACTCCACTCACGG and Reverse-
TGAAGACACCAGTAGACTCCACGAC), Ppp2r2a (Forward-
ATCTCTCACCCTTGCCCTTT and Reverse-CCCATTTTGTGTGCTTTCGT), Ublcp1 
(Forward-ATGACAGGGACAGGACAAGC and Reverse-
TACAATGACACCCGACTGGA), and Ndufv1 (Forward- GACCGTGCTAATGGACTTCG 
and Reverse-GGCATCTCCCTTCACAAATC). 
Blood Ethanol Concentrations 
ADX and SHAM D2 animals were treated with 2 g/kg ethanol and harvested 10 min., 1 
hour, 2 hours and 4 hours following ethanol administration (n = 9-10/group; 78 mice 
total).  D2 animals were pretreated with vehicle (VEH) or 35 mg/kg RU-486 30 minutes 
prior to being treated with 2 g/kg ethanol and harvested 10 min., 1 hour, 2 hours and 4 
hours following ethanol administration (n = 5-6/group; 48 mice total). Blood ethanol 
concentrations were measured by capillary column headspace gas chromatography.   
Corticosterone Time Course  
D2 mice were treated with saline or ethanol and harvested 5 minutes, 10 minutes, 1 hour 
and 2 hours following ethanol administration (n = 5-6/group; 52 mice total) and a RIA 
was performed to measure corticosterone levels.   
Statistics 
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Data were expressed as mean ± SEM and analyzed parametrically.  Data were analyzed 
with analysis of variance (ANOVA) or Kruskal-Wallis One Way Analysis of Variance on 
Ranks (jump counts) using appropriate between-and within subject factors.  All post hoc 
comparisons were made using Student Newman-Keul’s test or Dunn’s test (rank 
transformed, uneven sample number analysis). Values of p < 0.05 were considered 
statistically significant.   
 
RESULTS 
Ethanol-induced acute locomotor response following RU-486. 
The effect of two different doses of RU-486 on ethanol-induced locomotor activation was 
tested in Exp. 1. A one-way ANOVA showed a significant effect of treatment (F5,42 = 
20.88, p < 0.01).  Post-hoc analysis identified no difference between VS, RU20 S or 
RU35 S groups showing that RU-486 had no effect on basal locomotor activity (Fig. 2A).  
A significant increase in locomotor activity compared to saline controls was found with 
VE, RU20 E and RU35 E treatments, confirming locomotor activation following acute 
ethanol.  VE and RU20 E groups showed significantly greater locomotor activity 
compared to RU35 E treated animals indicating that higher doses of RU-486 blunted the 
locomotor activating effect of ethanol while having no effect on basal activity.  In 
examining corticosterone levels in mice following RU treatment, a one-way ANOVA 
showed a significant effect of treatment (F5,26 = 13.42, p < 0.01) and post-hoc analysis 
revealed significant increases in corticosterone levels in animals treated with R20 E, R35 
S and R35 E compared to those treated with VS, VE and R20 S (Fig. 2B). 
 
61	  	  
Acute locomotor activation and sensitization following adrenalectomy. 
Acute and repeated ethanol exposure was studied in a sensitization protocol (Table 1) 
with SHAM and ADX treated D2 mice.  A mixed model repeated measures ANOVA 
(phenotype x treatment x time) showed an overall effect of time (F1,112 = 212.14, p < 
0.01) indicating that both SHAM and ADX treated mice sensitized to the locomotor 
activating effects of ethanol (Fig. 3A.).  A two-way ANOVA (phenotype x treatment) 
evaluating animals on just day 3 of sensitization studies showed a significant effect of 
phenotype (F1,115 = 6.20, p < 0.01), treatment (F1,115 = 167.61, p < 0.01) and a significant 
interaction (F1,115 = 4.87, p < 0.03).  Both ADX and control animals showed locomotor 
activation following ethanol treatment.  Post-hoc analysis identified significant 
differences between ethanol treatment in ADX vs. SHAM, with ADX animals exhibiting 
a blunted locomotor activation response.  This suggests that ADX, like treatment with 
RU-486, blunted the ethanol-induced acute locomotor activation response while having 
no effect on basal locomotor activity.  A two-way ANOVA (phenotype x treatment) 
evaluating animals on day 14 of sensitization studies showed a significant effect of 
phenotype (F1,112 = 5.40, p < 0.05) and treatment (F1,112 = 153.45, p < 0.01), but no 
significant interaction.  Post-hoc analysis showed that while both SHAM and ADX 
animals sensitized to the locomotor activating effects of ethanol, chronically ethanol 
treated ADX mice showed a blunted locomotor activation response on day 14 of 
sensitization, similar to day 3.  These results suggest that ADX blunted the locomotor 
activating properties of ethanol in naïve and sensitized animals, but had no effect on 
sensitization per se. 
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SHAM and ADX mice treated with repeated ethanol also sensitized to jump 
counts (Fig. 3B.).  Both groups of mice showed significant increases in jump counts on 
day 14 of sensitization studies compared to day 3.  Acute ethanol (day 3 or day 14) 
completely abrogated jumping, whereas chronically ethanol treated mice showed jump 
counts similar to saline controls. 
 
Initiation of ethanol sensitization following RU-486 treatment. 
To determine whether direct glucocorticoid receptor blockade altered the initiation of 
ethanol sensitization, we pre-treated mice with RU-486 (25 mg/kg) or vehicle prior to 
saline or ethanol injections during the initiation phase of sensitization (Table 1).  From 
our earlier acute studies (Fig. 2), we hypothesized 25 mg/kg RU-486 was a dose of drug 
that would antagonize the GR without producing the effects on acute locomotor activity 
seen at 35 mg/kg in Fig. 1.  A mixed model repeated measures ANOVA showed a 
significant effect of treatment (F3,32 = 182.02, p < 0.01), day (F1,32 = 47.98, p < 0.01) and 
a significant interaction (treatment x day) (F3,32 = 20.42, p < 0.01) (Fig. 4A.).  Post-hoc 
analysis revealed that both vehicle and RU pre-treated mice showed significant increases 
in locomotor activation following ethanol treatment on day 3 of sensitization studies.  
Both groups of mice also showed significant increases in locomotor activation on day 14 
of sensitization studies compared to day 3, indicating both groups of mice sensitized to 
the locomotor activating effects of ethanol.  There were no differences between RU and 
VEH pre-treated animals on day 14 of sensitization studies, indicating that RU-486 had 
no effect on the initiation of the sensitized response.  Like SHAM and ADX treated 
animals, RU pre-treated animals also sensitized to jump counts (Fig. 4B.).    Both groups 
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of mice showed significant increases in jump counts on day 14 compared to day 3.   
 
Ethanol-induced anxiolysis and LORR responses to ADX or RU-486. 
To determine if glucocorticoid receptor blockade or adrenalectomy affected acute 
responses to ethanol other than locomotor activity, we tested anxiolytic-like responses to 
ethanol (2g/kg) or incoordinating responses to ethanol (3.8 g/kg).  A two-way ANOVA 
(phenotype x treatment) revealed an overall effect of treatment for % distance traveled in 
the light (F1,49 = 17.80, p < 0.01) and % time spent in the light (F1,49 = 24.46, p < 0.01), 
but no differences between phenotypes and no interaction (Figs. 5A-B).  Post-hoc 
analysis showed that both ethanol-treated ADX and SHAM animals spent a significantly 
greater percentage of time and traveled a larger distance in the light compared to saline 
treated control animals.  A student’s t-test between ADX vs. SHAM mice and RU-486 
vs. VEH pre-treated mice revealed no significant differences in the time taken to recover 
the righting reflex (Fig. 5C, D).   
 
Microarray analysis of ADX-induced changes in PFC gene expression.   
The data presented above suggests that glucocorticoid signaling modulates acute 
locomotor activation by ethanol. To initiate studies on the brain mechanisms that might 
underlie this action, we performed a study of gene expression in the PFC regulated by 
ADX. We reasoned that ADX-responsive genes might be involved in the mechanism of 
glucocorticoid modulation of acute ethanol locomotor activation. We chose the PFC for 
expression studies due to the known feedback interaction between the PFC and dopamine 
signaling (Durstewitz et al., 2000); because the PFC is well characterized as a 
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glucocorticoid-responsive brain region (Mizoguchi et al., 2003); and our prior microarray 
studies showed induction of a number of glucocorticoid-responsive genes by acute 
ethanol in the PFC (Kerns et al., 2005a). 
 Microarray analysis of the PFC identified 269 probesets (255 genes) with 
significant basal differences between SHAM and ADX mice. These included 75 
probesets up-regulated and 194 down-regulated by adrenalectomy.  Q-rtPCR was used to 
validate select genes from the microarray results. G protein-coupled receptor 6 (Gpr6) 
was significantly increased in ADX mice (Fig. 6A) while FK506 binding protein 5 
(Fkbp5) expression was decreased by adrenalectomy (Fig. 6B) (student’s t-test, p < 0.05).  
Bioinformatics functional over-representation analysis revealed significant differences 
between SHAM and ADX animals in gene groups involved in nerve impulse 
transmission and genes regulated by the synthetic glucocorticoid, dexamethasone (Table 
2).  Of particular interest, the entire ADX regulated set of genes had a highly significant 
overlap (p=1.8 x 10-8) with those identified in our prior microarray studies on acute 
ethanol with D2 mice (Kerns et al., 2005a). These overlapping genes included: heat shock 
70kDa protein (Hspa8), potassium large conductance calcium-activated channel, 
subfamily M, alpha member 1 (Kcnma1), phosphatase and tensin homolog (Pten), 
proteolipid protein 1 (Plp1), early growth response 2 (Egr2), early growth response 1 
(Egr1), and Fkbp5 (Table 2, *). Of note, all these genes showed significant decreased 
expression in the PFC of ADX mice, except for Plp1, which had increased expression.  
Acute ethanol increased the expression of all these genes in our prior studies.  Thus, 
except for Plp1, there was the expected inverse relationship between our prior microarray 
results on ethanol responses and results from ADX mice.  These results not only 
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demonstrate that ADX alters PFC gene expression, but that there is a potentially causal 
relationship between ethanol-evoked glucocorticoid release and at least a subset of acute 
ethanol-responsive genes in the PFC.  
 To provide further initial evidence for the role of glucocorticoids in acute ethanol-
responsive PFC gene expression, we determined whether RU-486 would block acute 
ethanol induction of Fkbp5, one of the genes mentioned above as overlapping between 
our microarray studies on acute ethanol and ADX, and which functions as a critical 
regulator of glucocorticoid receptor function (Sinars et al., 2003).   Q-rtPCR analysis of 
Fkbp5 mRNA levels in PFC four hours following ethanol or saline administration (+/- 
RU-486) was done with animals from behavioral Exp. 1.  One-way ANOVA showed an 
overall significant effect of treatment (F5,22 = 8.99, p < 0.01) (Fig. 6C.).  Post-hoc 
analysis showed that RU pre-treatment had no effect on basal Fkbp5 levels.  Ethanol 
significantly increased Fkbp5 levels compared to VS and RU-486 at the higher dose 
(RU35) blocked this response. These results indicated that higher doses of RU-486 
blunted both the acute locomotor activating effects of ethanol and ethanol-induced Fkbp5 
expression.  
 We used Ingenuity pathway analysis to identify networks overrepresented among 
genes identified through microarray and S-score analysis to be significantly different in 
SHAM vs. ADX treated D2 mice. Overrepresented networks include a network of genes 
involved in protein synthesis, behavior, and nervous system development and function 
(Fig. 7A.) and a network of genes involved in hereditary disorder, neurological disease 
and skeletal and muscular disorders (Figs. 7B.) These results indicate that genes 
regulated following ADX have functional implications for nervous system function and 
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behavioral responses. 
 
Blood Ethanol Concentration (BEC) 
ADX animals showed a lower peak BEC and unaltered rate of clearance following 2 g/kg 
ethanol. A two-way ANOVA (phenotype x time) showed an overall effect of time (F3,70= 
858.41, p < 0.001), an overall effect of phenotype (F1,70= 10.92, p < 0.001) and a 
significant interaction (F3,70= 3.02, p < 0.05). Post-hoc analysis revealed significant 
differences between BEC 10 minutes, 1 hour, 2 hours and 4 hours following 2 g/kg 
ethanol administration and significant differences between BEC in ADX and SHAM 
animals 10 minutes, 1 hour and 2 hours following 2 g/kg ethanol administration (Fig. 
8A.).  
In animals pre-treated with 35 mg/kg RU-486 versus those pre-treated with VEH 
10 min., 1 hour, 2 hours and 4 hours following 2 g/kg ethanol administration, a two-way 
ANOVA (treatment x time) showed an overall effect of time (F3,31 = 86.69, p < 0.001), 
but no effect of treatment. Post-hoc analysis revealed significant differences between 
BEC in VEH and RU-486 pre-treated animals 10 minutes, 1 hour, 2 hours and 4 hours 
following 2 g/kg ethanol administration, but no significant differences between VEH vs. 
RU-486 pretreated animals at any of these time points (Fig. 8B.). This indicates that there 
were no differences in BEC between D2 animals pretreated with VEH versus those 
pretreated with RU-486 10 min., 1 hour, 2 hours and 4 hours following 2 g/kg ethanol 
administration. 
 
Corticosterone Timecourse 
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A corticosterone (cort.) time course was performed to measure HPA axis activation 
following 2 g/kg ethanol administration. A two-way ANOVA (treatment x time) showed 
an overall effect of treatment (F1,41 = 28.79, p < 0.001) and time (F4,41 = 4.50, p < 0.01). 
Post hoc analysis revealed cort. levels were significantly elevated 5 minutes, 10 minutes, 
1 hour and 2 hours following ethanol administration (Fig. 9). There were no differences 
in cort. levels between saline treated animals. Levels peaked 1 hour following ethanol 
administration. Despite a strong trend towards elevated levels 4 hours following ethanol 
administration, cort. levels between saline vs. ethanol treated animals did not differ from 
one another at this time indicating that corticosterone levels returned to normal 4 hours 
following 2 g/kg ethanol administration.  
 
DISCUSSION  
 Defining the mechanisms underlying acute behavioral responses to ethanol has 
significant biomedical implications since acute responses to ethanol serve as a predictor 
of risk for alcoholism or excessive ethanol intake (Schuckit, 1994, Metten et al., 1998). 
Our prior genomic studies (Kerns et al., 2005a) suggest that glucocorticoid signaling in 
the PFC might play an important role in brain gene expression responses to acute ethanol.  
Here we characterized the role of glucocorticoid signaling in responses to acute ethanol, 
ethanol sensitization, and in regulating PFC gene expression.  We found that ADX and 
RU-486 both impair acute ethanol induced locomotor activation, but do not alter the 
induction of ethanol sensitization or basal locomotor activity.  Further, ADX altered 
expression of genes in PFC that include a significant number of previously identified 
ethanol responsive genes.  Overall, this work points to a previously uncharacterized 
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mechanism modifying acute locomotor responses to ethanol and identifies an important 
role for glucocorticoid signaling in ethanol-responsive gene expression.   
 One prior study showed that ADX reduced ethanol stimulated locomotor activity in 
female C3H mice (Wallis et al., 1984).  However, neither the effects of GR antagonists 
nor adrenalectomy on the acute locomotor activating effects of ethanol have been 
investigated in D2 mice, the strain most widely studied for motor responses to ethanol.  
We found that both higher doses of RU-486 and ADX blunted the acute locomotor 
activating effects of ethanol.  In addition, acute ethanol activated the HPA axis leading to 
significant increases in CORT as soon as 5 minutes following ethanol administration 
(Fig. 9).  Thus, ethanol-induced glucocorticoid release could partially modulate ethanol-
induced locomotor activation. The work presented here does not differentiate whether 
glucocorticoids mediate a portion of ethanol-induced locomotor activation, or simply 
provide a permissive effect in such a response to ethanol. However, since both RU and 
ADX treatments only affected a portion of the ethanol locomotor activation response, this 
clearly suggests a permissive effect. Future work will be needed to directly test this 
hypothesis. 
 Our results are consistent with prior studies on other drugs of abuse.  ADX reduces 
the acute psychomotor stimulant effects of cocaine (Marinelli et al., 1997, Deroche et al., 
1997) and amphetamine (Cador et al., 1993) in the rat and the locomotor response to 
psychomotor stimulants in ADX animals can be restored by corticosterone administration 
(Cador et al., 1993, Marinelli et al., 1997).  Discrepancies in the psychostimulant 
literature do exist, as a more recent study found that GR inactivation in the nervous 
system did not affect acute cocaine locomotor activation in mice, suggesting that the 
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acute locomotor effects of cocaine do not require GR signaling (Deroche-Gamonet et al., 
2003).  But it has been suggested that these divergent findings are due to methodological 
differences (Marinelli and Piazza, 2002).   
 Both RU-486 and ADX would affect more than just the glucocorticoid system as 
RU-486 is an antagonist of both the progesterone receptor (PR) and GR (Chrousos et al., 
1988).  Further, ADX alters the synthesis of numerous steroid hormones, in particular 
corticosterone and aldosterone, which both interact with the mineralocorticoid receptor 
(Piechota et al.).  ADX also removes adrenal medullary catecholamines such as 
epinephrine. However, the adrenal medulla does not provide the body’s only source of 
catecholamines and RU-486 presumably has no effect on catecholamine action and only 
minimal binding affinity for the MR (Ricordi et al., 1988). Thus, the combined use of 
both ADX and RU-486 in our studies increases the likelihood that the alterations in 
ethanol-induced locomotor activation with these treatments were due to GR actions.  
Additional evidence for a role of the GR comes from our studies of RU-486 and ethanol 
effects on circulating CORT levels.   Acting through hypothalamic and pituitary GR, RU-
486 disrupts negative feedback loops responsible for returning corticosterone levels to 
normal following HPA axis activation (De Kloet et al., 1998).  We only found significant 
basal RU-486 induced increases in circulating CORT at the higher dose of drug (35 
mg/kg), which was also the only dose inhibiting ethanol-induced locomotor activation.    
 Studies on other drugs of abuse also support GR rather than MR as a mediator of 
the locomotor response.  Blockade of MRs by spironolactone had no significant effects 
on locomotion induced by systemic morphine (Marinelli et al., 1998). Still, the possibility 
that other steroid hormones play a role in ethanol-induced locomotor activation cannot be 
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ignored.    
 ADX or RU-486 effects on ethanol pharmacokinetics could be an alternative 
explanation for our results with ethanol-induced locomotor activation. Gililland and Finn 
showed that ADX in D2 mice produced slightly increased ethanol clearance rates 
following 4 g/kg ethanol administration, but had no effect on peak BEC (Gililland and 
Finn, 2007).  We found slight decreases in peak BEC following 2 g/kg ethanol in ADX 
D2 mice (Fig. 8A).  However, decreased ethanol locomotor activation was seen with both 
ADX and RU-486 treatment and RU-486 pre-treatment did not alter ethanol metabolism 
(Fig. 8B). We also found that ADX and RU pre-treatment had no effect on ethanol-
induced LORR or anxiolysis (Fig. 5), indicating that ADX and RU selectively altered 
acute ethanol-induced locomotor activation. This combination of data strongly suggests 
that pharmacokinetic factors do not totally explain ethanol locomotor activation 
behavioral differences in ADX animals.   
 Our finding that RU-486 and ADX did not block initiation of behavioral 
sensitization (Figs. 3-4), were contrary to previously published findings showing that 
RU-486 blunted initiation of ethanol behavioral sensitization (Roberts et al., 1995).  
Some of the discrepancies could be due to differences in experimental design.  Roberts et. 
al. used female D2 mice, a shorter protocol with lower doses of ethanol and lower doses 
of RU-486 (Roberts et al., 1995). Interestingly, we found that not only did all groups of 
mice sensitize to the locomotor activating effects of ethanol, but they also sensitized to 
jump counts.  To our knowledge, this is the first report of ethanol sensitization to jumping 
behavior. 
 We hypothesized that basal differences in gene expression may be partially 
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responsible for the observed behavioral differences between SHAM and ADX animals 
following acute ethanol administration. IPA analysis showed that genes identified 
through microarray and S-score analysis to be significantly different in SHAM vs. ADX 
treated D2 mice were overrepresented in networks involved in behavior and neurological 
disease. This result supports our hypothesis that ethanol’s activation of the HPA axis may 
be responsible for regulating gene expression following ethanol administration and that 
this regulation may result in behavioral alterations and neurological alterations that may 
eventually lead to pathologies such as alcoholism. Our microarray studies showed 
prominent changes in basal gene expression of ADX animals in PFC, a brain region 
known to be sensitive to glucocorticoids (Mizoguchi et al., 2003), and a significant 
proportion of these were identified as ethanol-responsive genes in PFC in our prior 
studies.  For example, Fkbp5 was decreased basally in ADX mice whereas previously it 
was found to be induced by ethanol in D2 PFC (Kerns et al., 2005a). Of note, Fkbp5 
regulates glucocorticoid receptor sensitivity and polymorphisms in Fkbp5 lead to a 
dysregulated stress response and have been found in individuals with depression, bipolar 
disorder and post-traumatic stress disorder (Binder, 2009).  
 In addition, pre-treatment with doses of RU-486 that blunted ethanol locomotor 
activation also diminished ethanol induced Fkbp5 expression (Fig. 6C).  This overlap 
between ADX, RU-486 and ethanol-sensitive gene expression is consistent with our prior 
hypothesis that a subset of acute ethanol-responsive genes in PFC were possibly due to 
involvement of GR signaling.  Our results also suggest that such GR and ethanol-
responsive genes in PFC may play a role in modulating aspects of basal acute sensitivity 
to ethanol.  
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Table 1: Outline of experimental design for ethanol sensitization 
Phase of sensitization Initiation Expression 
Group Days 1-2 Day 3 Days 4-13 Day 14 Habituation Activity test Conditioning Activity Test 
SS Saline Saline Saline Saline 
SE Saline Saline Saline Ethanol 2.0 g/kg 
EE Saline Ethanol 2.0 g/kg Ethanol 2.5 g/kg Ethanol 2.0 g/kg 
Table 1.  Sensitization protocol. 
 
 
Table 2: Gene ontology over-representation analysis for ADX microarray results 
Ontological 
Category Gene Symbol Gene Name 
Entrez 
Gene 
ID 
q-value; 
s-score 
Nerve Impulse 
Transmission 
HRH1 histamine receptor H1 3269 0.0169; 4.01 
HSPA8* heat shock 70kDa protein 8 3312 0.0030; -4.52 
SLC6A13 solute carrier family 6 (neurotransmitter transporter, GABA), member 13 6540 
< 0.001; 
5.30 
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 4915 
0.0500; 
-3.62 
KCNMA1* 
potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 
3778 0.0257; -3.87 
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) 3791 
0.0022; 
4.62 
CLDN5 claudin 5 7122 < 0.001; 7.24  
SOD1 superoxide dismutase 1, soluble 6647 0.0126; -4.11 
CACNG3 calcium channel, voltage-dependent, gamma subunit 3 10368 
0.0257; 
3.88 
RAB11A RAB11A, member RAS oncogene family 8766 0.0013; -4.75 
RAB14 RAB14, member RAS oncogene family 51552 0.0080; -4.26 
CNP1 2',3'-cyclic nucleotide 3' phosphodiesterase 1267 
0.0482; 
3.63 
CPLX2 complexin 2 10814 0.0318; -3.79 
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 6507 
0.0259; 
3.87 
SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 6506 
0.0009; 
-4.87 
HOMER1 homer homolog 1 (Drosophila) 9456 0.0004; 
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-5.03 
ATXN1 ataxin 1 6310 0.0109; -4.15 
KIF1B kinesin family member 1B 23095 < 0.001; -6.42 
PTEN* phosphatase and tensin homolog 5728 0.0453; -3.66 
CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 773 
0.0061; 
-4.34 
CREB1 cAMP responsive element binding protein 1 1385 
0.0075; 
-4.28 
SYN2 synapsin II 6854 0.0274; -3.84 
PLP1* proteolipid protein 1 5354 0.0244; 3.89 
EGR2 early growth response 2 1959 < 0.001; -5.81  
EGR1* early growth response 1 1958 0.0014; -4.74 
HTR2C 5-hydroxytryptamine (serotonin) receptor 2C 3358 
0.0441; 
-3.68 
ARC activity-regulated cytoskeleton-associated protein 23237 
0.0005; 
-5.01 
GRIA1 glutamate receptor, ionotropic, AMPA 1 2890 0.0036; -4.48 
Dexamethasone 
DCN decorin 1634 0.0001; 5.30 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 3290 
< 0.001; 
5.65 
HRH1 histamine receptor H1 3269 0.0169; 4.01 
HSPA8* heat shock 70kDa protein 8 3312 0.0030; -4.52 
KCNMA1* 
potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 
3778 0.0257; -3.83 
KCNB1 potassium voltage-gated channel, Shab-related subfamily, member 1 3745 
< 0.001; 
-6.35 
SOD1 superoxide dismutase 1, soluble 6647 0.0126; -4.11 
FKBP5* FK506 binding protein 5 2289 0.0380; -4.12 
PLIN2 perilipin 2 123 0.0480; 3.64 
APCDD1 adenomatosis polyposis coli down-regulated 1 147495 
0.0316; 
3.80 
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EPHX2 epoxide hydrolase 2, cytoplasmic 2053 0.0274; 3.84 
EDNRB endothelin receptor type B 1910 0.0200; 3.95 
S100A9 S100 calcium binding protein A9 6280 0.0005; -5.01 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 781 
0.0009; 
-4.84 
SULT1A1 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 6817 
< 0.001; 
-7.05 
CXCL12 chemokine (C-X-C motif) ligand 12 6387 0.0365; 3.74 
TTR transthyretin 7276 < 0.001; 9.17 
FOS FBJ murine osteosarcoma viral oncogene homolog 2353 
< 0.001; 
-8.72 
EGR1 early growth response 1 1958 0.0014; -4.74 
NR2C2 nuclear receptor subfamily 2, group C, member 2 7182 
< 0.001; 
-6.11 
TPM1 tropomyosin 1 (alpha) 7168 0.0244; -3.90 
Table 2.  Over-represented gene ontology categories from analysis of genes with 
significant q-values using ToppGene (http://toppgene.cchmc.org/) with a Bonferroni 
correction and p-value cutoff of 0.05. A positive s-score indicates a gene that is 
significantly increased; conversely a negative s-score indicates a gene that is significantly 
decreased. *Represents a gene previously identified in our laboratory as an ethanol 
responsive gene (Kerns et al., 2005a).  
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Figure 2. Antagonism of glucocorticoid receptor function by RU-486 alters acute 
locomotor responses to ethanol and produces compensatory changes in serum 
corticosterone. Panel A: RU-486 at 35 mg/kg (RU 35), but not 20 mg/kg (RU 20), 
blunted the acute locomotor activating effects of ethanol in D2 mice.  * p < 0.05 vs. all 
saline-treated animals;  # p < 0.05 vs. VEH ethanol and RU 20 ethanol.  Panel B:  
Corticosterone levels were determined 4 hours after behavioral testing.  Corticosterone 
levels were significantly elevated in animals treated with RU 35 followed by saline or 
animals treated with RU 20 or RU35 following by ethanol. *p < 0.05 vs. VEH treated 
groups and RU 20 S;  # p < 0.05 vs. RU 35 S. 
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Figure 3.  Adrenalectomy (ADX) alters acute ethanol locomotor activation but not 
ethanol sensitization.  Panel A: ADX significantly blunted the acute locomotor activating 
response to ethanol, but not locomotor sensitization.  On day 3, locomotor responses were 
reduced in the ADX ethanol-treated group compared to sham controls. * p < 0.05 vs. day 
3 Saline-Saline treated mice; † p < 0.05 vs. Day 3 Ethanol-Ethanol treated SHAM mice; $ 
p < 0.05 vs. day 14 Saline-Saline treated mice; # p < 0.05 vs. day 3 Ethanol-Ethanol 
treated mice, Saline-Saline treated mice and Saline-Ethanol treated mice; § p < 0.05 vs. 
Day 14 Ethanol-Ethanol treated SHAM mice.  Panel B: SHAM and ADX mice also 
sensitized to Jump Counts. * p < 0.05 vs. SHAM Saline-Ethanol Day 14, ADX Saline-
Ethanol Day 14, SHAM Ethanol-Ethanol Day 3, ADX Ethanol-Ethanol Day 3; $ p < 0.05 
vs. SHAM Saline-Ethanol Day 14, ADX Saline-Ethanol Day 14, SHAM Ethanol-Ethanol 
Day 3, ADX Ethanol-Ethanol Day 3; # p < 0.05 vs. SHAM Saline-Ethanol Day 14, ADX 
Saline-Ethanol Day 14, SHAM Ethanol-Ethanol Day 3, ADX Ethanol-Ethanol Day 3; § p 
< 0.05 vs. SHAM Saline-Ethanol Day 14, ADX Saline-Ethanol Day 14, SHAM Ethanol-
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Ethanol Day 3; † p < 0.05 vs. SHAM Saline-Ethanol Day 14, ADX Saline-Ethanol Day 
14, SHAM Ethanol-Ethanol Day 3; ^ p < 0.05 vs. SHAM Saline-Ethanol Day 14. 
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Figure 4. Pretreatment with 25 mg/kg RU-486 had no effect on the initiation of ethanol 
sensitization as measured via locomotor activity and jump counts.  Panel A:  Pretreatment 
with 25 mg/kg RU-486 had no effect on the initiation of ethanol sensitization as 
measured via locomotor activation.  * p < 0.05 vs. Day 3 Saline-Saline treated mice; # p < 
0.05 vs. Day 3 Ethanol-Ethanol treated mice.  Panel B: VEH and RU-486 Ethanol-
Ethanol pretreated mice also sensitized to Jump Counts. * p < 0.05 vs. VEH Ethanol-
Ethanol Day 3, RU Ethanol-Ethanol Day 3;  $ p < 0.05 vs. VEH Ethanol-Ethanol Day 3 
and RU Ethanol-Ethanol Day 3;  # p < 0.05 vs. VEH Ethanol-Ethanol Day 3, RU Ethanol-
Ethanol Day 3;  § p < 0.05 vs. VEH Ethanol-Ethanol Day 3, RU Ethanol-Ethanol Day 3;  
† p < 0.05 vs. VEH Ethanol-Ethanol Day 3, RU Ethanol-Ethanol Day 3;  ^ p < 0.05 vs. 
VEH Ethanol-Ethanol Day 3, RU Ethanol-Ethanol Day 3. 
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Figure 5. Acute ethanol-responsive behaviors that do not differ between VEH vs. RU or 
ADX vs. SHAM treated mice.  Panel A:  Both SHAM and ADX ethanol-treated mice 
spent significantly greater time in the light than their respective saline-treated 
counterparts.  There were no differences in the % Time Spent in the Light between 
SHAM and ADX treated mice. Panel B:  Both SHAM and ADX ethanol-treated mice 
traveled significantly greater distance in the light than their respective saline-treated 
counterparts.  There were no differences in the % Distance Traveled in the Light between 
SHAM and ADX treated mice.  Panel C:  Pretreatment with 35 mg/kg RU-486 (RU 35) 
had no effect on ethanol-induced loss of righting reflex (LORR).  Panel D:  ADX had no 
effect on ethanol-induced loss of righting reflect (LORR).  * p < 0.05 vs. respective 
saline-treated mice.   
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Figure 6.  Genes identified through microarray and S-score analysis and confirmed to be 
significantly different in SHAM vs. ADX treated D2 mice and RU-486 pre-treated D2 
mice.  Panel A: Gpr6 was identified and confirmed as significantly increased in ADX vs. 
SHAM treated mice.  * p < 0.05 vs. SHAM treated mice.  Panel B:  Fkpb5 was identified 
and confirmed as significantly decreased in ADX vs. SHAM treated mice.  * p < 0.05 vs. 
SHAM treated mice.  Panel C:  Pre-treatment with higher doses of the GR antagonist RU-
486 blunted ethanol-induced Fkbp5 expression.  RU pre-treatment had no effect on basal 
Fkbp5 levels.  * p < 0.05 vs. VS, RU20 S, RU35 S, RU35 E.  # p < 0.05 vs. VS and RU20 
S. 
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Figure 7.  Networks overrepresented among genes identified through microarray and S-
score analysis to be significantly different in SHAM vs. ADX treated D2 mice.  Panel A: 
Network of genes involved in protein synthesis, behavior, and nervous system 
development and function. Panel B: Network of gene involved in hereditary disorder, 
neurological disease and skeletal and muscular disorders. Red signifies genes that 
increase following ADX. Green signifies genes that decrease. White signifies a molecule 
that is not user specified but incorporated into the network through relationships with 
other molecules. Respective S-scores are provided. Solid arrowheads reflect ‘‘acts on’’ 
interactions while lines without arrow indicate binding interactions only. Solid and dotted 
lines indicate, respectively, direct vs. indirect interactions. The molecule shapes represent 
their designation (ie. enzyme, kinase). For a detailed key of the main network features 
please see: 
http://physiolgenomics.physiology.org/content/suppl/2012/10/03/physiolgenomics.00092.
2012.DC1/supplegend.pdf. 
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Figure 8.  BEC in ADX vs. SHAM and RU-486 vs. VEH pre-treated animals. Panel A: 
ADX animals showed a lower peak BEC and unaltered rate of clearance following 2 g/kg 
ethanol. * p < 0.05 10 min. SHAM vs. 10 min. ADX, # p < 0.05 1 hour SHAM vs. 1 hour 
ADX: ** p < 0.05 10 min. vs. 1 hour, 2 hours and 4 hours; $ p < 0.05 1 hour vs. 2 and 4 
hours; $$ p < 0.05 2 hours vs. 4 hours. Panel B: There were no differences in BEC 
between D2 animals pre-treated with 35 mg/kg RU-486 vs. those pre-treated with VEH 
10 min., 1 hour, 2 hours and 4 hours following 2 g/kg ethanol administration. * p < 0.05 
vs. 4 hour, 2 hour, and 1 hour; # p < 0.05 vs. 4 hour and 2 hour; $ p < 0.05 vs. 4 hour. 
!
Supplementary Figure 1.  ADX animals showed a lower peak BEC and unaltered rate 
of clearance following 2 g/kg ethanol (n = 9-10/group; 78 mice total).  A two-way 
ANOVA (phenotype x time) showed an overall effect of time (F3,70= 858.41, p < 0.001), 
an overall effect of phenotype (F1,70= 10.92, p < 0.001) and a significant interaction 
(F3,70= 3.02, p < 0.05).  * p < 0.05 10 min. SHAM vs. 10 min. ADX, # p < 0.05 1 hour 
SHAM vs. 1 hour ADX:  ** p < 0.05 10 min. vs. 1 hour, 2 hours and 4 hours;  $ p < 0.05 1 
hour vs. 2 and 4 hours;  $$ p < 0.05 2 hours vs. 4 hours.   
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Figure 9. CORT levels were significantly elevated 5 minutes, 10 minutes, 1 hour and 2 
hours following ethanol administration.  There were no differences in cort. levels 
between saline treated animals.  Levels peaked 1 hour following ethanol administration.  
Despite a strong trend towards elevated levels 4 hours following ethanol administration, 
cort. levels between saline vs. ethanol treated animals did not differ from one another at 
this time indicating that corticosterone levels return to normal 4 hours following 2 g/kg 
ethanol administration. * p < 0.05 vs. saline 5 min,1 hr., 2 hr. and 4 hr.; # p < 0.05 vs. all 
saline groups; $ p < 0.05 vs. all groups; ** p < 0.05 vs. saline 5 min., 1 hr., 2 hr. and 4 hr. 
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CHAPTER 4 
Endocannabinoid Regulation of the Hypothalamic Pituitary Adrenal Axis following 
Ethanol Administration 
INTRODUCTION  
Previously, we hypothesized that basal differences in gene expression may be one 
explanation for differences in locomotor activity between D2 SHAM versus ADX mice 
(Costin et al., 2012). Basal differences in gene expression could facilitate different cell 
signaling events in D2 SHAM versus ADX mice that may lead to a blunted locomotor 
response to ethanol in ADX D2 mice. While our prior studies focused primarily on 
classical, genomic glucocorticoid actions mediated by glucocorticoids binding to 
intracellular receptors and causing eventual changes in gene expression, we wanted to 
additionally explore newly identified nongenomic glucocorticoid signaling mechanisms. 
Our previous findings demonstrated significant increases in corticosterone (Rosser et al.) 
levels as soon as five minutes following ethanol administration (Fig. 9). Via the 
hypothesized nongenomic pathway CORT binds to a yet-uncharacterized membrane-
bound glucocorticoid receptor that activates the Gs– cAMP/PKA pathway to induce 
endocannabinoid synthesis (Hill and McEwen, 2009). Endocannabinoids are released into 
the synapse where they bind to CB1 receptors and activate signaling cascades that can 
alter neurotransmitter release (Hill and McEwen, 2009, Di et al., 2003).  
Despite hypothesized nongenomic glucocorticoid signaling mechanisms, alternate 
findings exist on the relationship between cannabinoids and the HPA axis. A number of 
reports indicate that administration of cannabinoids stimulates the HPA axis by elevating 
ACTH and/or corticosterone plasma levels (Jackson and Murphy, 1997, Wenger et al., 
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1997, Wenger et al., 2003). Another report indicates that the CB1 antagonist SR141716A 
reduces the stimulation of ACTH release induced by THC (Manzanares et al., 1999). 
Alternatively, it has been shown that the administration of SR141716A has been able to 
increase ACTH and CORT release (Patel et al., 2004, Wade et al., 2006, Navarro et al., 
1997). From these varied results, it seems that factors including drug dose, environmental 
context, and genetic background of the subject tested may affect HPA axis activity.  
The CB1 receptor is expressed in the hypothalamus and pituitary of mice, rats and 
humans, but the literature does not totally support its role in nongenomic glucocorticoid 
signaling mechanisms (Herkenham et al., 1991, Pagotto et al., 2001, Wittmann et al., 
2007). It has been shown previously that basal and novelty stress-induced plasma levels 
of ACTH and corticosterone were higher in CB1 KO than in WT mice (Barna et al., 
2004), but other laboratories have failed to reproduce this result (Wenger et al., 2003). 
Still other laboratories have found that CB1 KO mice had an enhanced circadian HPA 
axis activity peak compared to WT controls (Cota et al., 2007). Finally and interestingly, 
the CB1 cannabinoid receptor antagonists AM251 and AM281 blocked the negative 
feedback of glucocorticoids on CRH secretion in hypothalamic slice preparations (Di et 
al., 2003), but other labs have not been able to replicate this result (Cota et al., 2007, 
Barna et al., 2004). Although alternate findings exist in the literature, we hypothesized 
that endocannabinoid signaling may mediate a fast negative feedback loop that decreases 
CORT release and therefore CB1 KO animals, animals with altered endocannabinoid 
signaling, would have significantly elevated CORT levels compared to their WT 
counterparts. According to our hypothesis, FAAH KO animals would likely have 
unaltered or blunted CORT levels because fast feedback loops would be intact or 
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heightened in these animals.  
To indirectly test our hypothesis, we evaluated CORT levels in FAAH and CB1 
KO mice following ethanol administration. Due to our limited timeframe, we were only 
able to obtain KO mice on a C57 background. In our previous studies, we used D2 mice. 
It is well known that D2 mice show an acute locomotor activation response following 
ethanol administration whereas C57 mice do not (Phillips et al., 1997a). This 
characteristic allowed us to indirectly explore whether or not CORT plays a causal or 
permissive role in the locomotor activation response. For example if CORT is causal in 
the locomotor activation response following acute ethanol administration, we might 
expect CORT levels to be lower in C57 vs. D2 mice following acute ethanol. Because we 
wanted to ensure C57 mice would allow for the evaluation of HPA axis activation 
following acute ethanol administration and further evaluate the role corticosterone may 
play in locomotor activation, we began our studies by evaluating CORT levels in C57 
versus D2 mice following acute ethanol administration. We hypothesized that both mouse 
strains would have significant and equal elevations in CORT following ethanol 
administration and therefore CORT may play a permissive rather than causal role in 
ethanol induced locomotor activity.  
 
MATERIALS AND METHODS 
Animals 
Mice were maintained in a temperature controlled room (23±1°C) with 12 h light/dark 
cycles and free access to standard chow (Harlan Teklad #7912, Madison, WI) and water.  
Cages and bedding (Harlan Sani-chips, #7090A, Harlan, Teklad, Madison, WI) were 
88	  	  
changed weekly.  All tests were carried out between 0900 and 1200 h. Procedures were 
approved by the Institutional Animal Care and Use Committee of Virginia 
Commonwealth University and followed the NIH Guide for the Care and Use of 
Laboratory Animals. Mice for Expt 1. were male D2 and C57 mice from Jackson 
Laboratories (Bar Harbor, Maine) purchased at 7-8 weeks of age. Adult male fatty acid 
amide hydrolase (FAAH) (Expt. 2), CB1 knockout (KO) (Expt. 3), and wild type mice 
born in the NIDA Center Transgenic Colony at Virginia Commonwealth University 
(Richmond, VA) also served as subjects.  All the genetically modified mice used in these 
studies were backcrossed thirteen generations onto a C57BL/6 background.  The CB1 
KO mice were derived from CB1 heterozyote parents (Zimmer et al., 1999) and the 
FAAH KO mice were derived from congenic FAAH KO parents (Varvel et al., 2007). 
Drugs 
All drugs were administered intraperitoneally (i.p.). Saline solutions were 0.9% w/v 
sterile saline.  Ethanol solutions were prepared from 200-proof absolute anhydrous 
ethanol (Pharmco-Aaper brand, Brookfield, CT).  Ethanol was administered at 20% v/v 
in 0.9% saline.   
Expt 1.—Acute Locomotor Responses and CORT Levels in D2 and C57 Mice 
Mice were habituated to saline injections in their home cage for 2 days prior to 
experiments and allowed a 1-hour acclimation period to the behavioral room prior to 
testing. Locomotor activity was measured immediately following injection with either 
saline or ethanol (2 g/kg) during a 10-minute session in locomotor activity chambers 
(Med-Associates, model ENV-515; St. Albans, VT). Mice were harvested 1 hour 
following saline or ethanol injections via decapitation. 
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Expt 2.—CORT Levels in FAAH WT and KO mice 
FAAH WT and KO mice were habituated to injections with saline in their home cage for 
2 days prior to experiments and allowed a 1-hour acclimation period to the behavioral 
room prior to injections on test day. Mice were injected with either saline or ethanol (2 
g/kg) and harvested 1 hour later via decapitation. 
Expt 3.—CORT Levels in CB1 WT and KO mice 
CB1 WT and KO mice were habituated to injections with saline in their home cage for 2 
days prior to experiments and allowed a 1-hour acclimation period to the behavioral room 
prior to injections on test day.  Mice were injected with either saline or ethanol (2 g/kg) 
and harvested 1 hour later via decapitation. 
Blood collection and Radioimmunoassay (RIA) 
In experiments 1-3, one hour following ethanol or saline administration, trunk blood was 
collected from individual mice. Serum was isolated by centrifugation at 2500 x g for 15 
minutes and stored at -80°C until RIA. A RIA containing I125 labeled corticosterone (MP 
Biomedicals, Cleveland, OH, United States) was performed according to the 
manufacturer’s instructions. 
Statistics 
Data were expressed as mean ± SEM and analyzed parametrically.  Data were analyzed 
with analysis of variance (ANOVA) using appropriate between-and within subject 
factors.  All post hoc comparisons were made using Student Newman-Keul’s test. Values 
of p < 0.05 were considered statistically significant.   
 
RESULTS 
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Acute locomotor responses and corticosterone levels in D2 and C57 mice 
Acute locomotor responses and corticosterone levels were measured following saline and 
ethanol administration in D2 and C57 mice (n = 3-4/group). A two-way ANOVA 
(genotype x treatment) measuring locomotor activity in D2 versus C57 mice showed an 
overall effect of treatment (F1,10 = 4.90, p < 0.01), but no overall effect of genotype (F1,10 
= 11.60, p = 0.051) and no genotype x treatment interaction. Because we wanted to know 
which saline versus ethanol treated groups of animals showed specific differences, we ran 
a one-way ANOVA comparing locomotor activity across treatment groups. A one-way 
ANOVA showed an overall effect of treatment (F3,10 = 6.33, p < 0.05).  Post-hoc analysis 
revealed that, as expected, D2 mice showed an acute locomotor activation response 
following 2 g/kg ethanol, but C57 mice did not (Fig. 10A).  
Additionally, CORT levels were significantly elevated 1 hour following 2 g/kg 
ethanol administration in both D2 and C57 mice. A two-way ANOVA (genotype x 
treatment) measuring CORT levels in C57 vs. D2 mice showed an overall effect of 
treatment (F1,11 = 102.71, p < 0.001), but no overall effect of genotype and no genotype x 
treatment interaction. Post-hoc analysis revealed that both D2 and C57 mice showed 
significantly elevated corticosterone levels in ethanol versus saline treated animals (Fig. 
10B).  
 
Corticosterone levels in FAAH WT and KO mice 
Corticosterone levels were measured in FAAH WT and KO mice. A two-way ANOVA 
(genotype x treatment) comparing CORT levels in FAAH WT versus KO mice showed 
an overall effect of treatment (F1,28 = 21.19, p < 0.001), but no effect of genotype and no 
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genotype x treatment interaction. Post-hoc analysis revealed significant differences 
between all saline treated and all ethanol treated animals indicating that corticosterone 
levels were significantly, but not differentially, elevated in both WT animals and their 
KO littermates (Fig. 11). 
 
Corticosterone levels in CB1 WT and KO mice 
Corticosterone levels were measured in CB1 WT and KO mice. A two-way ANOVA 
(genotype x treatment) measuring CORT levels in CB1 WT versus KO mice showed an 
overall effect of treatment (F1,24 = 259.40, p < 0.001), genotype (F1,24 = 6.32, p < 0.05) 
and a significant treatment x genotype interaction (F1,24 = 5.08, p < 0.05). Post-hoc 
analysis revealed significant differences between WT saline versus ethanol treated 
animals and a significant difference between KO saline versus ethanol treated animals. 
Post-hoc analysis also revealed no significant difference between saline treated WT and 
KO animals, but a significant difference between ethanol treated WT and KO animals 
with CB1 KO animals having significantly elevated CORT levels (Fig. 12). 
 
DISCUSSION 
Our prior studies focused primarily on classical, genomic glucocorticoid actions 
mediated by glucocorticoids binding to intracellular receptors and causing eventual 
changes in gene expression, but because we saw alterations in locomotor activity as soon 
as 10 minutes following ethanol administration in ADX versus SHAM animals (Fig. 3A) 
we also wanted to explore nongenomic glucocorticoid signaling mechanisms. Our 
previous findings demonstrated significant increases in CORT levels as soon as five 
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minutes following ethanol administration (Fig. 9) and there are many examples of the fast 
actions of glucocorticoids that are too rapid to be mediated through the usual genomic 
mechanisms (Dallman, 2005). For example, glucocorticoids also exert rapid effects on 
socially aggressive behavior in rats.  Male Wistar rats were significantly more aggressive 
in the increasing versus decreasing phase of their corticosterone fluctuation when 
confronting a male intruder. Additionally, males with experimentally increased plasma 
concentrations of corticosterone were more aggressive than counterparts with 
experimentally decreased plasma corticosterone concentrations (Haller et al., 2000, 
Haller et al., 1998).  
Via the nongenomic pathway it is hypothesized that CORT binds to a yet-
uncharacterized membrane-bound glucocorticoid receptor that activates the Gs– 
cAMP/PKA pathway to induce endocannabinoid synthesis (Hill and McEwen, 2009). 
Endocannabinoids are released into the synapse where they bind to CB1 receptors and 
activate signaling cascades that can alter neurotransmitter release (Hill and McEwen, 
2009, Di et al., 2003). We hypothesized that CB1 KO animals, animals with altered 
endocannabinoid signaling, would have significantly elevated CORT levels compared to 
their WT counterparts because they lack the fast feedback regulation provided by 
corticosterone’s actions at the CB1 receptor. 
Our prior results indicated that CORT levels were significantly elevated 5 minutes 
following ethanol administration (Fig. 9) and ADX animals, which could no longer 
release CORT, had a blunted locomotor activation response following ethanol 
administration (Fig. 3A). Therefore we hypothesized that CORT could potentially play a 
role in the locomotor activating effects of ethanol. Evaluating CORT levels in C57 versus 
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D2 mice allowed us to indirectly explore whether or not CORT plays a causal or 
permissive role in the locomotor activation response. If CORT plays a causal role in the 
locomotor activation response, then CORT levels in D2 mice that do show a locomotor 
activation response would be expected to be greater than those in C57 mice that do not 
show a locomotor activation response following ethanol administration  (Fig. 10A). 
CORT levels following ethanol treatment did not differ between D2 and C57 mice (Fig. 
10B), our results indirectly indicate that CORT may be permissive rather than causal in 
the locomotor activating effects of ethanol.  
This finding was not surprising because it has been shown that cocaine-induced 
locomotion depends on basal diurnal levels of glucocorticoids, but not on a drug-induced 
increase in these levels (Marinelli et al., 1997). In other words, Marienelli et al. showed 
the effect of adrenalectomy on cocaine-induced locomotion was dose-dependently 
compensated by corticosterone concentrations that were in the range of basal diurnal 
levels.  Plasma levels of corticosterone at least eight times lower than that those induced 
following cocaine administration led to a full recovery of the effects of adrenalectomy on 
cocaine-induced locomotion (Marinelli et al., 1997). Thus, corticosterone also appears to 
be permissive rather than causal in the locomotor activating effects of cocaine. 
To further investigate the role of CORT in mediating ethanol’s effects via the 
nongenomic pathway, we evaluated CORT levels in FAAH and CB1 KO mice following 
ethanol administration. As we hypothesized, CB1 KO animals had significantly elevated 
CORT levels compared to their WT counterparts following ethanol administration (Fig. 
12). Prior studies in other labs have produced varying results regarding CORT levels in 
CB1 WT versus KO animals. One report showed that CB1 KO mice display elevated 
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plasma corticosterone concentrations at the onset of the dark phase as compared to their 
WT littermates and thus we were careful to evaluate the mice at the onset of the light 
period when basal differences in CORT levels between WT and KO mice would not be 
expected (Cota et al., 2007). In addition, it has been shown previously that basal and 
novelty stress-induced plasma levels of ACTH and corticosterone were higher in CB1 
KO than in WT mice (Barna et al., 2004), but other laboratories failed to reproduce this 
result (Wenger et al., 2003). While we did not evaluate ACTH levels in KO versus WT 
mice, there were no differences in basal CORT levels between WT and KO mice in our 
studies. Our results somewhat indirectly support work by Di et. al which showed that the 
CB1 cannabinoid receptor antagonists AM251 and AM281 blocked the negative 
feedback of glucocorticoids on CRH secretion in hypothalamic slice preparations (Di et 
al., 2003). In line with our hypothesis, FAAH KO animals had CORT levels equal to 
their WT counterparts because fast feedback loops would be intact in both FAAH WT 
and KO animals (Fig. 11). Given our current hypothesis, this would make sense as FAAH 
KO mice have excess levels of the endocannabinoid AEA that can act at the CB1 
receptor so their fast feedback loops would not be altered following ethanol 
administration and HPA axis activation.  
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Figure 10.  Acute locomotor responses (A) and corticosterone levels (B) following saline 
and ethanol (2 g/kg) administration in D2 and C57 mice. Panel A: D2 mice showed an 
acute locomotor activation response following 2 g/kg ethanol, but C57 mice did not.  * p 
< 0.05 vs. D2 saline, C57 saline and C57 ethanol.  Panel B: Corticosterone levels were 
significantly elevated 1 hour following 2 g/kg ethanol administration in both D2 and C57 
mice. * p < 0.05 vs. D2 saline, C57 saline 
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Figure 11. Corticosterone levels in FAAH WT and KO mice following saline and 
ethanol administration. FAAH WT and KO mice show significant increases in 
corticosterone levels following ethanol administration.  * p < 0.05 vs. all saline treated 
animals.   
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Figure 12. Corticosterone levels in CB1 WT and KO mice following saline and ethanol 
administration. Both CB1 WT and KO mice show significant increases in corticosterone 
levels following ethanol administration, but corticosterone levels in CB1 WT mice are 
significantly elevated following ethanol administration compared to their WT littermates.  
* p < 0.05 vs. all saline treated animals,  # p < 0.05 vs. ethanol treated CB1 WT mice. 
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CHAPTER 5 
 
Ethanol Regulation of Serum Glucocorticoid Kinase 1 
INTRODUCTION 
Although alcohol dependence is a complex disease that develops over many years 
and includes cycles of withdrawal, craving, and relapse, acute responses to ethanol have 
predictive validity in terms of risk for high levels of ethanol intake in animal models or 
alcoholism in humans (Schuckit, 1994, Metten et al., 1998). Therefore, defining the 
cellular mechanisms underlying acute responses to ethanol has significant biomedical 
implications.  
Ethanol acutely activates the HPA axis leading to glucocorticoid release from the 
adrenal glands (Ellis, 1966). Glucocorticoid hormones are the final step in activation of 
the HPA axis and are known to function in the biological response to stress and circadian 
activity (Marinelli et al., 1997, De Kloet et al., 1998). Glucocorticoids are also well 
known to regulate gene expression (Webster et al., 1988). In alcohol dependence, the 
hypothalamic pituitary adrenal (HPA) axis is dysregulated in both humans (Costa et al., 
1996, Wand and Dobs, 1991a) and rodents (Richardson et al., 2008, Rasmussen et al., 
2000, Roberts et al., 1995), but the consequences of this dysregulation remain unclear. 
Our laboratory and others have used genome-wide expression profiling to identify 
gene networks functioning in acute and chronic behavioral responses to ethanol (Kerns et 
al., 2005a, Treadwell and Singh, 2004, Wolstenholme et al., 2011, Costin et al., 2012, 
Wolen et al., 2012, Piechota et al., 2010b). We previously identified a group of genes 
prominently regulated by acute ethanol in the prefrontal cortex (PFC) of DBA2/J (D2) 
mice (Kerns et al., 2005b). Contained in this group were well-characterized 
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glucocorticoid responsive genes including FK506 binding protein 5 (Fkbp5) and Serum 
Glucocorticoid Kinase I (Sgk1) (Binder, 2009, Webster et al., 1993). Sgk1 is a 
glucocorticoid responsive gene that regulates ion channel function, cell survival, and is 
involved in synaptic plasticity, learning and memory (Alvarez de la Rosa et al., 1999, 
Brunet et al., 2001, Lee et al., 2006, Ma et al., 2006, Tsai et al., 2002).  
Sgk1 has multiple transcript and protein isoforms generated though alternative 
promoter utilization, splicing, translation and post-translational modifications (Arteaga et 
al., 2008, Arteaga et al., 2007). It is known that there are 5 isoforms of Sgk1—4 resulting 
from translational processing of Sgk1 and one, Sgk1.1, resulting from alternative 
promoter utilization and splicing (Arteaga et al., 2008, Arteaga et al., 2007). Because 
Sgk1 is regulated by both glucocorticoids and acute ethanol and is known to regulate ion 
channel function, we hypothesized that Sgk1 signaling may be an important mechanism 
underlying acute behavioral and cellular responses to ethanol, and that it may modulate 
neuronal plasticity leading to more chronic behaviors such as sensitization. We have 
therefore performed a detailed analysis on ethanol regulation of Sgk1 from the 
transcriptional to protein level. Our results indicate a complex regulation of Sgk1 
transcription, protein abundance and post-translational modification following ethanol 
treatment. Altogether, these results suggest a critical role for the HPA axis and Sgk1 in 
regulating the acute and potentially chronic cellular response to ethanol. 
 
MATERIALS AND METHODS 
Animals 
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Mice were maintained in a temperature-controlled room (23±1°C) with 12 h light/dark 
cycles and free access to standard chow (Harlan Teklad #7912, Madison, WI, United 
States) and water. Cages and bedding (Harlan Sani-chips, #7090A, Harlan, Teklad, 
Madison, WI, United States) were changed weekly. All tests were carried out between 
0900 and 1200 h. All mice were DBA2/J mice from Jackson Laboratories (Bar Harbor, 
ME, United States) purchased at 10-13 weeks of age and group housed 4/cage. 
Adrenalectomized (ADX) and SHAM mice were treated at Jackson and delivered 
following recovery from surgery. ADX mice were supplemented with 1% w/v saline 
solution in their drinking water. All mice were allowed to habituate to the animal facility 
for at least 1 week prior to testing.  
Adrenalectomy 
All adrenalectomies and sham procedures were conducted using aseptic and atraumatic 
surgical techniques at Jackson laboratories and were approved by the institution’s Animal 
Care and Use Committee. Surgeries were performed using the lateral abdominal 
approach. Left and right adrenal glands were removed through separate incisions. The 
animals were anesthetized using tribromoethanol and carprofen was administered for 
analgesia and the surgical site was prepared. The animals were placed in right lateral 
recumbency and a 5-8mm incision was made parallel and ventral to the spine and 
midway between the last rib and iliac crest. The underlying muscle was opened and the 
adrenal gland was located cranial to the left kidney. The adrenal gland was grasped with 
ring forceps and exteriorized.  The adrenal and adjacent adipose tissues were excised. 
The incisions in the abdominal wall and skin were closed separately. Bupivacaine was 
applied topically to the incision site for local analgesia. Skin closure material was 
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removed prior to shipment. The same procedure was followed for excision of the right 
adrenal gland except the skin incision was made immediately caudal to the last rib. This 
adjustment was necessary to accommodate for the more cranial location of the right 
adrenal gland relative to the left in the abdomen. 
Drugs 
All drugs were administered intraperitoneally (i.p.). Saline solutions were 0.9% w/v 
sterile saline. Ethanol solutions were prepared from 200-proof absolute anhydrous 
ethanol (Pharmco-Aaper brand, Brookfield, CT, United States). Ethanol was 
administered at 20% v/v in 0.9% saline.   
Experimental Testing 
Mice were habituated to injections with saline in their home cage for 2 days prior to 
experimental testing. If behavioral testing was performed, mice were allowed a 1-hour 
acclimation period to the behavioral room prior to testing. All locomotor activity was 
measured immediately following injection with either saline or ethanol during a 10-
minute session in locomotor activity chambers (Med-Associates, model ENV-515; St. 
Albans, VT, United States). The system is interfaced with Med Associates software that 
allows for the automatic measurement of activity using a set of 16 infrared beam sensors 
along the X-Y plane. 
Exp. 1 – Time course and dose response analysis of Sgk1 and Sgk1.1 expression 
following acute ethanol administration: Prior to beginning the time course 
experiments, four groups of mice (n = 4), basal, 2 hour, 4 hour and 8 hour, were 
evaluated to determine the effect of saline injections on Sgk1 expression. The basal group 
of mice was handled for two days, and then harvested on day 3 and brain micropunch 
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dissections performed. The other 3 groups of mice were habituated to injections as 
described above and then harvested 2, 4 and 8 hours following saline injections on day 3 
and brain micropunch dissections performed. For the time course experiment, six groups 
of mice (n = 4) were administered either saline or 4 g/kg ethanol and groups of animals, 
one saline treated group and one ethanol treated group, were harvested 2, 4 and 8 hours 
following drug administration. For the dose response experiment, three groups of mice (n 
= 8) were administered saline, 2 g/kg ethanol or 4 g/kg ethanol and harvested 4 hours 
following injection and brain micropunch dissections performed.  
Exp. 2 – Sgk1 levels following ethanol sensitization: Animals (n = 4) received one of 
three treatments: saline-saline (SS), saline-ethanol (SE) or ethanol-ethanol (EE) (Table 
1). On conditioning days 3-13, animals received daily injections in their home cages of 
either saline (SS, SE) or 2.5 g/kg ethanol (EE). On test day 14 the SS group received 
saline and the SE and the EE groups received 2.0 g/kg ethanol and were placed in 
locomotor activity chambers. Four hours following drug administration, animals were 
harvested and brain micropunch dissections performed. 
Exp. 3 – Corticosterone levels following ethanol sensitization: Animals (n=6) received 
one of four treatments: saline-saline (SS), ethanol-saline (ES), saline-ethanol (SE) or 
ethanol-ethanol (EE) (Table 1). On days 3-13, animals received daily injections in their 
home cages of either saline (SS, SE) or 2.5 g/kg ethanol (ES, EE). On test day 14 the SS 
and ES groups received saline and the SE and the EE groups received 2.0 g/kg ethanol 
and were placed in locomotor activity chambers. One hour following drug administration, 
animals were harvested and blood collection performed. 
Exp. 4 – Effects of ADX on Sgk1 induction following ethanol administration:  
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ADX and SHAM animals (n=11-15) received either 4 g/kg ethanol or saline. Mice were 
harvested four hours following ethanol or saline administration and brain micropunch 
dissections performed. To ensure that mice were in fact adrenalectomized, a separate 
group of ADX and SHAM mice (n = 4-5) were administered either saline or acute 
ethanol. One hour following the last drug administration, animals were harvested and 
trunk blood collection performed. 
Exp. 5 – Glucocorticoid receptor binding to Sgk1 promoter following acute ethanol 
administration: Mice (n = 8/group, 48 total) were treated with saline or 4 g/kg ethanol 
and harvested via cervical dislocation 1 hour following drug administration. Following 
cervical dislocation, the brain was removed, the olfactory bulbs were removed from the 
brain and a cut was made just rostral to the optic chiasm to collect the frontal pole of the 
brain. 
Exp. 6 – Sgk1 phospho Serine (S422) and Sgk1 Levels following ethanol 
administration: Mice (n = 12, 6 animals treated with saline, 6 treated with 4 g/kg 
ethanol) were administered saline or ethanol and harvested 15 minutes, 1 hour, 2 hours, 4 
hours, 8 hours and 24 hours following drug administration and brain micropunch 
dissections performed. 
Brain Micropunch Dissection 
At designated times following ethanol or saline administration in experiments 1, 2, 4 and 
6 brain tissue was collected. Collection of brain tissue occurred exactly as described in 
Kerns et al. (Kerns et al., 2005a). The medial prefrontal cortex (PFC) dissection 
contained tissue from dorsal and ventral anterior cingulate and some secondary motor 
cortex.  
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RNA Isolation and Quantitative Real Time Polymerase Chain Reaction (Q-rtRCR) 
RNA was isolated from PFC tissue samples using the RNeasy Protect Mini Kit (Qiagen, 
Valencia, CA, United States) according to the manufacturer’s instructions. RNA 
concentration and quality was assessed by Experion automated electrophoresis (BioRad, 
Hercules, CA, United States). cDNA was generated from 1 ug total RNA by reverse 
transcription with the iScript CDNA kit (Bio-Rad, Hercules, CA, United States) 
following the manufacturer’s instructions. Q-rtPCR was performed using the iCycler 
iQTM system (Bio-Rad, Hercules, CA, United States) according to the manufacturer’s 
instructions for SYBR Green I-based detection. Quantification of gene expression levels 
was determined based on the threshold cycle for each well using the provided software 
and all results were normalized to multiple reference genes using Genorm as described in 
Vandesompele et al. (Vandesompele et al., 2002). Primers used were as follows, Sgk1 
(Forward- CGTCAAAGCCGAGGCTGCTCGAAGC and Reverse- 
GGTTTGGCGTGAGGGTTGGAGGAC), Sgk1.1 (Forward- 
ATGCCAACATCCTGACCAA and Reverse- TGCTGGCAATCTTCTGAATAAA), 
Gapdh (Forward-TTCCAGTATGACTCCACTCACGG and Reverse-
TGAAGACACCAGTAGACTCCACGAC), Ppp2r2a (Forward-
ATCTCTCACCCTTGCCCTTT and Reverse-CCCATTTTGTGTGCTTTCGT), Ublcp1 
(Forward-ATGACAGGGACAGGACAAGC and Reverse-
TACAATGACACCCGACTGGA), Ndufv1 (Forward- GACCGTGCTAATGGACTTCG 
and Reverse-GGCATCTCCCTTCACAAATC), and Nr3c1 (Forward-
AAGAGACAAACGAGAGTCCTTGG and Reverse- 
GTGTCCGGTAAAATAAGAGGCTT. 
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Blood collection and Radioimmunoassay (RIA) 
One hour following ethanol or saline administration in Exp. 3 and Exp. 4, trunk blood 
was collected from individual mice. Serum was isolated by centrifugation at 2500 x g for 
15 minutes and stored at -80°C until RIA. A RIA containing I125 labeled corticosterone 
(MP Biomedicals, Cleveland, OH, United States) was performed according to the 
manufacturer’s instructions. 
Chromatin Immunoprecipitation (ChIP) Assay 
Frontal poles from 8 D2 mice in Exp. 5 were combined to make one individual sample 
and the ChIP analyses were performed using the magnetic-bead-based Chip-IT Express 
Enzymatic kit following the manufacturer’s instructions for fresh tissue (Active Motif, 
Carlsbad, CA, United States). Brieﬂy, the tissue was cross-linked with 1% formaldehyde 
for 10 min, sheared enzymatically and the chromatin immunoprecipitated with the 
indicated antibodies: rabbit anti-Glucocorticoid Receptor (Santa Cruz Biotechnology, 
Santa Cruz, CA, United States) and rabbit anti-immunoglobulin G (IgG) (Cell Signaling, 
Danvers, MA, United States). Following immunoprecipitation, the chromatin was eluted 
from the magnetic beads, the cross-links were reversed, and the protein was digested. 
Samples were then subjected to a DNA clean-up step prior to Q-rtRCR using the 
QIAquick PCR Purification Kit (Qiagen, Valencia, CA, United States) according to the 
manufacter’s instructions. The resulting DNA fragments in the range of 150 to 500 bp 
were analyzed by Q-rtRCR using a pair of primers (Forward- 
ACCCCTGCTCCCTCTAACTC and Reverse-GCGGAAATAAGTCTCTGCTCT) 
spanning the glucocorticoid response element (GRE) in the Sgk1 promoter region. For Q-
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rtRCR, SsoAdvanced™ SYBR® Green Supermix (BioRad, Hercules, CA, United States) 
was used according to the manufacturer’s instructions. 
Western Blotting 
While frozen, PFC tissue from animals in Expt. 3 was homogenized using a Dounce 
Tissue Homogenizer (Fisher Scientific, Waltham, MA, United States) and then 
suspended in Lithium Dodecyl Sulfate Loading Buffer (Invitrogen, Grand Island, NY, 
United States) containing Halt protease and phosphatase inhibitors (ThermoFisher 
Scientific, Waltham, MA, United States) and sonicated. Western blotting was performed 
using the XCell Surelock Mini-Cell kit (Invitrogen, Grand Island, NY, United States) 
according to the manufacturer’s instructions. SGK1 blots were probed with rabbit anti-
SGK1 (AbCam, Cambridge, MA, United States) and rabbit anti-GAPDH (AbCam, 
Cambridge, MA, United States). phospho-SGK1 (pSgk1) blots were probed with rabbit 
anti-SGK1 phospho S422 (AbCam, Cambridge, MA, United States) and goat anti-SGK1 
phospho T256 (Santa Cruz Biotechnology, Santa Cruz, CA, United States), then stripped 
using Restore Western Blot Stripping Buffer (Thermo Scientific, Rockford, IL, United 
States) and re-probed with rabbit anti-SGK1 (AbCam, Cambridge, MA, United States). 
phospho-N-myc downstream-regulated 1 gene 1 (pNDRG1) blots were probed with 
rabbit anti-NDRG1 phospho S330 (AbCam, Cambridge, MA, United States), then 
stripped and re-probed with rabbit anti-NDRG1 (AbCam, Cambridge, MA, United 
States). Blots were also probed with IRDye goat anti-rabbit 680, IRDye goat anti-rabbit 
800, and IRDye donkey anti-goat 800 antibodies (Li-cor Biosciences, Lincoln, NE, 
United States). Western blot imaging was performed and images were quantified using 
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infrared imaging (Odyssey infrared imager, Li-cor Biosciences, Lincoln, NE, United 
States).  
Statistics 
Data were expressed as mean ± SEM and analyzed parametrically.  Data were analyzed 
with analysis of variance (ANOVA) using appropriate between-and within subject 
factors.  All post hoc comparisons were made using Student Newman-Keul’s test. Values 
of p < 0.05 were considered statistically significant.   
 
RESULTS 
Time course and dose response analysis of Sgk1 and Sgk1.1 expression following acute 
ethanol administration. 
 Because our prior microarray studies and the studies of other labs would have used 
probes that recognize cDNA regions common to all Sgk1 isoforms, we performed Q-
rtPCR studies to determine which Sgk1 isoform was specifically regulated by ethanol, 
Sgk1 or Sgk1.1. Q-rtPCR was used to evaluate Sgk1 and Sgk1.1 levels 2, 4 and 8 hours 
following ethanol or saline administration. Prior to performing these studies to evaluate 
the effects of injection stress on Sgk1 expression, we compared Sgk1 levels in the PFC of 
D2 mice basally (a 0 hour time point) to D2 mice harvested 2, 4 and 8 hours following 
saline injections. A two-way ANOVA (treatment x time) showed no overall effects of 
treatment or time and no significant treatment x time interaction indicating that injection 
stress did not alter Sgk1 levels (Fig. 13). Because we saw no significant effects of saline 
injections on Sgk1 expression, we did not include a 0 hour time point in the remainder of 
our studies. In evaluating Sgk1 levels 2, 4 and 8 hours following saline and ethanol 
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administration, a two-way ANOVA showed an overall effect of treatment, ethanol versus 
saline (F1,17 = 16.44, p < 0.01), but no overall effect of time and no significant treatment x 
time interaction (Fig. 14a). To examine treatment more carefully, we used a one-way 
ANOVA. A one-way ANOVA showed a significant effect of treatment (F5,22 = 4.51, p < 
0.01) and post-hoc analysis indicated that 4 hours following ethanol treatment Sgk1 levels 
were significantly increased compared to all saline treated animals and animals treated 
with ethanol 8 hours prior to harvest (Fig. 14a). In addition, Sgk1 levels were 
significantly increased in animals harvested 2 hours following 4 g/kg ethanol 
administration compared to those harvested 8 hours following saline administration (Fig. 
14a). This indicates that Sgk1 levels were significantly increased 2 and 4 hours following 
4 g/kg ethanol administration and returned to basal levels 8 hours following 4 g/kg 
ethanol administration. A two-way ANOVA evaluating Sgk1.1 levels showed no overall 
effect of treatment or time and no significant treatment x time interaction (Fig. 14b). A 
one-way ANOVA (F5,18 = 5.31, p < 0.01) indicated that animals harvested 8 hours 
following ethanol administration showed significantly greater levels of Sgk1.1 than those 
harvested 2 and 4 hours following ethanol administration and saline administration. In 
addition, animals harvested 8 hours following saline treatment showed greater levels of 
Sgk1.1 than those harvested 2 hours following ethanol treatment indicating that there was 
no effect of treatment on Sgk1.1 expression. These results suggest that Sgk1, not Sgk1.1, 
is the ethanol responsive isoform of Sgk1. 
 To further evaluate which isoform of Sgk1 was ethanol responsive, Q-rtPCR was 
used to evaluate Sgk1 and Sgk1.1 levels following an ethanol dose response assessment in 
which animals were administered saline, 2 g/kg and 4 g/kg ethanol. In evaluating Sgk1 
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levels, a one-way ANOVA showed a significant effect of treatment (F2,18= 50.58, p < 
0.01). Post-hoc analysis indicated significant differences between 4 g/kg ethanol versus 
saline, 2 g/kg ethanol versus saline and 4 g/kg ethanol versus 2 g/kg ethanol indicating 
that Sgk1 is dose dependently increased following ethanol administration (Fig. 14c). Q-
rtPCR was also used to evaluate Sgk1.1 levels following saline, 2 g/kg and 4 g/kg ethanol 
administration (Fig. 14d). A one-way ANOVA showed no significant effects between the 
3 groups (Fig. 14d). Once again this indicated that Sgk1, not Sgk1.1, is the ethanol 
responsive isoform. 
 
Sgk1 levels following ethanol sensitization  
 Prior microarray studies in our lab and others had identified Sgk1 to be an acute 
ethanol responsive gene and we confirmed this finding via Q-rtPCR (Fig. 14a-d), but we 
also wanted to know if Sgk1 or its isoform Sgk1.1 was regulated following chronic 
ethanol administration. To answer this question, we evaluated Sgk1 levels acutely and 
chronically following ethanol sensitization studies. A one-way ANOVA showed an 
overall effect of treatment (F2,21= 41.96, p < 0.01) (Fig. 15a). Post-hoc analysis revealed 
that ethanol-ethanol (EE) treated animals showed significantly greater locomotor activity 
compared to saline-ethanol (SE) and saline-saline (SS) treated animals. In addition, SE 
treated animals showed greater locomotor activity than SS treated animals. In evaluating 
Sgk1 levels in these animals, a one-way ANOVA found an overall significant effect of 
treatment (F2,9= 8.76, p < 0.01) (Fig. 15b). Post-hoc analysis showed that Sgk1 levels 
were significantly increased in animals treated acutely with ethanol compared to SS and 
EE treated animals. Interestingly, Sgk1 levels did not differ between SS and EE treated 
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animals. A one-way ANOVA identified no significant differences in Nr3c1 (Fig. 15c) or 
Sgk1.1 (Fig. 15d) levels in SS, SE or EE treated animals. These results indicated that 
Sgk1 is regulated by ethanol acutely, but not chronically, Sgk1, not Sgk1.1 is the ethanol 
responsive isoform of Sgk1, and changes in Nr3c1 do not appear to be responsible for the 
changes in Sgk1. 
 
Corticosterone levels following ethanol sensitization 
 Because Sgk1 levels were not regulated in animals chronically treated with ethanol, 
Sgk1 is a well-known glucocorticoid responsive gene and it is known that animals and 
human alcoholics show a blunted HPA axis while drinking and upon withdrawal, we 
hypothesized that corticosterone levels may be blunted in animals chronically treated 
with ethanol (EE animals). We sensitized animals to ethanol and collected blood from 
them one hour following behavioral testing to measure corticosterone levels across SS, 
SE, EE and Ethanol-Saline (ES) treated animals. In evaluating the sensitized response to 
ethanol, a one-way ANOVA showed an overall effect of treatment (F3,15= 159.67, p < 
0.01) (Fig. 16a). Post-hoc analysis revealed that EE treated animals showed a 
significantly greater locomotor response compared to SS, SE, and ES treated animals. In 
addition, SE treated animals showed a greater locomotor response compared to SS and 
ES treated animals. In evaluating corticosterone levels in SS, SE, EE and ES mice, a one-
way ANOVA showed an overall significant effect of treatment (F3,15= 47.37, p < 0.01) 
(Fig. 16b). Post-hoc analysis revealed that SE animals showed greater corticosterone 
levels than SS, EE and ES indicating that corticosterone levels were blunted in animals 
chronically treated with ethanol. 
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Effects of ADX on Sgk1 induction following ethanol administration 
 Because Sgk1 was not induced in EE treated animals and the corticosterone 
response to ethanol was also blunted in these animals, we hypothesized that Sgk1 
induction may be due to HPA axis activation following acute ethanol administration. 
Therefore, we hypothesized that Sgk1 would not be induced in ADX animals, animals 
lacking their adrenal glands, the organ responsible for corticosterone release and the final 
step in HPA axis activation. A two-way ANOVA (phenotype x treatment) evaluating 
Sgk1 levels in SHAM versus ADX animals indicated an overall effect of phenotype 
(F1,22= 7.16, p < 0.05), treatment (F1,22= 11.05, p < 0.01) and a significant (phenotype x 
treatment) interaction (F1,22= 5.31, p < 0.05) (Fig. 17a). Post-hoc analysis of phenotype 
indicated Sgk1 levels were significantly increased in ethanol versus saline treated SHAM 
animals, but not ADX animals. Post-hoc analysis of treatment indicated significant 
differences between ethanol, but not saline, treated SHAM versus ADX mice indicating 
that Sgk1 levels were blunted in ADX mice following ethanol administration. There were 
no significant differences in Sgk1.1 levels in SHAM versus ADX mice (Fig. 17c.). 
 To ensure that animals were, in fact, adrenalectomized, we evaluated 
corticosterone levels in ADX vs. SHAM animals. A two-way ANOVA (phenotype x 
treatment) evaluating corticosterone levels in ADX animals indicated an overall effect of 
phenotype (F1,14= 52.22, p < 0.05), treatment (F1,14= 60.83, p < 0.01) and a significant 
(phenotype x treatment) interaction (F1,14= 63.91, p < 0.05) (Fig. 17b). Post hoc analysis 
revealed that there were significant differences between saline versus ethanol treated 
SHAM animals and significant differences between ADX and SHAM ethanol treated 
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mice (Fig 4b.) indicating that ethanol caused corticosterone release in SHAM, but not 
ADX animals. Therefore, ADX mice did not experience increases in corticosterone 
following saline administration and the induction of Sgk1, but not Sgk1.1, may be due to 
HPA axis activation and glucocorticoid signaling following acute ethanol administration. 
 
Chromatin Immunoprecipitation (ChIP) Assay 
To test whether Sgk1 induction following ethanol administration was due to 
glucocorticoid receptor (GR) binding to the glucocorticoid response element (GRE) in 
the Sgk1 promoter, we performed a chromatin immunoprecipitation (ChIP) assay in 
which we isolated chromatin from ethanol and saline treated animals and conducted 
immunoprecipitation studies using an anti-GR antibody and a control anti-IgG antibody. 
A two-way ANOVA (antibody x treatment) showed an overall effect of antibody (F1,8= 
140.40, p < 0.01), treatment (F1,8= 13.13, p < 0.01) and a significant (treatment x 
antibody) interaction (F1,8= 5.85, p < 0.05) (Fig. 18). Post-hoc analysis revealed that 
looking at samples in which GR immunoprecipitations were performed, the level of Sgk1 
promoter region bound to the GR in ethanol treated samples was significantly greater 
than that bound in saline treated samples. Looking at samples in which IgG 
immunoprecipitations were performed, there were no significant differences between 
Sgk1 promoter region bound to the IgG antibody in ethanol versus saline treated samples. 
Additionally, looking at antibody effects within saline treated animals, there was a 
significantly greater amount of Sgk1 promoter region bound to the GR antibody versus 
the IgG antibody. Looking at antibody effects within ethanol treated animals, there was a 
significantly greater amount of Sgk1 promoter region bound to the GR antibody versus 
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the IgG antibody. Therefore, we surmise that Sgk1 induction in PFC following acute 
ethanol administration is due to activation of the HPA axis and the subsequent binding of 
corticosterone-activated GR to the GRE of the Sgk1 promoter. 
 
SGK1 phospho S422, SGK1 phospho T256, NDRG1 phospho S330, and SGK1 Levels 
following saline and ethanol administration 
Following our characterization of Sgk1, we also wanted to explore what was 
occurring at the protein level. We performed a time course analysis of SGK1 phospho 
S422 and SGK1 protein levels between ethanol versus saline treated animals 15 minutes, 
1 hour, 2 hours, 4 hours, 8 hours and 24 hours following 4 g/kg ethanol. We found no 
significant differences in SGK1 phospho S422 levels in saline versus ethanol treated 
animals 1 hour, 2 hours, 4 hours, 8 hours and 24 hours following drug treatment (Fig. 
19a-f). 15 minutes following ethanol administration we found significant increases in 
SGK1 phospho S422 and SGK1 phospho T256 in ethanol versus saline treated animals 
(student’s t-test, p < 0.05) (Fig. 20a-d). This indicates that SGK1 is phosphorylated at 
both S422 and T256 as early as 15 minutes following ethanol, but not saline 
administration. Because NDRG1 is a downstream target of phosphorylated, active SGK1 
we also evaluated NDRG1 phospho S330 levels in ethanol vs. saline treated animals 15 
minutes following ethanol administration. We found significant increases in NDRG1 
phospho S330 in ethanol versus saline treated animals (student’s t-test, p < 0.05) (Fig. 
21a-b). 
  We found no significant differences in SGK1 levels between saline and ethanol 
treated animals 15 minutes, 1 hour, 2 hours, 4 hours and 24 hours following drug 
114	  	  
treatment (Fig. 22a-f). 8 hours following ethanol administration we found significant 
decreases in SGK1 in ethanol versus saline treated animals (student’s t-test, p < 0.05) 
(Fig. 23a-b). This indicates that SGK1 is significantly decreased 8 hours following 
ethanol administration.  
 
DISCUSSION 
 Prior studies in our laboratory and others suggest that glucocorticoid signaling 
might play an important role in both behavioral and brain gene expression responses to 
acute ethanol (Kerns et al., 2005a, Costin et al., 2012, Piechota et al., 2010b).  For 
example, using genomic studies we previously identified a significant over-representation 
of glucocorticoid-responsive genes, including Sgk1, among those responding to acute 
ethanol in prefrontal cortex (Kerns et al., 2005a).  More recent studies from our 
laboratory showed that inhibition of glucocorticoid signaling by adrenalectomy or the 
glucocorticoid antagonist RU486, both impaired acute ethanol-induced locomotor 
activation, suggesting that glucocorticoid signaling may play a role in this behavioral 
response (Costin et al., 2012). Further, ADX altered the basal expression of genes in PFC 
that included a significant number of previously identified ethanol responsive genes 
(Costin et al., 2012). Although there are other conflicting reports about the role of 
glucocorticoids in ethanol behaviors, recent studies elegantly document that blockade of 
glucocorticoid signaling severely impairs escalated ethanol consumption in an animal 
model of progressive ethanol intake (Vendruscolo et al., 2012).  Furthermore, HPA axis 
dysregulation exists in alcohol dependent patients and individuals with a familial history 
of alcoholism (Sorocco et al., 2006, Dai et al., 2002). Thus, disrupted HPA 
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axis/glucocorticoid signaling may contribute to the risk for development of alcohol 
dependence.  In this report, we have provided mechanistic studies confirming that ethanol 
modulates brain (PFC) gene expression, in part, through glucocorticoid signaling and that 
alterations in this gene expression regulatory loop occur with chronic exposure. We 
propose that ethanol modulation of brain glucocorticoid-responsive gene expression 
acutely could contribute to the adaptive mechanisms leading to behavioral responses seen 
with chronic ethanol, such as sensitization, tolerance and addiction (Kerns et al., 2005a, 
Wolen et al., 2012, Farris and Miles, 2012). 
 Our prior work identified an important role for glucocorticoid signaling in ethanol-
responsive gene expression (Costin et al., 2012). ADX altered the expression of genes in 
the PFC that included a significant number of previously identified ethanol responsive 
genes (Costin et al., 2012). Interestingly, Sgk1 wasn’t basally regulated in ADX mice in 
these studies, although we latter showed that Sgk1 also wasn’t induced following ethanol 
administration in ADX animals (Fig. 17a) indicating that it is, in fact, a glucocorticoid 
responsive, ethanol responsive gene. Sgk1 was first identified in a screen of 
glucocorticoid responsive genes and since then our lab and others have consistently 
identified it as a glucocorticoid responsive, ethanol responsive gene (Webster et al., 1993, 
Piechota et al., 2010b, Kerns et al., 2005a). However, it has also been identified as being 
transcriptionally controlled by a wide variety of additional hormones and regulators 
including the increase of cytosolic Ca2+ activity and NO, transforming growth factor β, 
interleukin 6, thrombin, endothelin, cell shrinkage, and Rett syndrome, to name a few 
(Lang et al., 2010, Meng et al., 2005, BelAiba et al., 2006, Wolf et al., 2006, Chen et al., 
2009, Nuber et al., 2005). Sgk1 is a gene that is highly sensitive to multiple 
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environmental stimuli and therefore it may not have been blunted basally in ADX mice, 
but following ethanol administration and robust HPA axis activation, Sgk1 induction in 
SHAM mice, and lack thereof in ADX mice became apparent (Fig. 17b).   
Prior studies in our laboratory and others identified the glucocorticoid-regulated 
gene Sgk1 as an ethanol-responsive gene (Kerns et al., 2005a, Treadwell and Singh, 2004, 
Piechota et al., 2010b). Other investigators have described Sgk1 regulation following 
ethanol administration in whole brain (Treadwell and Singh, 2004) and in the striatum 
(Piechota et al., 2010b), but not in the PFC—a region known to be important in 
glucocorticoid signaling (Mizoguchi et al., 2003). Here we performed a rigorous analysis 
of Sgk1 regulation in PFC by ethanol. Although Sgk1 is the predominant transcript from 
the gene, an alternative promoter site produces the transcript Sgk1.1 that actually codes 
for a more stable form of the Sgk protein (Arteaga et al., 2008). However, ethanol only 
regulated expression of the Sgk1 form (Fig. 14a), which is modulated by a glucocorticoid 
response element (GRE) in its promoter (Arteaga et al., 2008, Webster et al., 1993). We 
show for the first time that ethanol regulation of Sgk1 occurred via evoked glucocorticoid 
signaling since adrenalectomy blocked ethanol induction of Sgk1 expression (Fig. 17a) 
and ethanol increased occupancy of glucocorticoid receptor binding to the Sgk1 promoter 
in ChIP assays (Fig. 18).  Ethanol regulation of Sgk1 transcription in prefrontal cortex is 
thus part of a HPA-PFC regulatory loop that could have an important role in modulating 
ethanol behaviors.  PFC is known to have high concentrations of glucocorticoid receptors 
and to modulate HPA activity (Mizoguchi et al., 2003). PFC is also an integral part of the 
mesolimbocortical dopamine pathway that is involved in the rewarding properties of 
ethanol and other drugs of abuse.   PFC is thus thought to contribute to the known 
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interaction between stress and ethanol consumption.  
Ethanol regulation of Sgk1 versus Sgk1.1 may have functional implications since 
the two isoforms have been described as having different downstream targets. Sgk1 
stimulates K+ channel activity and regulates the function and availability of the epithelial 
sodium channel (ENaC) in addition to its regulation of other targets (Gamper et al., 2002, 
Wang et al., 2001, Alvarez de la Rosa et al., 1999).  Sgk1.1 is a brain specific isoform of 
Sgk1 that has been shown to modulate the function of the acid-sensing ion channel-1, the 
δENaC and M-current (Arteaga et al., 2008, Wesch et al., 2010, Miranda et al., 2013).  
Interestingly, Sgk1.1 did show significant increases in both saline and ethanol treated 
animals at 8 hours (Fig 14b), perhaps reflecting regulation of this isoform by mechanisms 
responding to our overall experimental manipulation, rather than ethanol treatment per se. 
Following repeated ethanol treatment to produce locomotor sensitization, Sgk1 
and serum corticosterone levels no longer responded to ethanol treatment (Figs. 15b, 
16b). This provides further confirmation of a role for glucocorticoid signaling in ethanol 
regulation of Sgk1 and suggests that by dampening of the HPA response to ethanol, a 
network of glucocorticoid-responsive genes in PFC has undergone an adaptive response 
to chronic ethanol exposure. This could have functional consequences for behavioral 
responses to chronic ethanol although this will require the proof of future studies.   
Other investigators have shown a similar trend in corticosterone levels following 
chronic ethanol administration; as corticosterone levels are blunted in male rats 
administered ethanol following chronic operant self-administration, chronic intragastric 
ethanol administration and rats and mice following chronic i.p. injection (Richardson et 
al., 2008, Lee and Rivier, 1997, Spencer and McEwen, 1990, Roberts et al., 1995). 
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However, this is the first work relating HPA axis dampening (or “tolerance”) to changes 
in PFC gene expression. Although other explanations exist for lack of ethanol-
responsiveness in Sgk1 following chronic ethanol treatment, such as decreased 
glucocorticoid receptor (GR) expression in PFC, the dampened corticosterone response to 
ethanol (Fig. 16) and ChIP results showing increased GR binding to the Sgk1 promoter 
with acute ethanol (Fig. 18) are strong evidence linking the diminished Sgk1 response to 
corticosterone levels. Diminished GR (Nr3c1) expression has been seen in the rat PFC 
following chronic ethanol exposure (Vendruscolo et al., 2012) but our Q-rtPCR results 
showed no significant changes in Nr3c1 levels in the PFC of SS, SE vs EE treated 
animals (Fig 15c). Figure 15c actually showed a trend for increased Nr3c1 expression in 
ethanol sensitized animals, perhaps in compensation to dampened HPA tone.  Although 
we did not measure blood ethanol concentrations (BECs) in our studies, prior studies with 
chronic ethanol showed corticosterone levels were blunted despite elevated BECs 
(Richardson et al., 2008, Lee and Rivier, 1997).  Of possible mechanistic importance, 
Roberts et al. reported that co-treatment with the glucocorticoid antagonist RU486 
blocked the decrement in corticosterone during repeated ethanol treatment for 
sensitization (Roberts et al., 1995). RU486 also partially blocked ethanol locomotor 
sensitization in those experiments, although our prior work has not replicated this finding 
possible due to methodological differences (Costin et al., 2012). 
These studies also identified ethanol actions on Sgk1 expression at the level of 
protein expression and post-translational modification. The activation of SGK1 is 
triggered first by the phosphorylation of S422 lying within the C-terminal 
hydrophobic motif of Sgk1 followed by the phosphorylation of a threonine residue within 
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the T-loop of the kinase domain (Firestone et al., 2003). Mammalian target of rapamycin 
(mTORC) was recently identified as the kinase that phosphorylates SGK1 at Ser422, but 
there is debate as to whether mTOR complex 1 or 2 is responsible for this 
phosphorylation (Garcia-Martinez and Alessi, 2008, Hong et al., 2008). We found that 
phosphorylation of SGK1 at S422 and T256 is transiently increased at 15 minutes 
following ethanol administration (Fig 20) but that total SGK1 protein abundance is 
significantly decreased as early as 6 hours (data not shown) and as late as 8 hours (Fig. 
23) following ethanol administration. This is somewhat paradoxical since Sgk1 mRNA 
abundance is increased at 2-4 hours after ethanol treatment (Fig. 14a). The transient 
increase in SGK1 Ser422 phosphorylation appears to be functional in that there is 
concomitant phosphorylation of the known Sgk1 substrate protein, NDRG1 (Fig. 21) 
(Murray et al., 2004). 
This study is the first description for this complex ethanol regulation of Sgk1 
mRNA, protein and phosphorylation. Similar to our findings here, Piechota et al. showed 
Sgk1 mRNA is significantly increased 2 hours following ethanol, morphine, heroin and 
methamphetamine administration and that SGK1 protein is significantly decreased 4 
hours following morphine administration in the striatum. But those investigators did not 
study SGK1 phosphorylation or protein regulation following ethanol administration 
(Piechota et al., 2010b). It is possible that ethanol triggers a complex wave of signaling 
events leading to: 1) SGK1 activation by phosphorylation with subsequent 
phosphorylation of NDRG1 and other targets; 2) increased Sgk1 transcription by HPA 
activation and glucocorticoid action; and 3) compensatory SGK1 protein degradation.  Of 
note, Miyata et al. showed that a chronic stress paradigm that elevated plasma 
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corticosterone levels similar to those found in depressed individuals lead to activation of 
the phosphatidylinositol 3-kinase (PI3K)-3-phosphoinositide-dependent protein kinase 
(PDK1), Sgk1, and Ndrg1 pathway with increases in both Sgk1 mRNA and SGK1 
phosphorylation (Miyata et al., 2011).  Thus it is possible that HPA axis activation is 
causal in both Sgk1 activation and increased transcription of the Sgk1 gene. 
 
Table 3: Outline of experimental design for ethanol sensitization 
Group Days 1-2 Days 3-13 Day 14 
Habituation Conditioning Activity Test 
SS Saline Saline Saline 
SE Saline Saline Ethanol 2.0 g/kg 
EE Saline Ethanol 2.5 g/kg Ethanol 2.0 g/kg 
ES Saline Ethanol 2.5 g/kg Saline 
Table 3.  Sensitization protocol. 
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Figure 13. Sgk1 levels in the PFC of D2 mice basally (a 0 hour time point) and 2, 4 and 
8 hours following saline injections. Saline injections did not significantly alter Sgk1 
levels at any time point compared to basal Sgk1 levels. 
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Figure 14. Acute ethanol time course and dose response analysis for Sgk1 and Sgk1.1 
expression. Q-rtPCR analysis of Sgk1 and Sgk1.1. Panels show: (a) Sgk1 following 4 g/kg 
ethanol administration. * p < 0.05 versus all saline treated animals and 8 hour ethanol 
group, # p < 0.05 versus 8 hour saline group; (b) Sgk1.1 levels following 4 g/kg ethanol 
administration. * p < 0.05 versus ethanol and saline animals at 2 or 4 hours, # p < 0.05 
versus 2 hour ethanol group; (c) Ethanol dose response for Sgk1 at 4 hours. * p < 0.05 
versus saline treated animals, # p < 0.05 versus ethanol and saline treated animals (d) 
Sgk1.1 ethanol dose response at 4 hours. 
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Figure 15. Sgk1 mRNA expression following ethanol sensitization. Behavioral 
sensitization followed by Q-rtPCR analysis of Sgk1 and Nr3c1. Panels show: (a) Total 
locomotor activity (cm/10min.) for saline only (SS), acute ethanol (SE) and ethanol 
sensitized (EE) groups. * p < 0.05 versus chronic saline (SS), # p < 0.05 versus acute 
ethanol (SE) (b) Sgk1 levels in SS, SE and EE treated mice 4 hours following following 
saline (SS) or ethanol (SE, EE) treatment on day 14. * p < 0.05 versus SS and EE treated 
animals (c) Nr3c1 levels in SS, SE and EE treated mice as in panel b. (d) Sgk1.1 levels in 
SS, SE and EE treated mice as in panel b. 
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Figure 16. Serum corticosterone levels following ethanol sensitization. Behavioral 
sensitization followed by corticosterone quantification. Panels show: (a) Acute and 
sensitized locomotor response (cm/10 min.) following saline (SS, ES) or ethanol (EE, 
SE) administration. * p < 0.05 versus SS and ES groups, # p < 0.05 versus SE, ES and SS 
groups; (b) Corticosterone levels 1 hour following acute and chronic ethanol 
administration. * p < 0.05 versus SS, EE, and ES groups. 
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Figure 17. Effects of adrenalectomy on Sgk1 induction following ethanol administration. 
(a) Q-rtPCR analysis of Sgk1. Sgk1 in saline and ethanol treated SHAM versus ADX 
animals. * p < 0.05 versus saline treated SHAM animals and saline and ethanol treated 
ADX animals; (b) Corticosterone levels 1 hour following acute ethanol administration. * 
p < 0.05 versus saline treated SHAM animals and saline and ethanol treated ADX 
animals. (c) Q-rtPCR analysis of Sgk1.1. Sgk1.1 in saline and ethanol treated SHAM 
versus ADX animals. 
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Figure 18. Chromatin immunoprecipitation (ChIP) quantification of glucocorticoid 
receptor (GR) bound to Sgk1 promoter region. DBA2/J mice were treated with saline or 
ethanol (4 g/kg) by i.p. injection and chromatin isolated 1 hour later from a frontal pole 
dissection. Sgk1 promoter DNA was quantified by PCR following immunoprecipitation 
by control IgG or GR antibody. * p < 0.05 versus GR saline treated samples and IgG 
saline and ethanol treated samples, # p < 0.05 versus IgG saline and ethanol treated 
samples 
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Figure 19. Time Course Western blot analysis of pSGK1 S422. pSGK1 S422 was 
significantly increased 15 minutes following ethanol versus saline administration (a). 
There were no significant changes in pSGK1 S422 levels at any other time point (b-f). * 
p < 0.05 versus saline treated animals 
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Figure 20. pSGK1 following saline and ethanol administration. Western blot analysis of 
pS422 SGK1 and pT256 SGK1 at 15 minutes following ethanol (4g/kg) or saline 
treatment. Panels show: (a) Quantification of pS422 SGK1, (b) Representative Western 
blot, c) Quantification of pT256 SGK1, and (d) Representative Western blot. * p < 0.05 
versus saline treated animals 
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Figure 21. NDRG1 phospho S330 following ethanol administration. Western blot 
analysis of pS330 NDRG1 15 minutes following ethanol (4g/kg) or saline treatment. 
Panels show: (a) Quantification of pS330 NDRG1, (b) Representative Western blot. * p < 
0.05 versus saline treated animals 
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Figure 22. Time Course Western blot analysis of total SGK1. SGK1 was significantly 
decreased 8 hours following ethanol versus saline administration (e). There were no 
significant changes in SGK1 levels at any other time point (a-d, f). * p < 0.05 versus 
saline treated animals 
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Figure 23. Total SGK1 protein following ethanol administration. Western blot analysis 
of SGK1 8 hours following ethanol (4g/kg) or saline treatment. Panels show: (a) 
Quantification of SGK1, (b) Representative Western blot. * p < 0.05 versus saline treated 
animals 
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CHAPTER 6 
Viral Overexpression of Serum Glucocorticoid Kinase I and Behavioral Analysis 
Introduction 
Serum glucocorticoid kinase I (Sgk1) is a glucocorticoid responsive gene 
involved in synaptic plasticity and learning and memory that is known to regulate the 
function of ion channels and allow for the convergence of cell surface receptors, nuclear 
receptors, and cellular stress pathways (Lee et al., 2006, Ma et al., 2006, Tsai et al., 2002, 
Webster et al., 1993). Our laboratory previously showed that Sgk1, along with several 
other glucocorticoid responsive genes, was upregulated in the prefrontal cortex (PFC) of 
DBA/2J (D2) mice following acute ethanol exposure (Kerns et al., 2005a).  Other 
investigators have also shown Sgk1 induction in brain following acute ethanol (Treadwell 
and Singh, 2004, Piechota et al., 2010b), morphine (Piechota et al., 2010b), heroin 
(Piechota et al., 2010b), methamphetamine (Piechota et al., 2010b) or amphetamine 
(Gonzalez-Nicolini and McGinty, 2002).   
Sgk1 was first identified as a glucocorticoid responsive gene with a 
glucocorticoid response element (GRE) in its promoter (Webster et al., 1993). Since then, 
studies have shown that Sgk1 is involved in memory consolidation of spatial learning and 
synaptic plasticity in the brain and spinal chord (Lee et al., 2006, Tsai et al., 2002, Lee 
and Rivier, 1997, Ma et al., 2006, Geranton et al., 2007). Our recent work shows that 
Sgk1 is regulated transcriptionally and translationally by the glucocorticoid receptor 
binding to the GRE in the Sgk1 promoter following ethanol’s activation of the HPA axis 
and subsequent glucocorticoid release. In addition following ethanol administration, Sgk1 
is also regulated post-translationally as 15 minutes following ethanol administration, 
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SGK1 phosphorylation at S422 and T256, sites that are known to activate the kinase, is 
significantly increased (Park et al., 1999, Kobayashi et al., 1999a, Perrotti et al., 2001). 
Our prior results showed a complex regulation of Sgk1 transcription, protein abundance 
and post-translational modifications following ethanol treatment. They suggested a 
critical role for the HPA axis and Sgk1 in regulating acute and chronic cellular and 
behavioral responses to ethanol. In this work, we further explore how Sgk1 and the Sgk1 
gene network may regulate behavioral responses to ethanol, in particular ethanol 
sensitization. 
Behavioral sensitization, or the potentiation of drug-induced behavioral responses 
following repeated exposure, involves learning and memory processes, is mediated by the 
mesocorticolimbic dopamine pathway including the PFC, and represents a long-lasting 
change in the behavioral response to drugs (Lessov and Phillips, 2003).  Sensitization can 
be separated into two phases, induction and expression. The initiation of behavioral 
sensitization includes the sequence of cellular events that leads to enduring changes in 
neural function. The expression of behavioral sensitization refers to the enduring neural 
alterations that occur following repeated drug administration (Harrison and Nobrega, 
2009b). The initiation and expression of behavioral sensitization can be influenced by 
contextual cues surrounding drug administration suggesting that learning and memory 
processes influence the development of the sensitized state (Quadros et al., 2003).  Some 
investigators have suggested that the neuroadaptations underlying behavioral 
sensitization are similar to those mediating learning and memory processes and that 
sensitization reflects a sensitized activation of brain reward systems in the 
mesocorticolimibic dopamine pathway (Trujillo and Akil, 1995, Wise and Bozarth, 
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1987). In support of this, lesions of the PFC prevented the expression of behavioral 
sensitization to amphetamine or cocaine (Cador et al., 1999, Pierce et al., 1998).  
The role of the PFC has been less studied in ethanol sensitization and this is not 
surprising as ethanol sensitization has been less studied than sensitization to other drugs 
of abuse including cocaine and amphetamine (Phillips et al., 1997a). It is thought that 
sensitization across different classes of drugs may have common mechanisms as cross-
sensitization, wherein pretreatment with one drug results in the sensitized response to 
another, has been observed between drugs of abuse including ethanol, morphine and 
cocaine (Lessov and Phillips, 2003). Because of Sgk1’s regulation in the PFC following 
ethanol administration, its known role learning and memory, and its complex regulation 
following acute and chronic ethanol administration, we hypothesized that Sgk1 may play 
an role in modulating the sensitized response to ethanol.  
 
MATERIALS AND METHODS 
Animals 
Mice were maintained in a temperature-controlled room (23±1°C) with 12 h light/dark 
cycles and free access to standard chow (Harlan Teklad #7912, Madison, WI, United 
States) and water. Cages and bedding (Harlan Sani-chips, #7090A, Harlan, Teklad, 
Madison, WI, United States) were changed weekly. All tests were carried out between 
0900 and 1200 h. All mice were DBA2/J mice from Jackson Laboratories (Bar Harbor, 
ME, United States) purchased at 6-7 weeks of age and group housed 4/cage.  
Drugs 
All drugs were administered intraperitoneally (i.p.). Saline solutions were 0.9% w/v 
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sterile saline.  Ethanol solutions were prepared from 200-proof absolute anhydrous 
ethanol (Pharmco-Aaper brand, Brookfield, CT).  Ethanol was administered at 20% v/v 
in 0.9% saline.   
Viral Preparation 
All viral work was completed under biosafety level 2 conditions. FLAG-Sgk1-AAV 
plasmids were created by Dr. Sajida Rahman using standard cloning procedures. In brief, 
Sgk1 cDNA was cloned in frame with a 3X FLAG epitope tag into pAAV-IRES-hrGFP 
Vector (AAV Helper-Free System, Agilent). The recombinant AAV2 viral vectors were 
produced in 293 cells using three-plasmid cotransfection and puriﬁed following 
previously published methods (Zolotukhin et al., 1999) by the Vector Core Facility, Gene 
Therapy Center, University of North Carolina at Chapel Hill.  
Stereotaxic Microinjection 
24 hours prior to and 48 hours following stereotaxic microinjection, mice were provided 
children’s Motrin (30 mg/kg) in tap water for analgesia. Mice (n = 48, 24 animals 
microinjected with an AAV-2 virus overexpressing Sgk1, FLAG-SGK1-AAV, and 24 
animals microinjected with an empty vector AAV-2 virus, IRES-AAV) were anesthetized 
using Isoflurane and secured in a stereotaxic apparatus (myNeuroLab). They then 
received bilateral stereotaxic microinjections at a 10° angle of 1µl of AAV per injection 
site (2 µl total) into the anterior cingulate region of the PFC (+1 mm from Bregma, ± 0.6 
mm from midline and -2 mm ventral to pial surface). 0.1 µl of virus was injected per 
minute over a 10 minute time period and the injection needle was left in place for 10 
minutes following injection to avoid the backflow of virus. 
Sensitization of animals overexpressing FLAG-SGK1-AAV versus IRES-AAV 
136	  	  
injected control animals  
Following microinjection, mice were allowed 3 weeks for recovery and viral expression 
and then tested for locomotor activation and sensitization. All locomotor activity was 
measured immediately following injection with either saline or ethanol, during a 10-
minute session in locomotor activity chambers (Med-Associates, model ENV-515; St. 
Albans, VT, United States). All mice were allowed a 1-hour acclimation period to the 
behavioral room prior to testing. Mice were divided into 4 groups: saline treated IRES 
and Sgk1 mice and ethanol treated IRES and Sgk1 mice, n = 7-12 per group. Saline 
treated mice received only saline injections and ethanol treated mice received only 
ethanol injections. On days 1 and 2, all mice were habituated to saline injections and 
immediately placed in locomotor boxes for 10 minutes following injections. On test day 
3, 2 g/kg ethanol or saline was administered to mice and they were placed in activity 
chambers immediately following drug administration for 10 minutes to record the 
animal’s acute response to ethanol. On days 4-13 mice received daily injections of either 
2.5 g/kg ethanol or saline in their home cages. On test day 14, animals are once again 
given 2 g/kg ethanol or saline and locomotor activity documented to record the 
expression phase of sensitization. Following test day 14, 3 abstinence periods of 7 days 
are followed by activity testing on days 21, 28 and 35 identical to day 14 to record 
enduring neural alterations, which characterize the sensitized state (Table 4, summary of 
experimental design).   
Immunohistochemistry 
Following behavioral testing, viral expression and placement were examined. Animals 
were be deeply anesthetized with sodium pentobarbital (180 mg/kg i.p.) and perfused 
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transcardially with normal saline followed by 4% paraformaldehye. Their brains were 
removed and post-fixed overnight in 4% paraformaldehyde, cryoprotected in 30% w/v 
sucrose until they sank, and frozen using dry ice cooled 2-methylbutane. 25 micron-thick 
coronal sections were cut using a cryostat and viral placement was measured using 
immunohistochemistry through 3,3’-Diaminobenzidine (DAB) anti-FLAG (Cell 
Signaling) staining. DAB staining was performed using Vector’s DAB Substrate Kit 
(Vector Labs) per the manufacturer’s instructions. 
Statistics 
Data were expressed as mean ± SEM and analyzed parametrically.  Data were analyzed 
with analysis of variance (ANOVA) using appropriate between-and within subject 
factors.  All post hoc comparisons were made using Student Newman-Keul’s test. Values 
of p < 0.05 were considered statistically significant.   
 
RESULTS 
Sensitization of animals overexpressing FLAG-SGK1-AAV versus IRES-AAV injected 
control animals 
 A three-way mixed model repeated measures ANOVA (day x treatment x 
genotype) showed a significant effect of day (F3,106 = 61.0, p < 0.001) and treatment (F1,38 
= 800.7, p < 0.001) as well as a significant day x treatment interaction (F3,106 = 57.9, p < 
0.001). Additionally, a three-way mixed model repeated measures ANOVA (day x 
treatment x genotype) comparing only the expression phase of sensitization where 
ethanol was no longer being chronically administered showed a significant effect of day 
(F2,57 = 25.6, p < 0.001), treatment (F1,38 = 538.0, p < 0.001), a genotype x treatment 
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interaction (F1,38 = 5.1, p < 0.05) as well as a significant day x treatment interaction (F2,57 
= 39.8, p < 0.001) (Fig. 24). Looking more closely at individual test days, 3, 14, 21, 28, 
and 35, there was an overall effect of treatment on test days 3, 14 and 28 (F1,38 = 160.3, p 
< 0.001; F1,38 = 538.9, p < 0.001; and F1,38 = 654.6, p < 0.001, respectively). All animals 
showed significantly increased locomotor activation responses following ethanol 
treatment within their respective genotypes on days 3, 14, and 28. On test day 21, there 
was an overall effect of treatment (F1,38 = 522.8, p < 0.001) and genotype (F1,38 = 4.6, p < 
0.05) and a significant genotype x treatment interaction (F1,38 = 4.3, p < 0.05). Post-hoc 
analysis showed that FLAG-SGK1-AAV versus IRES-AAV injected animals showed a 
significantly increased locomotor activation response following ethanol administration 
within their respective genotype. Further and more importantly, post-hoc analysis also 
identified significant differences between ethanol treated FLAG-SGK1-AAV versus 
IRES-AAV injected animals, p = 0.008, indicating that mice overexpressing FLAG-
SGK1-AAV showed a significantly greater locomotor activation response following 
ethanol administration compared to IRES-AAV animals. On test day 35, there was an 
overall effect of treatment (F1,38 = 98.7, p < 0.001) and a significant genotype x treatment 
interaction (F1,38 = 4.7, p < 0.05). Post-hoc analysis showed that FLAG-SGK1-AAV 
versus IRES-AAV injected animals showed a significant locomotor activation response 
following ethanol administration within their respective genotype. More importantly, 
post-hoc analysis for day 35 also identified significant differences between ethanol 
treated FLAG-SGK1-AAV versus IRES-AAV injected animals, p = 0.037, indicating that 
once again mice overexpressing FLAG-SGK1-AAV showed a significantly greater 
locomotor activation response following ethanol administration compared to IRES-AAV 
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animals.   
Because we were also interested in testing the duration of the sensitized response, 
we also evaluated FLAG-SGK1-AAV versus IRES-AAV injected control animals 
independently to measure the duration of the sensitized response. A two-way mixed 
model ANOVA (day x treatment) evaluating the duration of the sensitized response in 
IRES-AAV mice showed an overall effect of treatment (F1,18 = 363.4, p < 0.001), day 
(F3,55 = 35.3, p < 0.001) and a significant treatment x day interaction (F3,55 = 41.8, p < 
0.001). Post-hoc analysis revealed that all mice showed significant increases in locomotor 
activity following ethanol administration compared to saline treated animals on every day 
tested, days 3, 14, 21, 28 and 35. Post-hoc analysis also showed significant differences in 
locomotor activity between days 3 versus days 14, 21, and 28 indicating that mice 
showed a robust, sensitized response on days 14, 21 and 28. Locomotor activity was not 
significantly different on days 14, 21 and 28, but locomotor activity significantly 
decreased on day 35 to day 3 levels indicating that mice were no longer sensitized on this 
day. 
A two-way mixed model ANOVA (day x treatment) evaluating the duration of the 
sensitized response in FLAG-SGK1-AAV mice showed an overall effect of treatment 
(F1,20 = 446.5, p < 0.001), day (F2,44 = 29.5, p < 0.001) and a significant treatment x day 
interaction (F2,44 = 23.7, p < 0.001). Post-hoc analysis showed that all mice showed 
significant increases in locomotor activity following ethanol administration compared to 
saline treated animals on every day tested, days 3, 14, 21, 28 and 35. Post-hoc analysis 
also showed significant differences in locomotor activity between days 3 versus days 14, 
21, 28 and 35 indicating that mice showed a robust, sensitized response on days 14, 21, 
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28 and 35. Locomotor activity was not significantly different on days 21 and 28, but it 
did show a significant decline on these days compared to day 14. Although mice 
remained sensitized on day 35, as indicated by their significantly increased locomotor 
response on day 35 versus day 3, locomotor activity significantly decreased on day 35 
compared to days 14, 21 and 28. 
 
Immunohistochemistry 
Viral placement and expression was verified in mice microinjected with FLAG-
SGK1-AAV (Fig. 25). Mice microinjected with IRES-AAV did not show positive anti-
FLAG staining in the PFC whereas those injected with FLAG-SGK1-AAV did (Fig 25a-
b). Additionally, viral expression in mice microinjected with FLAG-SGK1-AAV 
appeared specific as there was no positive staining in the most rostral brain regions, 
staining increased in the PFC moving caudally and then decreased (Fig 25c-f). 
 
DISCUSSION 
 Prior work in our lab showed a complex regulation of Sgk1 transcription, protein 
abundance and post-translational modifications following ethanol treatment and 
suggested a critical role for the HPA axis and Sgk1 in regulating acute and chronic 
cellular and behavioral responses to ethanol (Costin et al., 2012). In this work, we further 
explore the role of Sgk1 in modulating acute and chronic cellular and behavioral 
responses to ethanol including locomotor activation and sensitization. Here we suggest 
that Sgk1 and the Sgk1 gene network may mediate some of the changes in neuronal 
plasticity that are known to occur following repeated ethanol administration and 
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eventually lead to the maintenance of the sensitized response.  
 Ethanol sensitization remains less well characterized than sensitization to the 
classic psychomotor stimulants such as cocaine, amphetamine and morphine. It is known 
that sensitization to cocaine, amphetamine and morphine persists as long as 3 months 
(Shuster et al., 1977), 1 year (Paulson et al., 1991), and 8 months (Babbini et al., 1975) 
respectively. Lessov and Phillips have shown that ethanol sensitization may last for up to 
29 days in outbred female mice (Lessov and Phillips, 1998).  Fish et al. found that 
ethanol sensitization persisted for at least 58 days following cessation of ethanol 
administration in outbred CFW mice (Fish et al., 2002). Boehm et al. showed that the 
expression of locomotor sensitization to ethanol in female D2 mice persisted for at least 
14 days following cessation of ethanol administration and up to 28 days when repeated 
ethanol exposure was associated with a specific context (Boehm et al., 2008).  
We found that ethanol sensitization persisted 14 days post-ethanol administration 
in animals overexpressing IRES-AAV, but it persisted 21 days following the cessation of 
ethanol administration in mice overexpressing FLAG-SGK1-AAV. Our findings that 
IRES-AAV mice remained sensitized 14 days following the cessation of ethanol 
administration were similar to those of Boehm et al.. Our sensitization protocol mirrors 
the protocol used by Boehm et al. to determine the duration of locomotor stimulation 
without context pairing, except we did not move animals to a separate room for their 
daily home cage injections during the induction phase of sensitization and we tested 
animals in the locomotor chambers for 10 minutes rather than 15 minutes. In addition to 
their context learning and duration of sensitization experiments, Boehm et al. completed a 
separate experiment in which they had a separate group of mice that underwent 
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sensitization, but did not receive repeated ethanol injections on post-sensitization days 7, 
14 and 21. Rather, animals were divided into separate groups and tested for the duration 
of ethanol sensitization only once on their respective test day, ie. day 7, 14 or 21 
following the cessation of ethanol administration. This group of mice controlled for the 
effect of repeated ethanol injections on post-sensitization test days which Boehm et al. 
hypothesized may re-sensitize mice to ethanol. However, Boehm et al. showed that both 
animals repeatedly administered ethanol over 7 day intervals and those that were not 
subject to repeated ethanol administrations showed the same duration of sensitization, 14 
days following cessation of ethanol administration (Boehm et al., 2008). The only major 
difference between our experiments and those of Boehm et al. was they used female 
rather than male D2 mice (Boehm et al., 2008). Interestingly, in addition to being the first 
study examining locomotor activation and sensitization in mice overexpressing FLAG-
SGK1-AAV, it seems our study may also be the first examining the duration of the 
ethanol sensitized response in male D2 mice.  
It is known that locomotor sensitization is thought to occur due to alterations in 
the neural mechanisms mediating the acute locomotor stimulant response (Ron and Jurd, 
2005). These mechanisms become increasingly sensitive to the drug and remain sensitive 
for extended time periods following the cessation of drug administration. Such long-
lasting neuroadaptations may explain how addicted individuals relapse after long periods 
of abstinence. Still, it isn’t clear what mechanisms mediate the sensitized response, 
particularly ethanol sensitization, and to date only three studies have examined the 
duration of ethanol sensitization. These studies do not thoroughly examine the 
mechanism behind the duration of ethanol sensitization (Boehm et al., 2008, Lessov and 
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Phillips, 1998, Fish et al., 2002). Boehm et al. does suggest contextual pairing can 
prolong the sensitized response and Fish et al. suggests that sensitization increases 
aggression in certain mouse populations. The fact that the mechanisms behind the 
duration of ethanol sensitization have not been explored adds a novel aspect to our 
studies. We show that mice overexpressing FLAG-SGK1-AAV have significantly 
increased locomotor activity on day 21 of the experimental protocol, or 7 days following 
ethanol cessation, compared to IRES-AAV mice. Additionally, FLAG-SGK1-AAV mice 
show a significantly greater locomotor response compared to IRES-AAV mice on day 35 
of sensitization studies, 21 days following ethanol cessation. These findings indicate that 
overexpressing FLAG-SGK1-AAV may increase the intensity and duration of the 
sensitized response meaning that Sgk1 may play an important role in the expression 
phase of the sensitized response. We can use Sgk1 as a starting point to begin to decipher 
some of the mechanisms behind the expression phase of ethanol sensitization. 
One way in which SGK1 may alter the sensitized response is by regulating 
glutamate receptors. Yuen et al. showed that acute stress induced a potentiation of 
glutamatergic transmission in the PFC through an SGK1/3-induced increase in the 
delivery of NMDARs and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptors (AMPARs) to the synaptic membrane. More specifically, acute stress activates 
glucocorticoid receptors which regulate Sgk1/3 expression, SGK1/3 activation of Rab4 
increases the trafficking and function of NMDARs and AMPARs, NMDARs and 
AMPARs are recycled between early endosomes and the plasma membrane, and this 
process leads to potentiated synaptic transmission (Yuen et al., 2011). Glutamatergic 
transmission may play a role in mediating the sensitized response, although there have 
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been alternate findings in the literature. In male D2 and Swiss albino mice, the 
uncompetitive NMDA receptor antagonist MK-801 blocked the expression of ethanol-
induced sensitization (Broadbent et al., 2003, Kotlinska et al., 2006, Camarini et al., 
2000). However, in D2 mice Broadbent et al. showed that MK-801 reduced the stimulant 
effects of ethanol suggesting it is possible that MK-801’s ability to block the expression 
of sensitization may represent a non-specific suppression of locomotor activity (Kotlinska 
et al., 2006).  In male D2 mice, the NR2B selective uncompetitive NMDA antagonist 
ifenodil did not effect the expression of sensitization and the non-NMDA glutamate 
receptor antagonists DNQX and GYKI 52466 decreased or blocked the expression of 
ethanol sensitization, respectively (Kotlinska et al., 2006).  But, GYKI 52466 also 
reduced the locomotor activity of control saline treated animals at the same doses at 
which it blocked the expression of ethanol sensitization (Broadbent et al., 2003).  Still, if 
NMDA antagonists do block the expression of the sensitized response, perhaps increasing 
glutamatergic transmission would potentiate the sensitized response. To indirectly 
determine if FLAG-SGK1-AAV may be extending the duration of the sensitized response 
through alterations in glutamate receptor levels, we can compare glutamate receptor 
levels in the brains of FLAG-SGK1-AAV versus IRES-AAV mice. Yuen et al. showed 
increased surface NMDAR and AMPAR clusters in the PFC following stress.  
 Our previous studies also showed that Sgk1 expression is blunted following chronic 
ethanol administration as seen in ethanol sensitization and this blunting of Sgk1 
expression may be due to HPA axis habituation (Costin unpublished data, 2013). We 
measured Sgk1 levels (Fig. 15) and corticosterone levels (Fig. 16) acutely and chronically 
following ethanol sensitization and found that Sgk1 and corticosterone were both 
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increased acutely, but blunted chronically (Costin unpublished data, 2013). Our prior 
studies also showed that while Sgk1 is increased as early as 2 hours following ethanol 
administration (Fig. 14a), total SGK1 protein abundance is significantly decreased 8 
hours following ethanol administration (Fig. 23) and we believe that the SGK1 protein 
degradation is a compensatory response to increases in Sgk1. Previously, we also 
explored ethanol regulation of SGK1 phosphorylation. We found that phosphorylation of 
SGK1 at S422 and T256, sites well-known to activate the protein, is transiently increased 
15 minutes following ethanol administration (Fig. 20, Costin unpublished, 2013). It could 
be that increases in Sgk1 followed by SGK1 decreases are necessary to induce some of 
the plastic changes leading to the sensitized state and when Sgk1 is overexpressed, as 
with FLAG-SGK1-AAV, these changes show a longer duration. Our chronic 
corticosterone and Sgk1 measures were taken on day 14 of sensitization studies so we do 
not know when HPA axis and Sgk1 habituation occurred during the sensitization 
paradigm, ie. day 5 or day 12 of chronic ethanol administration, and therefore increases 
in Sgk1 followed by decreases in SGK1 could be important during the initiation phase of 
sensitization. Since Sgk1 is no longer regulated by ethanol during the expression phase of 
sensitization, we would hypothesize that phosphorylation of SGK1 rather than induction 
of Sgk1 followed by decreases in SGK1 is responsible for the increased duration of the 
sensitized response seen in FLAG-SGK1-AAV mice. Additional studies are necessary to 
better characterize SGK1 and phospho-SGK1 chronically, particularly during ethanol 
sensitization.   
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Table 4: Outline of experimental design for viral ethanol sensitization 
Phase of Sensitization Induction Phase Expression Phase 
Group Days 1-2 Days 3 Days 4-13 Days 14-35 Habituation Acute test Daily injections Expression test 
SS Saline Saline Saline Saline 
EE Saline Ethanol 2 g/kg Ethanol 2.5 g/kg Ethanol 2.0 g/kg 
Activity test yes yes no yes 
Table 1.  Sensitization protocol. 
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Figure 24. Ethanol sensitization following viral overexpression of Sgk1. * p < 0.05 vs. 
all saline treated animals; # p < 0.05 vs. all saline treated animals, day 3 IRES EtOH 
treated animals, and day 35 IRES EtOH treated animals; & p < 0.05 vs. all saline treated 
animals, day 3 SGK1 EtOH treated animals and day 35 SGK1 treated animals; $ p < 0.05 
vs. all saline treated animals, day 3 EtOH treated IRES animals, and day 35 IRES EtOH 
treated animals; ** p < 0.05 vs. all saline treated animals, day 3 EtOH treated SGK1 
animals, day 21 EtOH treated IRES animals, day 14 EtOH treated SGK1 animals and day 
35 EtOH treated SGK1 animals; ^ p < 0.05 vs. all saline treated animals, day 3 EtOH 
treated IRES animals, and day 35 EtOH treated IRES animals; ¢ p < 0.05 vs. all saline 
treated animals, day 3 EtOH treated SGK1 animals, day 14 EtOH treated SGK1 animals 
and day 35 EtOH treated SGK1 animals; § p < 0.05 vs. all saline treated animals; + p < 
0.05 vs. all saline treated animals, SGK1 day 3 EtOH treated animals and IRES Day 35 
EtOH treated animals 
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Figure 25. Viral placement and expression in mice microinjected with IRES-AAV versus 
those microinjected with FLAG-SGK1-AAV (a-b) and rostral to caudal movement in 
mice microinjected with FLAG-SGK1-AAV (c-f). Panels show: (a) anti-FLAG staining 
in mice expressing IRES-AAV, (b) anti-FLAG staining in mice expressing FLAG-SGK1-
AAV, (c)-(f) rostral (c) to caudal (f) movement through the brain of a mouse 
microinjected with FLAG-SGK1-AAV. Arrows indicate positive staining. 
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CHAPTER 7   
Concluding Remarks & Future Directions 
CONCLUDING REMARKS 
Overall our findings support clinical reports showing stress hypo-responsiveness 
in human alcoholics and provide evidence for how HPA axis tolerance can alter ethanol 
responses in brain stress/reward related regions such as PFC (Lovallo et al., 2000, 
O'Malley et al., 2002, Kiefer et al., 2011). HPA axis dysregulation exists in alcohol 
dependent patients and individuals with a familial history of alcoholism. Individuals who 
are low in sociability with a familial history of alcohol dependence show blunted cortisol 
responses (Sorocco et al., 2006). Individuals at high risk for alcoholism also show lower 
basal ACTH levels, lower stress-induced increases in plasma ACTH concentration, and 
delayed post-stress recovery of plasma ACTH and cortisol (Dai et al., 2002). Thus, 
disrupted stress responses may contribute to the risk for development of alcohol 
dependence, and our findings suggest that altered basal gene expression in PFC could be 
a mediating factor. While changes occurring at the endocrine level are characterized, less 
defined are molecular changes in brain stress/reward related regions that are mediated by 
HPA axis tolerance.  
Studies of acute, sub acute and chronic ethanol administration in animal models 
have helped to better define ethanol’s actions. Such studies have led to the development 
of treatments for alcohol abuse and alcoholism. Our work better defines the mechanism 
behind ethanol’s regulation of Sgk1 both acutely and chronically. In the case of Sgk1, it 
seems that ethanol triggers a complex wave of signaling events leading to: 1) Sgk1 
activation by phosphorylation with subsequent phosphorylation of Ndrg1 and other 
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targets; 2) increased Sgk1 transcription by HPA activation and glucocorticoid action; and 
3) compensatory Sgk1 protein degradation (Fig. 26). Additionally, our work identifies 
behavioral modifications induced by Sgk1 following chronic ethanol administration. 
Chronically, Sgk1 may alter neural mechanisms that mediate the addicted state, but 
additional studies are necessary to characterize this response. Future studies are needed to 
further characterize the mechanism behind ethanol’s regulation of Sgk1, the inter-
relations of glucocorticoid signaling, PFC gene expression networks, and mechanisms 
underlying risk for alcohol dependence. 
 
Figure 26. Brief summary of project findings. Ethanol triggers a complex wave of 
signaling events beginning with the activation of the HPA axis and leading to eventual 
changes in gene expression in the anterior cingulate region of the PFC. Sgk1 is an ethanol 
responsive, glucocorticoid responsive gene. Following ethanol administration a series of 
events occurs including: 1) SGK1 activation by phosphorylation with subsequent 
phosphorylation of NDRG1 and possibly other targets; 2) increased Sgk1 transcription by 
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HPA activation and glucocorticoid action; and 3) compensatory SGK1 protein 
degradation. These events are responsible for changes in cellular function that alter 
behavioral responses to ethanol. 
 
FUTURE DIRECTIONS 
 We are currently working to verify viral placement in FLAG-SGK1-AAV and 
IRES-AAV mice and identify candidates in the Sgk1 gene network that may mediate 
some of the behavioral differences we saw between FLAG-SGK1-AAV versus IRES-
AAV mice during the expression phase of sensitization. We are completing 
immunohistochemistry experiments to verify FLAG-SGK1-AAV placement in the 
anterior cingulate region of the PFC of D2 mice. In addition, we are verifying IRES-AAV 
and FLAG-SGK1-AAV placement and hrGFP expression through in vivo imaging 
(Xenogen). Additionally, we are performing ethanol metabolism studies in FLAG-SGK1-
AAV and IRES-AAV mice. We will also harvest IRES-AAV and FLAG-SGK1-AAV 
animals to possibly perform microarray analysis and Q-rtPCR verification of microarray 
results. Microarray experiments may help us to identify candidates in the Sgk1 gene 
network that are working to alter synaptic plasticity and behavioral responses to ethanol.  
Additionally, future experiments should address SGK1 and phospho-SGK1 levels 
chronically following ethanol sensitization. We showed that Sgk1, SGK1 and phospho-
SGK1 levels were modified following acute ethanol administration, but we found 
differences in mice overexpressing FLAG-SGK1-AAV versus IRES-AAV chronically 
during the expression phase of ethanol sensitization and it is thus important to 
characterize SGK1 and phospho-SGK1 chronically. We could begin this process by 
measuring SGK1 and phospho-SGK1 in FLAG-SGK1-AAV and IRES-AAV treated 
animals. We might expect FLAG-SGK1-AAV animals to have greater SGK1 expression 
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compared to IRES-AAV control animals. But it would be interesting to see if 
overexpressing SGK1 also increases levels of phospho-SGK1 basally.  
The PFC is one of the primary targets of stress hormones (Yuen et al., 2011). 
Miyata et al. showed that a chronic stress paradigm that elevated plasma corticosterone 
levels similar to those found in depressed individuals lead to activation of the 
phosphatidylinositol 3-kinase (PI3K)-3-phosphoinositide-dependent protein kinase 
(PDK1), Sgk1, and Ndrg1 pathway with increases in both Sgk1 mRNA and SGK1 
phosphorylation (Miyata et al., 2011).  Thus, it is possible that HPA axis activation is 
causal in both Sgk1 activation and increased transcription of the Sgk1 gene. Our prior 
results did not explore the upstream regulation of phospho-SGK1. Future studies could 
address whether the HPA axis plays a role in the phosphorylation and activation of SGK1 
in the PFC through evaluating phospho-SGK1 in ADX versus SHAM ethanol treated 
animals. Additionally, phospho-SGK1 could also be evaluated following RU-486 versus 
vehicle administration. We would hypothesize that mechanisms other than HPA axis 
activation may be responsible for ethanol’s activation of SGK1. Earlier we hypothesized 
that the phosphorylation of SGK1 may be responsible for mediating the differences seen 
in FLAG-SGK1-AAV and IRES-AAV mice as we know that Sgk1 regulation following 
ethanol administration is no longer present early in the expression phase of sensitization. 
We also know the HPA axis habituates following repeated ethanol administration. It 
appears that SGK1 does, however, play a role in regulating the duration and extent of the 
sensitized response and therefore an alternative mechanism other than the HPA axis may 
be responsible for this regulation. It might also be interesting to perform a more detailed 
characterization of Sgk1 and corticosterone during the initiation phase of the sensitized 
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response to learn at what point during the initiation of sensitization do Sgk1 and 
corticosterone levels no longer increase following acute ethanol administration. These 
findings should correspond, ie. Sgk1 should decrease as corticosterone decreases, if Sgk1 
is in fact regulated by ethanol’s activation of the HPA axis. 
 In the future, we could repeat the viral overexpression experiment, but lower the 
test day ethanol doses to 1.5 g/kg ethanol rather than 2 g/kg ethanol for animals receiving 
ethanol on activity test days (see Table 5 below for experimental details). It is well-
known that D2 mice show a robust locomotor activation response following ethanol 
administration and it may be difficult to see differences in FLAG-SGK1-AAV versus 
IRES-AAV mice on test days following the administration of 2 g/kg ethanol as this dose 
may be masking differences in locomotor activity between FLAG-SGK1-AAV versus 
IRES-AAV mice. In other words, FLAG-SGK1-AAV mice could have a greater 
locomotor activation response than IRES-AAV following acute ethanol administration 
like we saw during the expression phase of sensitization, but due to a ceiling effect, we 
may be unable to detect differences in locomotor activity between these two groups of 
mice.  
Table 5: Outline of experimental design for future ethanol sensitization 
Phase of Sensitization Induction Phase Expression Phase 
Group Days 1-2 Days 3 Days 4-13 Days 14-35 Habituation Acute test Daily injections Expression test 
SS Saline Saline Saline Saline 
EE Saline Ethanol 1.5 g/kg Ethanol 2.5 g/kg Ethanol 1.5 g/kg 
Activity test yes yes no yes 
Table 5. Plan for future ethanol sensitization studies comparing locomotor activity during 
the initiation and expression phases of sensitization in in FLAG-SGK1-AAV versus 
IRES-AAV mice. 
 
 Ideally, we could perform dose response experiments comparing locomotor activity 
in FLAG-SGK1-AAV versus IRES-AAV D2 mice both acutely and during the 
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expression phase of ethanol sensitization (see Table 6 below for experimental details). 
This set of experiments would be challenging to execute. Because we are overexpressing 
Sgk1 in a small proportion of the cells in one brain region and due to the sensitive and 
variable nature of behavior, we would need n = 12 for IRES-AAV mice and n = 12 for 
FLAG-SGK1-AAV. This would require performing approximately 100 stereotaxic 
injections. Such injections should be performed during the same time period to control 
for the rate of viral expression following microinjection. Because the sensitized response 
has been shown to be subject to alterations in corticosterone levels and corticosterone 
levels are known to change throughout the day according to circadian rhythms, we must 
be careful to execute our experiments at the same time daily. Perhaps these experiments 
could be staggered, but their difficult nature should not be overlooked in planning future 
experimental procedures. 
Table 6: Outline of experimental design for future ethanol sensitization 
Phase of Sensitization Induction Phase Expression Phase 
Group Days 1-2 Days 3 Days 4-13 Days 14-35 Habituation Acute test Daily injections Expression test 
SS Saline Saline Saline Saline 
EE Saline Ethanol 1.5 g/kg Ethanol 2.5 g/kg Ethanol 1.5 g/kg 
EE Saline Ethanol 2.0 g/kg Ethanol 2.5 g/kg Ethanol 2.0 g/kg 
EE Saline Ethanol 2.5 g/kg Ethanol 2.5 g/kg Ethanol 2.5 g/kg 
Activity test yes yes no yes 
Table 6. Plan for future ethanol sensitization studies comparing locomotor activity during 
the initiation and expression phases of sensitization in in FLAG-SGK1-AAV versus 
IRES-AAV mice. Varying doses of ethanol are administered to animals on days 3 and 
14-35 as indicated above. 
 
 Like Boehm et al. (2008), we could also avoid administering repeated ethanol 
injections to animals during the expression phase of sensitization and have separate 
groups for testing on days 7, 14 and 21 (see Table 7 below for experimental details). 
Administering repeated injections to animals over 7 day intervals as we did initially may 
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re-sensitize the animals and may make it difficult to determine the true duration of the 
sensitized response. However, as mentioned above, Boehm et al. (2008) showed that both 
animals repeatedly administered ethanol over 7 day intervals and those that were not 
subject to repeated ethanol administrations showed the same duration of sensitization 
(Boehm et al., 2008). In fact, Boehm et al. even continued with their repeated ethanol 
challenge approach in further experiments after learning that is did not seem to affect the 
duration of the sensitized response (Boehm et al., 2008). This set of experiments would 
also be challenging to execute. We would need n = 12 for IRES-AAV mice and n = 12 
for FLAG-SGK1-AAV. This would require performing approximately 144 stereotaxic 
injections. Such injections should be performed during the same time period and we must 
carefully execute our experiments at the same time daily. Perhaps these experiments 
could be staggered, but their difficult nature should not be overlooked in planning future 
experimental procedures. 
Table 7: Out line of experimental design for future ethanol sensitization  
Phase of Sensitization Induction Phase Expression Phase 
Group Days 1-2 Days 3 Days 4-13 Days 14-35 Habituation Acute test Daily injections Expression test 
SS Saline Saline Saline Saline-7 
EE Saline Ethanol 1.5 g/kg Ethanol 2.5 g/kg Ethanol 1.5 g/kg-7 
SS Saline Saline Saline Saline-14 
EE Saline Ethanol 1.5 g/kg Ethanol 2.5 g/kg Ethanol 1.5 g/kg-14 
SS Saline Saline Saline Saline-21 
EE Saline Ethanol 1.5 g/kg Ethanol 2.5 g/kg Ethanol 1.5 g/kg-21 
Activity test yes yes no yes 
Table 7. Plan for future ethanol sensitization studies comparing locomotor activity during 
the initiation and expression phases of sensitization in in FLAG-SGK1-AAV versus 
IRES-AAV mice. “7” mice are only tested on day 7 following the cessation of ethanol 
administration. “14” mice are only tested on day 14 following the cessation of ethanol 
administration. “21” mice are only tested on day 21 following the cessation of ethanol 
administration. 
 
 In the future, we could also overexpress IRES-AAV and FLAG-SGK1-AAV in the 
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anterior cingulate region of the PFC of C57 mice and compare locomotor activation and 
sensitization in these mice. FLAG-SGK1-AAV prolonged the duration of the sensitized 
response possibly by altering plasticity in the PFC of D2 mice, a genotype of mouse best 
known to show an ethanol induced locomotor activation response and to sensitize to the 
locomotor activating effects of ethanol. It would be interesting to examine how the 
overexpression of FLAG-SGK1-AAV may affect locomotor activity in animals not 
known to show an ethanol induced locomotor activation response and sensitize to the 
locomotor activating effects of ethanol. This set of experiments could also help us to 
better decipher the mechanism through which Sgk1 may be altering synaptic plasticity. 
For example, C57 mice have higher basal levels of Sgk1, but they do not experience the 
robust induction of Sgk1 following acute ethanol administration. Perhaps increasing 
levels of Sgk1 through microinjection of FLAG-SGK1-AAV would alter locomotor 
activity in C57 mice.  
 Finally, one of the reasons we originally hypothesized that Sgk1 may mediate the 
sensitized response to ethanol is that Sgk1 has a known role in memory consolidation of 
spatial learning and regulates neuronal plasticity in the brain and spinal chord and it is 
known that behavioral sensitization involves learning processes (Lee et al., 2006, Tsai et 
al., 2002, Lee and Rivier, 1997, Ma et al., 2006, Quadros et al., 2003).  Although 
statistically significant, the differences between FLAG-SGK1-AAV and IRES-AAV 
mice in our ethanol sensitization studies were small. Perhaps we could accentuate 
differences between FLAG-SGK1-AAV and IRES-AAV in our sensitization studies by 
the pairing of ethanol injections and the testing chamber for both FLAG-SGK1-AAV and 
IRES-AAV mice during the initiation phase of sensitization. FLAG-SGK1-AAV may be 
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altering neuroadaptations underlying behavioral sensitization that may be closely related 
to those mediating learning and memory processes and including a contextual pairing 
component in our studies would enhance such differences. 
Additionally, we want to further decipher the mechanism by which Sgk1 regulates 
cellular responses to ethanol by identifying the cell type in which SGK1 primarily acts; 
ie. is Sgk1 mediating its effects in neuronal cell populations, oligodendrocytes, or 
astrocytes? The AAV-2 serotype shows neuron-specific expression and we used it to 
overexpress Sgk1 (Daya and Berns, 2008, Terzi and Zachariou, 2008). Overexpressing 
Sgk1 neuronally seemed to alter synaptic events that prolonged and intensified the 
sensitized response during the expression phase of sensitization. We show that NDRG1, a 
downstream target of phosphorylated, active SGK1, phospho S330 levels were 
significantly increased in ethanol vs. saline treated animals 15 minutes following ethanol 
administration (Fig. 21). Miyata et al. showed that a chronic stress paradigm that elevated 
plasma corticosterone levels lead to activation of the PDK1, SGK1, and NDRG1 pathway 
in mouse oligodendrocytes, not neurons (Miyata et al., 2011). NDRG1 is a well-known 
SGK1-specific substrate minimally phosphorylated by other kinases (Garcia-Martinez 
and Alessi, 2008, Sahin et al., 2013, Murray et al., 2004). It is known that NDRG1 
deﬁciency leads to Schwann cell dysfunction and that NDRG1 is essential for 
maintenance of the myelin sheaths in peripheral nerves (Okuda et al., 2004). Okuda et al. 
identified NDRG1 as mainly localized in oligodendrocytes in mouse cerebrum (Okuda et 
al., 2008). Another report demonstrated that the location of NDRG1 changed from 
hippocampal neurons to astrocytes during postnatal development in the rat brain (Okuda 
et al., 2008). Other works examining SGK1 location in in human brain of aged 
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Alzheimer’s versus control patients document the SGK1 location to be primarily 
neuronal (Sahin et al., 2013). Another study found neurons, oligodendrocytes, and 
microglial cells, but no astrocytes, were positive for SGK1 in the rat (Warntges et al., 
2002).  
We could determine the cell population through which SGK1 is mediating its 
effects by performing immunohistochemistry studies in 10-13 week old D2 mice, as that 
is the age of animal used in our prior studies. We could use neuronal, oligodendrocyte, 
and astrocyte markers in addition to NDRG1 and SGK1 staining to determine the cell 
type where SGK1 (Table 8) and NDRG1 (Table 9) are most prominently expressed 
basally, following saline injections and following ethanol administration. Ethanol 
administration could potentially change the distribution of SGK1 or NDRG1 so it is 
important that we evaluate NDRG1 and SGK1 expression both basally and following 
ethanol administration. Including the saline group will control for the effect of injection 
stress on the distribution of SGK1 and NDRG1. Please see Tables 8 & 9 below for the 
hypothesized staining combinations. We would be most interested in evaluating the PFC 
of D2 mice. 
Table 8. Staining combinations for future studies 
 
Neuronal 
Marker 
(NeuN) 
Oligodendrocyte 
Marker 
(CNPase) 
Astrocyte 
Marker 
(GFAP) 
NDRG1 
SGK1 X    
SGK1  X   
SGK1   X  
SGK1    X 
Table 8. Staining combinations for future studies determining the cell population or 
populations expressing SGK1. SGK1 expression would be examined basally, following 
saline treatment and following ethanol administration. Co-localization experiments would 
be performed between SGK1 and the following: NeuN, CNPase, GFAP and NDRG1. 
NeuN, CNPase, GFAP co-localization experiments with SGK1 would reveal the cell type 
where SGK1 is most prominently expressed. SGK1 and NDRG1 co-localization 
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experiments would verify that NDRG1 and SGK1 are co-expressed in cell populations, 
although it would not necessarily determine the type of cell population where the two 
proteins are co-expressed. All staining would have to be evaluated basally and following 
saline and ethanol treatment. 
 
Table 9. Staining combinations for future studies. 
 
Neuronal 
Marker 
(NeuN) 
Oligodendrocyte 
Marker 
(CNPase) 
Astrocyte 
Marker 
(GFAP) 
NDRG1 X   
NDRG1  X  
NDRG1   X 
Table 9. Staining combinations for future studies determining the cell population or 
populations expressing NDRG1. NDRG1 expression would be examined basally, 
following saline treatment and following ethanol administration. NeuN, CNPase, GFAP 
co-localization experiments with NDRG1 would reveal the cell type where NDRG1 is 
most prominently expressed. Co-localization experiments would be performed between 
NDRG1 and the following: NeuN, CNPase, and GFAP. All staining would have to be 
evaluated basally and following saline and ethanol treatment. 
 
This would be a first step to determining which cell population or populations are 
mediating the effects of SGK1. Since AAV-2 is well known to display neuronal tropism 
(Terzi and Zachariou, 2008, Daya and Berns, 2008), we know that alterations in plasticity 
leading to alterations in the sensitized response are occurring primarily in neuronal 
populations in our viral animals (Fig. 25). If overexpressing Sgk1 in neurons is not a 
biologically relevant experimental procedure, we would have to consider using a serotype 
of AAV that targets the biologically relevant cell type or types and repeat our 
experiments using the new serotype of AAV. 
While we believe CORT levels were significantly elevated in CB1 KO mice 
following ethanol administration because they lack the fast feedback negative HPA axis 
regulation mediated by CORT’s actions at the CB1 receptor, future studies will be 
necessary to draw this conclusion. We recognize that there is much additional work 
remaining in this line of experimentation. Due to our limited time and resources, we only 
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evaluated CORT levels at the one-hour time point, the time point following ethanol 
administration where CORT levels peaked in our time course evaluation of CORT (Fig. 
9). We also only evaluated CORT levels following 2 g/kg ethanol administration. Future 
studies could evaluate CORT levels in CB1 KO versus WT animals following an ethanol 
time course and dose response curve. Perhaps we would see additional and larger 
differences in CORT levels in CB1 KO versus WT animals at time points earlier or latter 
than one hour or doses smaller or greater than 2 g/kg. Because results in KO animals 
could be due to compensatory mechanisms or altered developmental events known to 
occur in these animals, we should also follow up our findings with studies using CB1 
receptor antagonist administration prior to ethanol administration, blood collection and 
RIA determination. 
We did not evaluate locomotor activity in CB1 KO animals because they were on 
a C57 background and therefore WT animals would not show a locomotor activation 
response following acute ethanol administration. In order to evaluate whether 
nongenomic glucocorticoid signaling mechanisms were involved in the locomotor 
activating effects of ethanol in D2 mice, we could start by measuring the ethanol 
mediated locomotor activation response in D2 mice following the administration of a 
CB1 antagonist. To our knowledge, these studies have not yet been performed in D2 
mice; but, CB1 KO mice on a CD1 background display a blunted locomotor activation 
response following acute ethanol administration compared to their WT counterparts 
(Naassila et al., 2004). CB1 KO mice on a CD1 background also displayed a significant 
reduction in basal levels of locomotion and cocaine-enhanced locomotion compared to 
their WT littermates and pharmacological blockade of CB1 receptors by SR141716, a 
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CB1 antagonist, inhibited locomotion in CB1 WT mice (Li et al., 2009). In CB1-R-
deficient mice on a C57BL/6N background, locomotor responses to cocaine and D-
amphetamine were decreased and sensitization was impaired (Corbille et al., 2007). 
These findings suggest that drugs causing an acute locomotor activation response in mice 
which also activate the HPA axis including ethanol, cocaine and amphetamine (Sarnyai et 
al., 2001) have diminished locomotor activating properties in CB1 KO mice. Thus, the 
idea that corticosterone may mediate some of the locomotor activating properties in D2 
mice through nongenomic signaling mechanisms may warrant further investigation.  
Our above findings are suggestive of a mechanism that remains illusive in the 
literature, but the fact remains that in our previous work high doses of RU-486, a 
glucocorticoid receptor antagonist, blunted the acute locomotor activating effects of 
ethanol in D2 mice.  This suggests a possible role for the receptor itself in mediating 
ethanol’s acute locomotor activating effects. The GR is subject to posttranslational 
modifications including phosphorylation on at least seven serine residues (Ser-113, Ser-
134, Ser-141, Ser-203, Ser-211, Ser-226 and Ser-404); ubiquitination at a conserved 
lysine residue located in a PEST degradation motif and this modification targets the 
receptor for degradation by the 26S proteasome; and sumoylation at residues Lys-277, 
Lys-293 and Lys-703 (Ramamoorthy and Cidlowski, 2013). Perhaps future studies could 
examine post-translational GR modifications beginning with GR phosphorylation as GR 
phosphorylation has not yet been examined following ethanol administration to our 
knowledge. Although this project has made a strong argument for the role of the GR in 
regulating gene expression following ethanol administration, perhaps the receptor is 
regulated in more than one way following ethanol administration. 
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